U.S. patent number RE43,596 [Application Number 11/788,948] was granted by the patent office on 2012-08-21 for .alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors.
This patent grant is currently assigned to G.D. Searle LLC. Invention is credited to Deborah E. Bertenshaw, Gary A. DeCrescenzo, John N. Freskos, Daniel P. Getman, Robert M. Heintz, Richard A. Mueller, John J. Talley, Michael L. Vazquez.
United States Patent |
RE43,596 |
Vazquez , et al. |
August 21, 2012 |
.alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides
useful as retroviral protease inhibitors
Abstract
.alpha.- and .beta.-amino acid hydroxyethylamino sulfonamide
compounds are effective as retroviral protease inhibitors, and in
particular as inhibitors of HIV protease.
Inventors: |
Vazquez; Michael L. (Gurnee,
IL), Mueller; Richard A. (Glencoe, IL), Talley; John
J. (St. Louis, MO), Getman; Daniel P. (Chesterfield,
MO), DeCrescenzo; Gary A. (St. Peters, MO), Freskos; John
N. (Clayton, MO), Heintz; Robert M. (Ballwin, MO),
Bertenshaw; Deborah E. (Brentwood, MO) |
Assignee: |
G.D. Searle LLC (Chicago,
IL)
|
Family
ID: |
25466397 |
Appl.
No.: |
11/788,948 |
Filed: |
April 23, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
PCT/US93/07814 |
Aug 24, 1993 |
|
|
|
|
07934984 |
Aug 25, 1992 |
|
|
|
Reissue of: |
08204827 |
Mar 2, 1994 |
6060476 |
May 9, 2000 |
|
|
Current U.S.
Class: |
514/277; 548/204;
546/337; 514/365; 514/256; 544/335; 546/323; 560/13; 546/139 |
Current CPC
Class: |
C07C
311/29 (20130101); C07D 317/62 (20130101); C07D
213/82 (20130101); C07D 307/79 (20130101); C07K
5/06026 (20130101); C07D 209/08 (20130101); C07D
213/89 (20130101); A61P 31/12 (20180101); C07C
317/14 (20130101); C07K 5/06139 (20130101); C07C
311/14 (20130101); C07D 213/73 (20130101); C07D
233/64 (20130101); C07C 311/41 (20130101); C07D
213/81 (20130101); C07D 215/48 (20130101); C07C
311/24 (20130101); C07C 311/32 (20130101); A61P
31/18 (20180101); C07C 311/13 (20130101); C07D
239/26 (20130101); A61P 31/14 (20180101); C07C
317/28 (20130101); C07D 417/12 (20130101); C07D
333/34 (20130101); C07D 405/12 (20130101); C07C
323/67 (20130101); C07C 317/44 (20130101); C07C
323/49 (20130101); C07C 311/46 (20130101); C07D
213/30 (20130101); C07D 307/42 (20130101); C07C
311/18 (20130101); C07D 277/82 (20130101); C07C
311/05 (20130101); C07C 317/04 (20130101); C07D
307/20 (20130101); C07D 277/24 (20130101); C07C
311/11 (20130101); C07C 311/20 (20130101); C07C
317/10 (20130101); C07D 213/64 (20130101); C07C
2601/08 (20170501); C07C 2601/04 (20170501); C07C
2601/18 (20170501); C07C 2601/02 (20170501); C07C
2601/14 (20170501); A61K 38/00 (20130101); C07C
2602/10 (20170501) |
Current International
Class: |
A61K
31/435 (20060101); C07D 277/30 (20060101); C07D
213/56 (20060101); C07D 213/81 (20060101); C07D
239/02 (20060101); C07D 239/20 (20060101); C07D
317/04 (20060101); A61K 31/425 (20060101) |
Field of
Search: |
;514/256,277,365
;544/335 ;546/323,337,139 ;548/204 ;560/13 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
A-79823/87 |
|
Apr 1988 |
|
AU |
|
2026382 |
|
Mar 1991 |
|
CA |
|
2045008 |
|
Dec 1991 |
|
CA |
|
2352452 |
|
Apr 1975 |
|
DE |
|
3635907 |
|
Apr 1988 |
|
DE |
|
0 104 041 |
|
Mar 1984 |
|
EP |
|
0 114 993 |
|
Jun 1984 |
|
EP |
|
0 172 347 |
|
Feb 1986 |
|
EP |
|
0 223 437 |
|
May 1987 |
|
EP |
|
0 264 795 |
|
Apr 1988 |
|
EP |
|
0 337 714 |
|
Oct 1989 |
|
EP |
|
0 342 541 |
|
Nov 1989 |
|
EP |
|
0 346 847 |
|
Dec 1989 |
|
EP |
|
356223 |
|
Feb 1990 |
|
EP |
|
389898 |
|
Oct 1990 |
|
EP |
|
389898 |
|
Oct 1990 |
|
EP |
|
393445 |
|
Oct 1990 |
|
EP |
|
393457 |
|
Oct 1990 |
|
EP |
|
402646 |
|
Dec 1990 |
|
EP |
|
0434365 |
|
Jun 1991 |
|
EP |
|
468641 |
|
Dec 1992 |
|
EP |
|
0541168 |
|
May 1993 |
|
EP |
|
0560268 |
|
Sep 1993 |
|
EP |
|
0580402 |
|
Jan 1994 |
|
EP |
|
1435386 |
|
May 1976 |
|
GB |
|
2184730 |
|
Jul 1987 |
|
GB |
|
2200115 |
|
Jul 1988 |
|
GB |
|
2209752 |
|
May 1989 |
|
GB |
|
50041814 |
|
Apr 1975 |
|
JP |
|
WO-84/03044 |
|
Aug 1984 |
|
WO |
|
WO 86/06726 |
|
Nov 1986 |
|
WO |
|
WO 92/00750 |
|
Jan 1992 |
|
WO |
|
WO 92/08688 |
|
May 1992 |
|
WO |
|
WO-92/08699 |
|
May 1992 |
|
WO |
|
WO 92/008701 |
|
May 1992 |
|
WO |
|
WO 93/07128 |
|
Apr 1993 |
|
WO |
|
WO 93/008184 |
|
Apr 1993 |
|
WO |
|
WO 93/09096 |
|
May 1993 |
|
WO |
|
WO 93/023388 |
|
Nov 1993 |
|
WO |
|
WO-94/04492 |
|
Mar 1994 |
|
WO |
|
WO 94/05300 |
|
Mar 1994 |
|
WO |
|
WO 94/05639 |
|
Mar 1994 |
|
WO |
|
WO-94/05639 |
|
Mar 1994 |
|
WO |
|
WO 94/26749 |
|
Nov 1994 |
|
WO |
|
WO 95/06030 |
|
Mar 1995 |
|
WO |
|
WO 95/09843 |
|
Apr 1995 |
|
WO |
|
WO95/33464 |
|
Dec 1995 |
|
WO |
|
WO 97/01349 |
|
Jan 1997 |
|
WO |
|
WO97/27319 |
|
Jul 1997 |
|
WO |
|
WO97/27480 |
|
Jul 1997 |
|
WO |
|
WO98/07888 |
|
Feb 1998 |
|
WO |
|
WO98/56781 |
|
Dec 1998 |
|
WO |
|
WO 99/33792 |
|
Jul 1999 |
|
WO |
|
WO 99/67417 |
|
Dec 1999 |
|
WO |
|
Other References
McQuade, "A Synthetic HIV-1 Protease Inhibitor with Antiviral
Activity Arrests HIV-Like Particle Maturation," Science, vol. 247,
454-456, no date provided. cited by other .
Rich, et al., "Peptide Inhibitors of Protease," Design of Protease
Inhibitors, 511-520, no date provided. cited by other .
Roberts, et al., "Rational Design of Peptide-based Proteinase
Inhibitors," Science, vol. 248, p. 358 (1990). cited by other .
Erickson, et al., "Design Activity, and 2.8A Crystal Structure of a
C.sub.2 Symmetric Inhibitor Complexed to HIV-1 Protease," Science,
vol. 249, p. 527 (1990). cited by other .
Pearl, et al., "Sequence specificity of retroviral proteases,"
Nature, 328, (1987). cited by other .
Martin, "Drugs of the Future, 16" vol. 3, pp. 210-212 (1991). cited
by other .
Meek, et al., "Letter to Nature," vol. 343, pp. 90-92 (1990). cited
by other .
Rosenberg, et al., J. Med. Chem., vol. 30, pp. 1224-1228 (1987).
cited by other .
Kwan Y. Hui et al., A rational approach in the search for potent
inhibitors against HIV Proteinase, 5 FASEB J. 2606 (1991). cited by
other .
Thomas D. Meek, Inhibitors of HIV-1 Protease, 6 J. Enzyme
Inhibition 65 (1992). cited by other .
Tameo Iwasaki et al. Simultaneous Cleavage of N-Tosyl and S-Benzyl
Groups in Amino Acid and Peptide by Electrolytic Reduction, 50(3)
Bull. Inst. Chem. Res., Kyoto Univ. 220 (1972). cited by other
.
Sigeru Torii et al. Indirect Electrochemical Radical Cyclization of
Bromo Acetals by Cobaloxime(I) as an Electron-Transfer Catalyst, J.
Org. Chem. 1985, 50, 5875-5877. cited by other .
Yasuhiro Kojima et al. Synthesis of Perhydrofuru [2.3-b] furan
Compounds and the Structure-Activity Relationships of the
Antifeeding Active Compounds, Agric. Biol. Chem. 44(4), 855-862,
1980. cited by other .
M. Pezechk et al. A New Route to Perhydro- and Tetrahydro-furo-2,3b
Furans via Radical Cyclisation, Tet. Lett. vol. 27, No. 32 pp.
3715-3718 (1986). cited by other .
Jan Vader et al. The Steroselective Synthesis of Substituted
Furo[2,3b]furans, Tetrahedron, vol. 45, No. 7 pp. 2131-2142 (1989).
cited by other .
Jean Boivin et al. Novel Radical Chain Reactions Based on O-Alkyl
Tin Dithiocarbonates, J. Am. Chem. Soc. 1992, 114, 7909-7910. cited
by other .
Claus Hackmann et al. New Methods for Reductive Free-Radical
Cyclizations of a-Bromoacetals to 2-alkoxytetrahydrofurans with
activated chromium(II)-Acetate, Tetrahedron vol. 49, No. 21, pp.
4559-4574 (1993). cited by other .
Tsutomu Inokuchi et al. Indirect Electrochemical Radical
Cyclization of Bromo Acetals by the Combined use of Cobaloxime and
Sacrificial Electrode, Bull. Chem. Soc. Jpn. 67, 595-598 (1994).
cited by other .
Andrea Vaupel et al. Stereoselective Synthesis of Substituted
Tetrahydrofurans and Butyrolactones by a New Nickel Catalyzed
Carbozincation, Tet. Lett. vol. 35, No. 45 pp. 8349-8352 (1994).
cited by other .
Steven A. Wrighton et al. The Human Hepatic Cytochromes P450
Involved in Drug Metabolism, 22 Critical Rev. Toxicology 1, 1,
(1992). cited by other .
James R. Halpert et al. Contemporary Issues in Toxicology:
Selective Inhibitors of Cytochromes P450, 125 Toxicology &
Applied Pharmacology 163, 163 (1994). cited by other .
J. Gregory Gillum et al, Pharmacokinetic Drug Interactions with
Antimicrobial Agents, 25(6) Clinical Pharmacokinetics 450, 452-53
(1993). cited by other .
Edward King, ABT-538 in Combination Trial, 28 AIDS Treatment Update
1 (1995). cited by other .
Arun K. Ghosh et al. Potent HIV Protease Inhibitors Incorporating
High-Affinity P2-Ligands and (R)-(Hydroxyethylamino)Sulfonamide
Isostere, 8 Bioorganic & Medicinal Chem. Letters 687, 689
(1998). cited by other .
Yasuhiro Koh et al. Novel bis-Tetrahydrofuranylurethane-Containing
Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) With Potent
Activity Against Multi-PI-Resistant Human Immunodeficiency Virus In
Vitro, 47 Antimicrobial Agents and Chemotherapy 3123, 3124 (2003).
cited by other .
Arun K. Ghosh et al. The Development of Cyclic Sulfolanes as Novel
and High-Affinity P.sub.2 Ligands for HIV-1 Protease Inhibitors, J.
Med. Chem. 1994, 37, 1177-1188. cited by other .
Wayne J. Thompson et al. 3'-Tetrahydrofuranylglycine as a Novel,
Unnatural Amino Acid Surrogate for Asparagine in the Design of
Inhibitors of the HIV Protease, J. Am. Chem. Soc. 1993, 115,
801-803. cited by other .
Arun K. Ghosh et al. Darunavir, a conceptually new HIV-1 protease
inhibitor for the treatment of drug-resistant HIV, Bioorganic &
Medicinal Chemistry 15 (2007) 7576-7580. cited by other .
Arun K. Ghosh et al. Chiral Auxiliary Mediated Conjugate Reduction
and Asymmetric Protonation: Synthesis of High Affinity Ligands for
HIV Protease Inhibitors, J. Org. Chem. 1995, 60, 6198-6201. cited
by other .
Arun K. Ghosh et al. Cyclic Sulfolanes as Novel and High Affinity
P.sub.2 Ligands for HIV-1 Protease Inhibitors, J. Med. Chem. 1993,
36, 924-927. cited by other .
Arun K. Ghosh et al. Cyclic Sulfone-3-Carboxamides as Novel
P.sub.2-Ligands for Ro 31/8959 Based HIV-1 Protease Inhibitors,
Bioorganic & Medicinal Chemistry Letters, vol. 5, No. 1, pp.
83-88, 1995. cited by other .
Arun K. Ghosh et al. Highly Stereoselective Reduction of
.alpha.-Keto Esters: Utility of Cis-1-Arylsulfonamido-2-indanols as
Chiral Auxiliaries. Tetrahedron Letters, vol. 36, No. 38, pp.
6811-6814, 1995. cited by other .
Arun K. Ghosh et al. HIV-1 Protease Inhibitors: Synthesis and
Biological Evaluation of Glycopeptidemimetics, Drug Design and
Discovery, 1993, vol. 10, pp. 77-88, 1993. cited by other .
Arun K. Ghosh et al. Potent HIV Protease Inhibitors: The
Development of Tetrahydrofuranylglycines as Novel P.sub.2-Ligands
and Pyrazine Amides as P.sub.3-Ligands, J. Med. Chem. 1993, 36,
2300-2310. cited by other .
Arun K. Ghosh et al. Potent HIV-1 Protease Inhibitors:
Stereoselective Synthesis of a Dipeptide Mimic, J. Org. Chem. 1993,
58, 1025-1029. cited by other .
M. Katharine Holloway et al. A Priori Prediction of Activity for
HIV-1 Protease Inhibitors Employing Energy Minimization in the
Active Site, J. Med. Chem. 1995, 38, 305-317. cited by other .
Arun K. Ghosh et al. Synthesis and Optical Resolution of High
Affinity P.sub.2-Ligands for HIV-1 Protease Inhibitors, Tetrahedron
Letters, vol. 36, No. 4 pp. 505-508, 1995. cited by other .
Arun K. Ghosh et al. Synthetic Studies of Antitumor Macrolide
Laulimalide: Enantioselective Synthesis of the C.sub.3-C.sub.14
Segment by a Catalytic Hetero Diels-Alder Strategy, Tetrahedron
Letters, vol. 38, No. 14, pp. 2427-2430, 1997. cited by other .
V.A. Eagling et al. The Metabolism of Zidovudine by Human Liver
Microsomes in Vitro: Formation of 3'-Amino-3'Deoxythymidine, 48
Biochem. Pharmacology 267-76 (1994). cited by other .
Factual and Legal Basis for Mylan's Paragraph IV Certification(s)
that U.S. Patent Nos. 5,843,946, 6,248,775, 6,037,157 and 6,703,403
are Invalid, Unenforceable and/or Will Not Be Infringed Jun. 20,
2011, (redacted) 148 pages. cited by other .
Factual and Legal Basis for Lupin's Paragraph IV Certification that
U.S. Patent Nos. 5,843,946 and 6,248,775 are Invalid, Unenforceable
and/or Will Not Be Infringed Jun. 21, 2011, (redacted) 85 pages.
cited by other .
Teva Pharmaceuticals USA Inc., "Detailed Statement of the Factual
and Legal Bases of Teva Pharmaceuticals USA Inc.'s Opinion that U.S
Patent Nos. 6,037,157 and 6,703,403 are Invalid, Unenforceable or
not Infringed and Detailed Statement of the Factual and Legal Bases
for Its Opinion that U.S. Patent Nos. 5,843,946; 6,248,775;
7,470,506; and 7,700,645 are Invalid, Unenforceable or Not
Infringed by the Manufacture, Use or Sale of its Darunavir Hydrate
Tablets, Eq. 75 mg Base, Eq. 150 mg Base, Eq. 400 mg Base, and Eq.
600 mg Base," (redacted) Jan. 2011 79 pages. cited by other .
U.S. Appl. No. 08/061,897, filed May 14, 1993, Merck & Co.,
Inc. cited by other .
U.S. Appl. No. 07/345,808. cited by other .
U.S. Appl. No. 08/485,524, filed Jun. 7, 1995, Vazquez et al. cited
by other .
U.S. Appl. No. 07/934,984, filed Aug. 25, 1995, Vazquez et al.
cited by other .
Barry et al., "Protease Inhibitors in Patients with HIV Disease",
Clinical Pharma., 1997, 32(3), 194-209. cited by other .
Darke et al., "Human Immunodeficiency Virus Protease", The Journal
of Biological Chemistry, 1989, 264(4), 2307-2312. cited by other
.
Ghosh et al., "3-Tetrahydrofuran and Pyran Urethanes as
High-Affinity P.sub.2-Ligands for HIV-1 Protease Inhibitors",
Journal of Medicinal Chemistry., 1993, 36(2), 292-294. cited by
other .
Merry et al., "Saquinavir Pharmacokinetics Alone and in Combination
with Ritonavir in HIV-Infected Patients", AIDS, 1997 11(4),
F29-F33. cited by other .
Toyoda et al., "Preparation of Dipeptide Renin Inhibitors", Jan.
29, 1992, CA117:449265. cited by other .
Yun et al. "Oxidation of the antihistaminic drug terfenadine in
human liver microsames. Role of Cytochrome P-450 3A(4) in
N-dealkylation and C-hydroxylation," Drug Metabol. And Dispos.
21(3):403-409, 1993. cited by other .
Lewis et al. "Role of cytochrome P-450 from the human CYP3A gene
family in the potentiation of morpholino doxorubicin by human liver
microsomes," Cancer Res. 52:4379-4384, 1992. cited by other .
Le Blanc et al. "Interaction of anticancer drugs with hepatic
monooxygenase enzymes," Drug Metab. Rev. 20:395-439, 1989. cited by
other .
Robins et al. "HIV Protease Inhibitors: Their Anti-HIV Activity and
Potential Role in Treatment," J. of Acquired Immune Deficiency
Syndromes 6:162-170, 1993. cited by other .
Wlodawer et al. "Structure-based inhibitors of HIV-1 Protease,"
Annual Review of Biochemistry, 62:543-585, 1993. cited by other
.
Fittkau, J. Prakt. Chem. 1973, 315, 1037-1044 (No English
translation available, but for indication of relevance, see col.
14, lines 24-28 of the reissue specification.). cited by other
.
Pauwels et al., "Rapid and Automated Tetrazolium-based Colorimetric
Assay for the Detection of Anti-HIV Compounds", J. Virol. Methods,
1988, 20, 309-321. cited by other .
Hetero Drugs Ltd., "Certificate of Non-Infringement and/or
Invalidity of United States Patent Nos. 5,843,946; 6,037,157;
6,248,775; 6,335,460; 6,703,403; 7,470,506 and 7,700,645", Feb.
2011, 73 pages. cited by other .
Teva Pharmaceuticals USA Inc., "Detailed Statement of the Factual
and Legal Bases of Teva Pharmaceuticals USA Inc.'s Opinion that
U.S. patent Nos. 6,037,157 and 6,703,403 are Invalid, Unenforceable
or not Infringed and Detailed Statement of the Factual and Legal
Bases for it's Opinion that U.S. Patent Nos. 5,843,946; 6,248,775;
7,470,506 and 7,700,645 are Invalid, Unenforceable or Not Infringed
by the Manufacture, Use or Sale of its Darunavir Hydrate Tablets,
Eq. 75 mg Base, Eq. 150 mg Base, Eq. 400 mg Base, and Eq. 600 mg
base", Jan. 2011, 76 pages. cited by other .
Lupin Paragraph IV Letter of Mar. 28, 2012 (Redacted). cited by
other .
Bruce D. Johnson et al. Indinavir Sulfate, in Analytical Profiles
of Drug Substances and Excipients 319-57 (Academic Press 1999).
cited by other .
Howard C. Ansel et al., Pharmaceutical Dosage Forms and Drug
Delivery Systems LippinCott Williams & Wilkins 7.sup.th ed.
1999, p. 296-304, p. 301. cited by other .
John Bauer et al., Ritonavir: An Extraordinary Example of
Conformational Polymorphism, 18 Pharmaceutical Res. 859 (2001).
cited by other .
Michael J. Jozwiakowski, Alteration of the Solid State of the Drug
Substance: Polymorphs, Solvates, and Amorphous Forms, in
Water-Insoluble Drug Formation 525-68 (Rong Liu ed., 2000). cited
by other .
Stephen Byrn et al., Pharmaceutical Solids: A Strategic Approach to
Regulatory Considerations, 12 Pharmaceutical Res. 945 (1995). cited
by other .
ICH Harmonized Tripartite Guideline--Specifications: Test
Procedures and Acceptance Criteria for New Drug Substances and New
Drug Products: Chemical Substances, Q6A (Oct. 6, 1999). cited by
other .
Center for Drug Evaluation and Research, Guideline for Submitting
Supporting Documentation in Drug Applications for the Manufacture
of Drug Substances (Feb. 1987). cited by other .
De Meyer et al., TMC114, A Novel Human Immunodeficiency Virus Type
1 Protease Inhibitor Active Against Protease Inhibitor-Resistant
Viruses, Including a Broad Range of Clinical Isolates, 49
Antimicrobial Agents & Chemotherapy 2314 (Jun. 2005). cited by
other .
Dominique L. N. G. Surleraux et al., Discovery and Selection of
TMC114, a Next Generation HIV-1 Protease Inhibitor, 48 J. Med.
Chem. 1813 (2005). cited by other .
Arun K. Ghosh, Harnessing Nature's Insight: Design of Aspartyl
Protease Inhibitors from Treatment of Drug Resistant HIV to
Alzheimer's Disease, 52 J. Med. Chem. 2163 (2009). cited by other
.
EE Kim et al., Structural Comparison of Clinically Relevant
Inhibitors of the HIV-1 Protease, Tenth Int'l Conf. on AIDS,
Abstract 319A (Aug. 7-12, 1994). cited by other .
Julie C. Adkins & Diana Faulds, Amprenavir, 55 Drugs 837-844,
838 (1998). cited by other .
R.D. Tung et al., Design and Optimization of Potent, Orally Active
HIV Aspartyl Protease Inhibitors, Abstract No. 426A, Tenth Int'l
Conf. AIDS (Aug. 7-12, 1994). cited by other .
Stein, Xth Int'l Conf. on AIDS, 2(9) Int'l Antiviral News 138
(1994). cited by other .
Larder et al., Zidovudine resistance predicted by direct detection
of mutations in DNA from HIV-infected lymphocytes, 5(2) AIDS
137-144 (1991). cited by other .
Schuurman et al. State of the art of genotypic HIV-1 drug
resistance, 10(6) Current Opinion in Infectious Diseases 480-484
(1997). cited by other .
Eron et al. Susceptibility testing by polymerase chain reaction DNA
quantitation: A method to measure drug resistance of human
immunodeficiency virus type I isolates, 89 Proc. Nat'l Acad. Sci.
USA 3241 (1992). cited by other .
Virco HIV Drug Resistance Tests Will be Commercialized by LabCorp.,
PR Newswire, Financial News (Apr. 29, 1998), 3 pages. cited by
other .
LabCorp/Virco HIV Resistance Testing, PR Newswire, Financial News
(Jun. 30, 1998), 2 pages. cited by other .
Japour, et al., Prevalence and Clinical Significance of Zidovudine
Resistance Mutations in Human Immunodeficiency Virus Isolated from
Patients after Long-Term Zidovudine Treatment, 171 J. Infectious
Diseases 1172-1179 (1995). cited by other .
Roberts, Drug-resistance Patterns of Saquinavir and Other HIV
Proteinase Inhibitors, 9(suppl 2) AIDS S27 (1995). cited by other
.
Roberts, Progress of saquinavir (Ro 31/8959) in clinical trials.
Int. Antiviral News 1995, 3:2-3. cited by other .
Levin, New Protease Drug Shows Early Promise, 27 Bulletin of
Experimental Treatments for AIDS 27, 33 (1995). cited by other
.
Defendants Lupin Limited's Lupin Pharmaceuticals, Inc.'s, Mylan
Pharmaceuticals Inc.'s and Mylan Inc.'s Joint Invalidity
Contentions Pursuant to Local Patent Rule 3.6(b), 178 pages, Nov.
18, 2011. cited by other .
Teva Pharmaceuticals USA, Inc.'s and Teva Pharmaceutical
Industries, Ltd.'s Invalidity Contentions Under Local Patent Rules
3.3 and 3.6, 123 pages, Nov. 18, 2011. cited by other .
Ghosh, A.K. et al., Structure-Based Design of HIV-1 Proteinase
Inhibitors: Replacement of Two Amides and a 10.pi.-Aromatic System
by a Fused Bis-tetrahydrofuran. J. Med Chem. 37, 1994, 2506-2508.
cited by other .
Response to Defendants Teva Pharmaceuticals USA, Inc. and Teva
Pharmaceutical Industries, Ltd.'s Invalidity Contentions for U.S.
Patent No. 6,248,775 Pursuant to Local Patent Rules 3.6(i) and
3.4A, Mar. 29, 2012 92 pages. cited by other .
Grobelny, D., et al., Selective Phosphinate Transition-State
Analogue Inhibitors of the Protease of Human Immunodeficiency
Virus, Biochem. Biophys. Res. Commun. 169:1111-16 (1990). cited by
other .
Stowasser, B., et al., New Hybrid Transition State Analog
Inhibitors of HIV Protease with Peripheric C2-Symmetry, Tetrahedron
Lett. 33:6625 (1992). cited by other .
Ikeda, S. et al. .psi.[PO.sub.2-CH.sub.2N.sup.+], A New Amide Bond
Replacement: Potent Slow-Binding Inhibition of the HIV Protease, J.
Am. Chem. Soc. 114:7604 (1992). cited by other .
Mimoto, T., et al., Kynostatin (KNI)-227 and -272, highly potent
anti-HIV agents: Conformationally constrained tripeptide inhibitors
of HIV protease containing allophenylnorstatinem, Chem. Pharm.
Bull. 40:2251 (1992). cited by other .
Tam, T.F., et al., Intriguing Structure-Activity Relations Underlie
the Potent Inhibition of HIB Protease by Norstatine-Based Peptides,
J. Med. Chem. 35:1318 (1992). cited by other .
Sham, H.L. et al., Synthesis of (2S, 5S,
4R)-2,5-diamino-3,3-difluoro-1,6-diphenylhydroxyhexane: The Core
Unit of a Potent HIB Proteinase Inhibitor, J. Chem. Soc., Chem.
Commun. 110 (1991). cited by other .
Schirlin, D., et al., Short and Unexpectedly Potent Difluorostatone
Type Inhibitors of HIV-1 Protease, Bioorg. Med. Chem. Lett.,
3(2):253, 255 (1993). cited by other .
Schirlin, D., et al., Beneficial Replacement of the P.sub.1
Phenylalanine Side Chain in HIV-1 Protease Inhibitors of the
Difluorstatone Type, Bioorg. Med. Chem. Lett., 4(2):241 (Jan.
1994). cited by other .
Craig, J.C., et al. Antiviral properties of Ro 31-8959, an
inhibitor of human immunodeficiency virus (HIV) proteinase,
Antiviral Research 16(4):295 (1991). cited by other .
Craig, J.C., et al., Effects of a specific inhibitor of HIV
protease (Ro 31-8959) on virus maturation in a chronically infected
promonocytic cell line (U1), Antiviral Chemistry &
Chemotherapy, 2:181 (1991). cited by other .
Nitschko, H., et al., Long term treatment of HIV-infected MT-4
cells in culture with HIV proteinase inhibitor Ro 31-8959 leads to
complete cure of infections, Antiviral Chemistry &
Chemotherapy, 5:236 (Jul. 1994). cited by other .
Johnson, V.A., et al., Human Immunodeficiency Virus Type 1 (HIV-1)
Inhibitory Interactions between Protease Inhibitor Ro 31-8959 and
Zidovudine, 2',3'-dideoxycytidine, or Recombinant
Interferon-.alpha.A aginst Zidovudine-Sensitive or Resistant HIV-1
in vitro, J. Infectious Diseases, 166(5):1143 (1992). cited by
other .
Craig, J.C., et al., Antiviral synergy between inhibitors of HIV
proteinase and reverse transcriptase. Antiviral Chem. Chemother.
4:161, 161-63 (1993). cited by other .
Vacca, J.P., et al., L-735,524: An orally bioavailable human
immunodeficiency virus type 1 protease inhibitor, Proc. Nat'l Acad.
Sci. 91(9):4096, 4099 (Apr. 1994). cited by other .
Fischl, M.A. et al., Combination antiviral therapy for HIV
infection, Hospital Practice 29(1):43, 43-44 (Jan. 1994). cited by
other .
Shaw, T.M. et al., Tolerability and Pharmacokinetics of Single Oral
Doses of Ro 31-8959, an HIV Proteinase Inhibitor, Br. J. Clin.
Pharmacol. 34:166P-167P (1992). cited by other .
Williams, P.E.O., et al., Disposition and Bioavailability of the
HIV-Proteinase Inhibitor, Ro 31-8959, After Single Doses in Healthy
Volunteers, Br. J. Clin. Pharmacol. 31:155P-156P (1992). cited by
other .
Muirhead, G.J., et al., Pharmacokinetics of the HIV-proteinase
Inhibitor, Ro 318959, After Single and Multiple Oral Doses in
Healthy Volunteers, Br. J. Clin. Pharmacol. 34:170P-171P (1992).
cited by other .
Tucker, T.J., et al., A Series of Potent HIV-1 protease inhibitors
containing a hydoxyethyl secondary amine transition state isostere:
Synthesis, enzyme inhibition, and antiviral activity, J. Med. Chem.
35:2525 (1992). cited by other .
Swain, A.L. et al., X-ray crystallographic structure of a complex
between a synthetic protease of human immunodeficiency virus 1 and
a substrate-based hydroxyethylamine inhibitor, Proc. Nat'l Acad.
Sci., 87:8805 (1990). cited by other .
Getman, D., et al. Discovery of a Novel Class of Potent HIV-1
Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere,
J. Med. Chem. 36:288-91 (1993). cited by other .
Dreyer, G.D., et al., Hydroxyethylene Isostere Inhibitors of Human
Immunodeficiency Virus-1 Protease: Structure-Activity Analysis
Using Enzyme Kinetics, X-ray Crystallography, and Infected T-Cell
Assays, Biochemistry, 31:6646, 6647 (1992). cited by other .
deSolms, S. J. et al., Design and Synthesis of HIV Protease
Inhibitors: Variations of the Carboxyterminus of the HIV Protease
Inhibitor L-682,679, J. Med. Chem. 34:2852, 2852-53 (1991). cited
by other .
Lingham, R. B., et al., HIV-1 protease inhibitory activity of
L-694,746, a novel metabolite of L-689,502, Biochem. Biophys. Res.
Commun. (1991). cited by other .
Lambert, D.M., et al,, Human Immunodeficiency Virus Type 1 Protease
Inhibitors Irreversibly Block Infectivity of Purified Virions from
Chronically Infected Cells, Amtimicrob. Agents Chemother. 36:982,
983 (1992). cited by other .
Lambert D.M., et al. Synergistic drug interactions of an HIV-1
protease inhibitor with AZT in different in vitro models of HIV-1
infection. Antiviral Res. 21:327-342 (1993). cited by other .
Murthy, K.H.M., et al., The Crystal Structures of 2.2 .ANG.
Resolution of Hydroxyethylene-based Inhibitors Bound to Human
Immunodeficiency Virus Type 1 Protease Show That The Inhibitors are
present in two distinct orientations, J. Biol. Chem. 267:22770
(1992). cited by other .
Kempf, D., et al., Structure-Based, C.sub.2 Symmetric Inhibitors of
HIV Protease, J. Med. Chem. 33:2687-89 (1990). cited by other .
Kempf, D. et al. Symmetry-Based Inhibitors of HIV Protease:
Structure-Activity Studies of Acylated
2,4-Diamino-1,5-diphenyl-3-hydroxypentane and
2,5-diamino-1,6-diphenylhexane-3,4-diol, J. Med. Chem. 36:320-330
(1993). cited by other .
Bone, R., et al., X-ray crystal structure of the HIV protease
complex with L-400,417, an inhibitor with pseudo C.sub.2 symmetry,
J. Am. Chem. Soc., 113:9382 (1991). cited by other .
Kageyama, S. et al., In vitro inhibition of human immunodeficiency
virus (HIV) type 1 replication by C2 symmetry-based HIV protease
inh bitors as single agents or in combinations, Antimicrob. Agents
Chemother. 36:926 (1992). cited by other .
Hosur, M.V. et al., Influence of Stereochemistry on Activity and
Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1
Protease, J. Am. Chem. Soc. 116:847 (Feb. 1994). cited by other
.
Babine, R. E. et al. The Use of HIV-1 protease structure in
inhibitor design, Bioorg. Med. Chem. Lett. 2:541 (1992). cited by
other .
Humber, D. C. et al., Penicillin-derived C2-symmetric dimers as
novel inhibitors of HIV-1 proteinase, J. Med. Chem. 35:3080 (1992).
cited by other .
Wonacott, A., et al., A series of Penicillin-Derived C2-Symmetric
Inhibitors of HIV-1 Proteinase: Structural and Modeling Studies, J.
Med. Chem, 36:3113 (1993). cited by other .
Sham, D.A., et al., Facile-Synthesis of Potent HIV-1 Protease
Inhibitors Containing a Novel Pseudo-symmetric Dipeptide Isostere,
J. Chem. Soc., Chem. Commun. 1052-53 (1993). cited by other .
Lam, P.Y.S. et al., Rational design of potent, bioavailable,
nonpeptide cyclic ureas as HIV protease inhibitors, Science 263:380
(Jan. 1994). cited by other .
Otto, M.J., et al., In Vitro Anti-Human Immunodeficiency Virus
(HIV) Activity of XM323, a Novel HIV Protease Inhibitor,
Antimicrobial Agents and Chemo. 37(12):2606-11 (Dec. 1993). cited
by other .
Rayner, M.M. et al., DMP 323, a nonpeptide cyclic urea inhibitor of
human immunodeficiency virus (HIV) protease, specifically and
persistently blocks intracellular processing of HIV gag
polyprotein, Antimicrob. Agents and Chemo. 38:1635 (1994). cited by
other .
1 Burger's Medicinal Chemistry, 462-67 (Manfred E. Wolff, ed.,
4.sup.th ed. 1980). cited by other .
National Cancer Institute, Bioassay of Aniline Hydrochloride for
Possible Carcinogenicity, Technical Reports Series No. 130,
Department of Health, Education, and Welfare, 1978. cited by other
.
NCI/NTP, Ashby, J. & Tennant, R.W., Chemical structure,
Salmonella mutagenicity and extent of carcinogenicity as indicators
of genotoxic carcinogenesis among 222 chemicals tested in rodents
by the U.S. NCI/NTP, Mutation Research 204:17 (1988). cited by
other .
Ashby, J. et al., Classification according to chemical structure,
mutagenicity to Salmonella and level of carcinogenicity of a
further 42 chemicals tested for carcinogenicity by the U.S.
National Toxicology Program, Mutation Research, 223:73 (1989).
cited by other .
Ashby, J. & Tennant, R.W., Definitive relationships among
chemical structure, carcinogenicity, and mutagenicity for 301
chemicals tested by the U.S. NTP, Mutation Research, 257:229
(1991). cited by other .
Ashby, J. & Paton, D., The influence of chemical structure on
the extent and sites of carcinogenesis from 522 rodent carcinogens
and 55 different human carcinogen exposures, Mutation Research,
286:3 (1993). cited by other .
U.S. Department of Health and Human Services, General Principles
for Evaluating the Safety of Compounds Used in Food-Producing
Animals, Appendix I (Jul. 1994). cited by other .
World Health Organization, Carbamate Pesticides: A General
Introduction, Environmental Health Criteria 64, (1986). cited by
other .
Mount, M.E. et al., Carbaryl residues in tissues and cholinesterase
activities in brain and blood of rats receiving carbaryl,
Toxicology and Applied Pharmacology, 58:282 (1981). cited by other
.
Ray, S.K. & Poddar, M.K. Carbaryl-induced elevation of
corticosterone level and cholinergic mechanism, Bioscience Reports,
3:973, 975-76 (1983). cited by other .
Ferguson, P.W., et al., Carbofuran metabolism and toxicity in rats,
Fund. Appl. Toxicol., 4:14 (1984). cited by other .
Shear, N. H. et al. Differences in Metabolism of Sulfonamides
Predisposing to Idiosyncratic Toxicity, Ann. Int. Med. 105:179
(1986). cited by other .
Duncan, C. Sulfonamide Cross-Allergenicity--Answers to Common
Questions, Hosp. Pharmacy 24:666 (1989). cited by other .
2 Burger's Medicinal Chemistry, 1-40 (Manfred E. Wolff, ed.,
4.sup.th ed. 1980). cited by other .
Rieder, M.J. et al. Synthesis and in vitro toxicity of
hydroxylamine metabolites of sulfonamides, J. Pharm. Exp.
Therapeutics, 244:724 (1988). cited by other .
Rieder, M.J. et al., Prominence of slow acetylator phenotype among
patients with sulfonamide hypersensitivity reactions, Clin.
Pharmacol. Ther. 39:13 (1991). cited by other .
Shear, N. H. & Spielberg, S.P. In vitro evaluation of a toxic
metabolite of sulfadiazine, Can. J. Physiol. and Pharmacol. 63:1370
(1985). cited by other .
Cribb, A.E. & Spielberg, S.P. SUlfamethoxazole is metabolized
to the hydroxylamine in humans, Clin. Pharmacol. &
Therapeutics, 51:522 (May 1992). cited by other .
FDA Drug Bulletin, 14:5 (1984). cited by other .
Carr, A. et al., Clinical and laboratory markers of
hypersensitivity to trimethoprim-sulfamethoxazole in patients with
Pneumocystis carinii pneumonia and AIDS, J. Infec. Dis. 167:180
(1993). cited by other .
Pezechk, M. et al., A new route to perhydro- and
tetrahydro-furo-2,3-b furans via radical cyclisation, Tetrahedron
Letters 27:3715 (1986). cited by other .
Design of Prodrugs (Hans Bundgaard, ed. 1985). cited by other .
Pro-Drugs as Novel Drug Delivery Systems (Higuchi, T. & Stella,
V. eds. 1975). cited by other .
Beauchamp, L.M. et al., Amino acid ester prodrugs of acyclovir,
Antiviral Chem. & Chemotherapy 3:157 (1992). cited by other
.
Canonico, P.G., et al. Carrier-Mediated Delivery of Antiviral
Agents in Advances in Virus Research, 35:271 (1986). cited by other
.
Vazquez et al., Inhibitors of HIV-1 Protease Containing the Novel
and Potent (R)-(Hydroxyethyl)sulfonamide Isostere, J. Med. Chem.
38(4), 581 (1995). cited by other .
Plaintiff's Response to Defendants Teva Pharmaceuticals USA Inc.'s
and Teva Pharmaceutical Industries Ltd.'s Invalidity Contentions
for U.S. Patent No, 5,842,946 Pursuant to local Patent Rule 3.6(i)
and 3.4A, Mar. 29, 2012, 21 pages. cited by other .
Response to Defendants Lupin Limited's, Lupin Pharmaceuticals,
Inc.'s, Mylan Pharmaceuticals Inc.'s and Mylan Inc.'s Joint
Invalidity Contentions for U.S. Patent No. 5,843,946 Pursuant to
Local Patent Rules 3.6(i) and 3.4A, Mar. 29, 2012, 99 pages. cited
by other .
Szelke, M., et al., Potent new inhibitors of human renin, Nature,
299:555 (1982). cited by other .
Corvol., P. et al., Human renin inhibitor peptides, Hypertension
16:1, 3 (1990). cited by other .
Response to Defendants Lupin Limited's, Lupin Pharmaceuticals,
Inc.'s, Mylan Pharmaceuticals Inc.'s and Mylan Inc's Joint
Invalidity Contentions for U.S. Patent No. 6,248,775 Pursuant to
Local Patent Rules 3.6(i) and 3.4A, Mar. 29, 2012, 96 pages. cited
by other.
|
Primary Examiner: Wilson; James O
Assistant Examiner: Sackey; Ebenezer
Attorney, Agent or Firm: Connolly Bove Lodge & Hutz
LLP
Parent Case Text
RELATED APPLICATION
This .Iadd.is an .Iaddend.application .Iadd.to reissue U.S. Pat.
No. 6,060,476, which .Iaddend.is a continuation in part application
of co-owned .[.and.]. PCT/US93/07814, filed Aug. 24, 1993, which is
a continuation in part application of co-owned U.S. patent
application Ser. No. 07/934,984.Iadd., .Iaddend.filed Aug. 25,
1992, now abandoned. .Iadd.This application is also related to U.S.
patent application Ser. No. 11/788,947, which is an application to
reissue U.S. Pat. No. 5,968,942..Iaddend.
Claims
What is claimed is:
.[.1. A compound represented by the formula: ##STR00495## or a
pharmaceutically acceptable salt thereof wherein R.sup.2 is an
alkyl, aryl, cycloalkyl, cycloalkylalkyl or aralkyl radical, which
radical is optionally substituted with a radical selected from the
group consisting of alkyl, halo, nitro, cyano, CF.sub.3,
--OR.sup.9, and --SR.sup.9 radicals, wherein R.sup.9 is hydrogen or
alkyl radicals; R.sup.3 is alkyl, haloalkyl, alkenyl, alkynyl,
hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfonylalkyl,
cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl,
heterocycloalkylalkyl, aryl, aralkyl or heteroaralkyl radicals;
R.sup.4 is heterocycloalkyl, heteroaryl or aryl radicals; Y is O or
S; and A is heterocycloalkyl, heterocycloalkoxy,
heterocycloalkylalkyl, heterocycloalkylalkoxy, heteroaralkyl,
heteroaralkoxy, heteroaryloxy or heteroaryl radicals; and wherein
alkyl, alone or in combination, is a straight-chain or
branched-chain alkyl radical containing 1 to 8 carbon atoms;
alkenyl, alone or in combination, is a straight-chain or
branched-chain hydrocarbon radial having at least one double bond
and containing 2 to 8 carbon atoms; alkynyl, alone or in
combination, is a straight-chain or branched chain hydrocarbon
radical having at least one triple bond and containing 2 to 10
carbon atoms; aryl, alone or in combination, is an unsubstituted
phenyl or naphthyl radical or a phenyl or naphthyl radical
substituted with alkyl, alkoxy, halogen, hydroxy, amino,
alkylamino, dialkylamino, nitro, cyano, carboxy, alkoxycarbonyl,
amido, alkylamido, dialkylamido, trifluoromethyl, methylthio,
methylsulfinyl or methylsulfonyl radicals; cycloalkyl, alone or in
combination, is a saturated or partially saturated monocyclic,
bicyclic or tricyclic alkyl radical wherein each cyclic moiety
contains 3 to 8 carbon atoms; heterocycloalkyl, alone or in
combination, is a monocyclic, bicyclic or tricyclic heterocycle
radical having 1-4 nitrogen, nitrogen oxide, oxygen, sulphur,
sulfone or sulfoxide heteroatom ring members, optionally benz-fused
and optionally substituted on one or more carbon atoms by halogen,
alkyl, alkoxy, hydroxy, oxo, aryl or aralkyl radicals, or on a
secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl,
alkanoyl, phenyl or phenylalkyl radicals; and heteroaryl, alone or
in combination, is an aromatic heterocycloalkyl, optionally
substituted with respect to aryl and heterocycloalkyl
radicals..].
.[.2. Compound of claim 1 or a pharmaceutically acceptable salt
thereof wherein R.sup.2 represents alkyl, cycloalkylalkyl or
aralkyl radicals, which radicals are optionally substituted with
alkyl, halogen or --OR.sup.9 radicals, wherein R.sup.9 represents
hydrogen or alkyl radicals; and R.sup.3 is alkyl, alkenyl, alkynyl,
hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfonylalkyl,
cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, aryl, aralkyl
or heteroaralkyl radicals; wherein heterocycloalkyl, alone or in
combination, is a 5-6 ring membered monocyclic heterocycle radical
having 1-4 nitrogen, nitrogen oxide, oxygen, sulphur, sulfone or
sulfoxide heteroatom ring members, optionally benz-fused and
optionally substituted on one or more carbon atoms by halogen,
alkyl, alkoxy, hydroxy, oxo, aryl or aralkyl radicals, or on a
secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl,
alkanoyl, phenyl or phenylalkyl radicals; and heteroaryl, alone or
in combination, is an aromatic heterocycloalkyl, optionally
substituted with respect to aryl and heterocycloalkyl
radicals..].
.[.3. Compound of claim 2 or a pharmaceutically acceptable salt
thereof wherein A is heterocycloalkyl, heterocycloalkoxy,
heterocycloalkylalkyl, heteroaralkoxy or heteroaryl radicals;
R.sup.3 represents alkyl, cycloalkyl or cycloalkylalkyl radicals;
and R.sup.4 is heterocycloalkyl or aryl radicals; wherein alkyl,
alone or in combination, is a straight-chain or branched-chain
hydrocarbon radical containing from 1-5 carbon atoms; alkenyl,
alone or in combination, is a straight-chain or branched-chain
hydrocarbon radical having at least one double bond and containing
from 2-5 carbon atoms; alkynyl, alone or in combination, is a
straight-chain or branched-chain hydrocarbon radical having at
least one triple bond and containing from 2-5 carbon atoms;
heterocycloalkyl, alone or in combination, is a 5-6 ring membered
heterocycle or a benzfused 5-6 ring membered heterocycle having one
or two nitrogen, nitrogen oxide, oxygen, sulphur, sulfone or
sulfoxide heteroatoms; and heteroaryl means an aromatic 5-6 ring
membered heterocycle or an aromatic benzfused 5-6 ring membered
heterocycle having one or two nitrogen, nitrogen oxide, oxygen,
sulphur or sulfone heteroatoms..].
.[.4. Compound of claim 3 or a pharmaceutically acceptable salt
thereof wherein A is heterocycloalkyl or heterocycloalkoxy
radicals; R.sup.2 represents alkyl, cycloalkylalkyl or aralkyl
radicals; R.sup.3 represents alkyl, cycloalkyl or cycloalkylalkyl
radicals; R.sup.4 is an aryl radical; and Y is O; wherein
heterocycloalkyl, alone or in combination, is a 5-6 ring membered
heterocycle having an oxygen, sulphur, sulfone or sulfoxide
heteroatom..].
.[.5. Compound of claim 4 or a pharmaceutically acceptable salt
thereof wherein A is heterocycloalkyl or heterocycloalkoxy
radicals; R.sup.2 represents butyl, benzyl, cyclohexylmethyl or
2-naphthylmethyl radicals; R.sup.3 represents isobutyl, isoamyl,
cyclohexyl, cyclohexylmethyl, n-butyl or n-propyl radicals; and
R.sup.4 is phenyl, methoxyphenyl, cyanophenyl, chlorophenyl,
hydroxyphenyl, nitrophenyl, fluorophenyl or aminophenyl radical;
wherein heterocycloalkyl, alone or in combination, is a 5-6 ring
membered heterocycle having an oxygen, sulphur, sulfone or
sulfoxide heteroatom..].
.[.6. Compound of claim 2 or a pharmaceutically acceptable salt
thereof wherein R.sup.2 is butyl, cyclohexylmethyl, benzyl,
4-fluorobenzyl or naphthylmethyl radicals; R.sup.3 is methyl,
ethyl, propyl, butyl, pentyl, hexyl, iso-butyl, iso-amyl,
3-methoxypropyl, 3-methylthiopropyl, 4-methylthiobutyl,
4-methylsulfonylbutyl, 2-(1-morpholino)ethyl, 4-hydroxybutyl,
allyl, propargyl, cyclohexylmethyl, cyclopropylmethyl, phenyl,
benzyl, 4-fluorobenzyl, 4-methoxybenzyl, 1-phenylethyl,
2-phenylethyl, naphthylmethyl, 3-pyridylmethyl or 4-pyridylmethyl
radicals; R.sup.4 is phenyl, naphthyl, chlorophenyl, fluorophenyl,
hydroxyphenyl, methylphenyl, methoxyphenyl, ethoxyphenyl,
methylthiophenyl, methylsulfinylphenyl, methylsulfonylphenyl,
acetamidophenyl, methoxycarbonylphenyl, aminophenyl,
dimethylaminophenyl, nitrophenyl, trifluoromethylphenyl or thienyl
radicals; Y is O; and A is quinolinyl, indolyl, pyridyl,
methylpyridyl, furanyl, oxazolyl, thiazolyl, pyridylmethoxy,
hydroxypyridylmethoxy, aminopyridylmethoxy, pyrimidinylmethoxy,
N-oxo-pyrimidinylmethoxy, thiazolylmethoxy, tetrahydrothiophenoxy,
1,1-dioxotetrahydrothiophenoxy or tetrahydrofuranoxy
radicals..].
.[.7. A compound of claim 1 which is Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)(2-methylpropyl)amino]-1S-(phenyl-
methyl)propyl-, 3(S)-1,1-dioxotetrahydrothiophen-3-yl-ester;
Carbamic acid,
[2R-hydroxy-3-[(4-methoxyphenylsulfonyl)(2-methylpropyl)amino]-1S-(-
phenylmethyl)propyl-, 3(S)-1,1-dioxotetrahydrothiophen-3-yl-ester;
Carbamic acid,
[2R-hydroxy-3-[(4-methoxyyphenylsulfonyl)(2-methylpropyl)amino]-1S-(pheny-
lmethyl)propyl-, 3-S-tetrahydrothiophen-3-yl-ester; Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)(2-methylpropyl)amino]-1S-(phenyl-
methyl)propyl-, 3-S-tetrahydrothiophen-3-yl-ester; Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)(2-methylpropyl)amino]-1S-(phenyl-
methyl)propyl-, 3-S-tetrahydrofuran-3-yl-ester; Carbamic acid,
[2R-hydroxy-3-[(4-methoxyphenylsulfonyl)(2-methylpropyl)amino]-1S-(phenyl-
methyl)propyl-, 3-S-tetrahydrofuran-3-yl-ester; Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 5-(thiazolyl)methyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 5-(thiazolyi)methyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-aminopyridyl)methyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-aminopyridyl)methyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-hydroxypyridyl)methyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 5-pyrimidyimethyl ester; 4-Pyridinecarboxamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)
sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]; Carbamic
acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-pyridylmethyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-pyridylmethyl ester, N-oxide; Carbamic acid,
[2R-hydroxy-3-[[phenylsulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)pr-
opyl]-, 3-pyridylmethyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 4-pyridylmethyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 4-pyridylmethyl ester, N-oxide; Carbamic acid,
[2R-hydroxy-3-[[(4-chlorophenyl)sulfonyl](2-methylpropyl)amino]-1S-(pheny-
lmethyl)propyl]-, 3-pyridylmethyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenyl-
methyl)propyl]-, 3-pyridylmethyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-1S-(pheny-
lmethyl)propyl]-, 3-pyridylmethyl ester; Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-pyridylmethyl ester; or Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 5-pyrimidylmethyl ester..].
8. A pharmaceutical composition comprising a compound of claim
.[.1.]. .Iadd.13 .Iaddend.and a pharmaceutically acceptable
carrier.
.[.9. The compound of claim 1 wherein said heterocycloalkyl or
heteroaryl is selected from optionally substituted pyrrolidinyl,
piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl,
imidazolyls, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl,
thienyl, triazolyl, oxazolyl, thiazolyl, indolyls, quinolynyls,
isoquinolinyls, tetrahydroquinolinyls,
1,2,3,4-tetrahydroisoquinolinyls, quinoxalinyl, .beta.-carbolinyl,
2-benzofurancarbonyl, and benzimidazolyls radicals..].
.[.10. A compound represented by the formula: ##STR00496## or a
pharmaceutically acceptable salt thereof wherein R.sup.2 is an
aralkyl radical; R.sup.3 is alkyl; R.sup.4 is an aryl radical; Y is
O; and A is a 5-membered ring containing one oxygen or one sulfur
atom..].
.[.11. Compound of claim 1 wherein said heterocycloalkyl is a 5-6
ring membered monocyclic, heterocycle radical having 1-4 nitrogen,
nitrogen oxide, oxygen, sulphur, sulfone or sulfoxide heteroatom
ring members, optionally benzfused and optionally substituted on
one or more carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo
aryl or aralkyl radicals, or on a secondary nitrogen atom by
hydroxy alkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl
radicals, and said heteroaryl is an aromatic heterocycloalkyl
optionally benzfused and optionally substituted..].
.[.12. Compound of claim 11 wherein said heterocycloalkyl is a 5-6
ring membered heterocycle or a benzfused 5-6 ring membered
heterocycle having one or two nitrogen, nitrogen oxide, oxygen,
sulfur, sulfone or sulfoxide heteroatoms; and said heteroaryl is an
aromatic 5-6 ring membered heterocycle or an aromatic benzfused 5-6
ring membered heterocycle having one or two nitrogen, nitrogen
oxide, oxygen sulphur or sulfone heteroatoms..].
.Iadd.13. A compound represented by the formula ##STR00497## or a
pharmaceutically acceptable salt thereof wherein R.sup.2 is an
aralkyl radical; R.sup.3 is an alkyl radical; R.sup.4 is a
heterocycloalkyl or an aryl radical; Y is O; and A is a
heterocycloalkoxy radical; wherein alkyl, alone or in combination,
is a straight-chain or branched-chain alkyl radical containing 1 to
8 carbon atoms; aryl, alone or in combination, is a phenyl radical
optionally substituted with an amino radical; and heterocycloalkyl,
alone or in combination, is a bicyclic heterocycle radical having
1-4 oxygen heteroatom ring members..Iaddend.
.Iadd.14. The compound of claim 13 wherein R.sup.2 is unsubstituted
phenylalkyl..Iaddend.
.Iadd.15. The compound of claim 13 wherein R.sup.2 is
benzyl..Iaddend.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to retroviral protease inhibitors
and, more particularly, relates to novel compounds and a
composition and method for inhibiting retroviral proteases. This
invention, in particular, relates to sulfonamide-containing
hydroxyethylamine protease inhibitor compounds, a composition and
method for inhibiting retroviral proteases such as human
immunodeficiency virus (HIV) protease and for treating a retroviral
infection, e.g., an HIV infection. The subject invention also
relates to processes for making such compounds as well as to
intermediates useful in such processes.
2. Related Art
During the replication cycle of retroviruses, gag and gag-pol gene
products are translated as proteins. These proteins are
subsequently processed by a virally encoded protease (or
proteinase) to yield viral enzymes and structural proteins of the
virus core. Most commonly, the gag precursor proteins are processed
into the core proteins and the pol precursor proteins are processed
into the viral enzymes, e.g., reverse transcriptase and retroviral
protease. It has been shown that correct processing of the
precursor proteins by the retroviral protease is necessary for
assembly of infectious virons. For example, it has been shown that
frameshift mutations in the protease region of the pol gene of HIV
prevents processing of the gag precursor protein. It has also been
shown through site-directed mutagenesis of an aspartic acid residue
in the HIV protease that processing of the gag precursor protein is
prevented. Thus, attempts have been made to inhibit viral
replication by inhibiting the action of retroviral proteases.
Retroviral protease inhibition may involve a transition-state
mimetic whereby the retroviral protease is exposed to a mimetic
compound which binds to the enzyme in competition with the gag and
gag-pol proteins to thereby inhibit replication of structural
proteins and, more importantly, the retroviral protease itself. In
this manner, retroviral replication proteases can be effectively
inhibited.
Several classes of compounds have been proposed, particularly for
inhibition of proteases, such as for inhibition of HIV protease.
Such compounds include hydroxyethylamine isosteres and reduced
amide isosteres. See, for example, EP O 346 847; EP O 342,541;
Roberts et al, "Rational Design of Peptide-Based Proteinase
Inhibitors, "Science, 248, 358 (1990); and Erickson et al, "Design
Activity, and 2.8.ANG. Crystal Structure of a C.sub.2 Symmetric
Inhibitor Complexed to HIV-1 Protease," Science, 249, 527
(1990).
Several classes of compounds are known to be useful as inhibitors
of the proteolytic enzyme renin. See, for example, U.S. Pat. No.
4,599,198; U.K. 2,184,730; G.B. 2,209,752; EP O 264 795; G.B.
2,200,115 and U.S. SIR H725. Of these, G.B. 2,200,115, GB
2,209,752, EP O 264,795, U.S. SIR H725 and U.S. Pat. No. 4,599,198
disclose urea-containing hydroxyethylamine renin inhibitors. EP 468
641 discloses renin inhibitors and intermediates for the
preparation of the inhibitors, which include sulfonamide-containing
hydroxyethylamine compounds, such as
3-(t-butoxycarbonyl)amino-cyclohexyl-1-(phenylsulfonyl)amino-2(5)-butanol-
. G.B. 2,200,115 also discloses sulfamoyl-containing
hydroxyethylamine renin inhibitors, and EP 0264 795 discloses
certain sulfonamide-containing hydroxyethylamine renin inhibitors.
However, it is known that, although renin and HIV proteases are
both classified as aspartyl proteases, compounds which are
effective renin inhibitors generally cannot be predicted to be
effective HIV protease inhibitors.
BRIEF DESCRIPTION OF THE INVENTION
The present invention is directed to virus inhibiting compounds and
compositions. More particularly, the present invention is directed
to retroviral protease inhibiting compounds and compositions, to a
method of inhibiting retroviral proteases, to processes for
preparing the compounds and to intermediates useful in such
processes. The subject compounds are characterized as
sulfonamide-containing hydroxyethylamine inhibitor compounds.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided a
retroviral protease inhibiting compound of the formula:
##STR00001## or a pharmaceutically acceptable salt, prodrug or
ester thereof wherein: R represents hydrogen, alkoxycarbonyl,
aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,
aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,
heterocyclylcarbonyl, heterocyclyloxycarbonyl,
heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, alkyl,
alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl,
heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and
mono- and disubstituted aminocarbonyl and mono- and disubstituted
aminoalkanoyl radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or
where said aminocarbonyl and aminoalkanoyl radicals are
disubstituted, said substituents along with the nitrogen atom to
which they are attached form a heterocycloalkyl or heteroaryl
radical; R' represents hydrogen, radicals as defined for R.sup.3 or
R''SO.sub.2-wherein R'' represents radicals as defined for R.sup.3;
or R and R' together with the nitrogen to which they are attached
represent heterocycloalkyl and heteroaryl radicals; R.sup.1
represents hydrogen, --CH.sub.2SO.sub.2NH.sub.2,
--CH.sub.2CO.sub.2CH.sub.3, --CO.sub.2CH.sub.3, --CONH.sub.2,
--CH.sub.2C(O)NHCH.sub.3, --C(CH.sub.3).sub.2(SH),
--C(CH.sub.3).sub.2(SCH.sub.3), --C(CH.sub.3).sub.2(S[O]CH.sub.3),
--C(CH.sub.3).sub.2(S[O].sub.2CH.sub.3), alkyl, haloalkyl, alkenyl,
alkynyl and cycloalkyl radicals, and amino acid side chains
selected from asparagine, S-methyl cysteine and the sulfoxide (SO)
and sulfone (SO.sub.2) derivatives thereof, isoleucine,
allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine,
ornithine, histidine, norleucine, glutamine, threonine, glycine,
allothreonine, serine, O-alkyl serine, aspartic acid, beta-cyano
alanine and valine side chains; R.sup.1' and R.sup.1''
independently represent hydrogen and radicals as defined for
R.sup.1, or one of R.sup.1' and R.sup.1'', together with R.sup.1
and the carbon atoms to which R.sup.1, R.sup.1' and R.sup.1'' are
attached, represent a cycloalkyl radical; R.sup.2 represents alkyl,
aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which
radicals are optionally substituted with a group selected from
alkyl and halogen radials, --NO.sub.2, --CN, --CF.sub.3, --OR.sup.9
and --SR.sup.9, wherein R.sup.9 represents hydrogen and alkyl
radicals, and halogen radicals; R.sup.3 represents hydrogen, alkyl,
haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heteroaryl,
heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and
mono- and disubstituted aminoalkyl radicals, wherein said
substituents are selected from alkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and
heterocycloalkylalkyl radicals, or in the case of a disubstituted
aminoalkyl radical, said substituents along with the nitrogen atom
to which they are attached, form a heterocycloalkyl or a heteroaryl
radical; R.sup.4 represents radicals as defined by R.sup.3 except
for hydrogen; R.sup.6 represents hydrogen and alkyl radicals; x
represents 0, 1 or 2; t represents either 0 or 1; and Y represents
O, S and NR.sup.15 wherein R.sup.15 represents hydrogen and
radicals as defined for R.sup.3.
A family of compounds of particular interest within Formula I are
compounds embraced by Formula II:
##STR00002## wherein: R represents hydrogen, alkoxycarbonyl,
aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,
aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,
heterocyclylcarbonyl, heterocyclyloxycarbonyl,
heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl,
alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl,
heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and
mono- and disubstituted aminocarbonyl and mono- and disubstituted
aminoalkanoyl radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or
where said aminoalkanoyl radical is disubstituted, said
substituents along with the nitrogen atom to which they are
attached form a heterocycloalkyl or heteroaryl radical; R'
represents hydrogen and radicals as defined for R.sup.3 or R and R'
together with the nitrogen to which they are attached represent
heterocycloalkyl and heteroaryl radical; R.sup.1 represents
hydrogen, --CH.sub.2SO.sub.2NH.sub.2, --CH.sub.2CO.sub.2CH.sub.3,
--CO.sub.2CH.sub.3, --CONH.sub.2, --CH.sub.2C(O)NHCH.sub.3,
--C(CH.sub.3).sub.2(SH), --C(CH.sub.3).sub.2(SCH.sub.3),
--C(CH.sub.3).sub.2(S[O]CH.sub.3),
--C(CH.sub.3).sub.2(S[O].sub.2CH.sub.3), alkyl, haloalkyl, alkenyl,
alkynyl and cycloalkyl radicals, and amino acid side chains
selected from asparagine, S-methyl cysteine and the sulfoxide (SO)
and sulfone (SO.sub.2) derivatives thereof, isoleucine,
allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine,
ornithine, histidine, norleucine, glutamine, threonine, glycine,
allo-threonine, serine, O-methyl serine, aspartic acid, beta-cyano
alanine and valine side chains; R.sup.2 represents alkyl, aryl,
cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals
are optionally substituted with a group selected from alkyl and
halogen radials, --NO.sub.2, --C.ident.N, CF.sub.3, --OR.sup.9,
--SR.sup.9, wherein R.sup.9 represents hydrogen and alkyl radicals;
R.sup.3 represents alkyl, haloalkyl, alkenyl, alkynyl,
hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl,
heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl
radicals, wherein said substituents are selected from alkyl, aryl,
aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,
heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the
case of a disubstituted aminoalkyl radical, said substituents along
with the nitrogen atom to which they are attached, form a
heterocycloalkyl or a heteroaryl radical; and R.sup.4 represents
radicals as defined by R.sup.3.
A more preferred family of compounds within Formula II consists of
compounds wherein: R represents hydrogen, alkoxycarbonyl,
aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,
aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,
heterocyclylcarbonyl, heterocyclyloxycarbonyl,
heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl,
alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl,
heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and
mono- and disubstituted aminocarbonyl and mono- and disubstituted
aminoalkanoyl radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or
where said aminoalkanoyl radical is disubstituted, said
substituents along with the nitrogen atom to which they are
attached form a heterocycloalkyl or heteroaryl radical; R'
represents hydrogen and radicals as defined for R.sup.3 or R and R'
together with the nitrogen to which they are attached represent
heterocycloalkyl and heteroaryl radical; R.sup.1 represents
CH.sub.2C(O)NHCH.sub.3, C(CH.sub.3).sub.2(SCH.sub.3),
C(CH.sub.3).sub.2(S[O]CH.sub.3),
C(CH.sub.3).sub.2(S[O].sub.2CH.sub.3), alkyl, alkenyl and alkynyl
radicals, and amino acid side chains selected from the group
consisting of asparagine, valine, threonine, allo-threonine,
isoleucine, tert-leucine, S-methyl cysteine and the sulfone and
sulfoxide derivatives thereof, alanine, and allo-isoleucine;
R.sup.2 represents alkyl, cycloalkylalkyl and aralkyl radicals,
which radicals are optionally substituted with halogen radicals and
radicals represented by the formula --OR.sup.9 and --SR.sup.9
wherein R.sup.9 represents alkyl radicals; and R.sup.3 and R.sup.4
independently represent alkyl, alkenyl, alkoxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl,
aralkyl and heteroaralkyl radicals.
Of highest interest are compounds within Formula II wherein R
represents alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl,
cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl,
alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl,
aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl,
heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl,
aminocarbonyl, aminoalkanoyl, and mono- and disubstituted
aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals
wherein the substituents are selected from alkyl, aryl, aralkyl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,
heterocycloalkyl, heterocycloalkyalkyl radicals, or where said
aminoalkanoyl radical is disubstituted, said substituents along
with the nitrogen atom to which they are attached form a
heterocycloalkyl or heteroaryl radical; R' represents hydrogen and
radicals as defined for R.sup.3 or R and R' together with the
nitrogen to which they are attached represent heterocycloalkyl and
heteroaryl radical; R.sup.1 represents CH.sub.2C(O)NHCH.sub.3,
C(CH.sub.3).sub.2(SCH.sub.3), C(CH.sub.3).sub.2(S[O]CH.sub.3),
C(CH.sub.3).sub.2(S[O].sub.2CH.sub.3), methyl, propargyl, t-butyl,
isopropyl and sec-butyl radicals, and amino acid side chains
selected from the group consisting of asparagine, valine, S-methyl
cysteine, allo-iso-leucine, iso-leucine, and beta-cyano alanine
side chains; R.sup.2 represents CH.sub.3SCH.sub.2CH.sub.2--,
iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and
cyclohexylmethyl radicals; R.sup.3 represents isoamyl, n-butyl,
isobutyl and cyclohexyl radicals; and R.sup.4 represents phenyl,
substituted phenyl and methyl radicals.
Another family of compounds of particular interest within Formula I
are compounds embraced by Formula III:
##STR00003## wherein: R represents hydrogen, alkoxycarbonyl,
aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,
aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,
heterocyclylcarbonyl, heterocyclyloxycarbonyl,
heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl,
alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl,
heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and
mono- and disubstituted aminocarbonyl and mono- and disubstituted
aminoalkanoyl radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroaralkyl; heterocycloalkyl, heterocycloalkyalkyl radicals, or
where said aminoalkanoyl radical is disubstituted, said
substituents along with the nitrogen atom to which they are
attached form a heterocycloalkyl or heteroaryl radical; R'
represents hydrogen and radicals as defined for R.sup.3 or R and R'
together with the nitrogen to which they are attached represent
heterocycloalkyl and heteroaryl radical; R.sup.1 represents
hydrogen, --CH.sub.2SO.sub.2NH.sub.2, --CH.sub.2CO.sub.2CH.sub.3,
--CO.sub.2CH.sub.3, --CONH.sub.2, --CH.sub.2C(O)NHCH.sub.3,
--C(CH.sub.3).sub.2(SH), --C(CH.sub.3).sub.2(SCH.sub.3),
--C(CH.sub.3).sub.2(S[O]CH.sub.3),
--C(CH.sub.3).sub.2(S[O].sub.2CH.sub.3), alkyl, haloalkyl, alkenyl,
alkynyl and cycloalkyl radicals, and amino acid side chains
selected from asparagine, S-methyl cysteine and the sulfoxide (SO)
and sulfone (SO.sub.2) derivatives thereof, isoleucine,
allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine,
ornithine, histidine, norleucine, glutamine, threonine, glycine,
allo-threonine, serine, aspartic acid, beta-cyano alanine and
valine side chains; R.sup.2 represents alkyl, aryl, cycloalkyl,
cycloalkylalkyl and aralkyl radicals, which radicals are optionally
substituted with a group selected from alkyl and halogen radicals,
--NO.sub.2, --C.ident.N, CF.sub.3, --OR.sup.9, --SR.sup.9; wherein
R.sup.9 represents hydrogen and alkyl; R.sup.3 represents alkyl,
haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heteroaryl,
heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and
mono- and disubstituted aminoalkyl radicals, wherein said
substituents are selected from alkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and
heterocycloalkylalkyl radicals, or in the case of a disubstituted
aminoalkyl radical, said substituents along with the nitrogen atom
to which they are attached, form a heterocycloalkyl or a heteroaryl
radical; and R.sup.4 represents radicals as defined by R.sup.3.
A more preferred family of compounds within Formula III consists of
compounds wherein R represents hydrogen, alkoxycarbonyl,
aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,
aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,
heterocyclylcarbonyl, heterocyclyloxycarbonyl,
heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl,
alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl,
heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and
mono- and disubstituted aminocarbonyl and mono- and disubstituted
aminoalkanoyl radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or
where said aminoalkanoyl radical is disubstituted, said
substituents along with the nitrogen atom to which they are
attached form a heterocycloalkyl or heteroaryl radical; R'
represents hydrogen and radicals as defined for R.sup.3 or R and R'
together with the nitrogen to which they are attached represent
heterocycloalkyl and heteroaryl radical; R.sup.1 represents
hydrogen, alkyl and alkenyl radicals, and amino acid side chains
selected from the group consisting of asparagine, valine,
threonine, allo-threonine, isoleucine, tert-leucine, S-methyl
cysteine and the sulfone and sulfoxide derivatives thereof,
alanine, and allo-isoleucine; R.sup.2 represents alkyl,
cycloalkylalkyl and aralkyl radicals, which radicals are optionally
substituted with halogen radicals and radicals represented by the
formula --OR.sup.9 and --SR.sup.9 wherein R.sup.9 represents
hydrogen and alkyl and halogen radicals; and R.sup.3 and R.sup.4
independently represent alkyl, alkenyl, alkoxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl,
aralkyl, heteroaryl and heteroaralkyl radicals.
Of highest interest are compounds within Formula III wherein R
represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,
alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl,
cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl,
aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,
heterocyclyloxycarbonyl, heterocyclylalkanoyl,
heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl,
aminocarbonyl, aminoalkanoyl, and mono- and disubstituted
aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals
wherein the substituents are selected from alkyl, aryl, aralkyl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,
heterocycloalkyl, heterocycloalkyalkyl radicals, or where said
aminoalkanoyl radical is disubstituted, said substituents along
with the nitrogen atom to which they are attached form a
heterocycloalkyl or heteroaryl radical; R' represents hydrogen and
radicals as defined for R.sup.3 or R and R' together with the
nitrogen to which they are attached represent heterocycloalkyl and
heteroaryl radical; R.sup.1 represents hydrogen, methyl, propargyl,
t-butyl, iso-propyl and sec-butyl radicals, and amino acid side
chains selected from the group consisting of asparagine, valine,
S-methyl cysteine, allo-iso-leucine, iso-leucine, threonine,
serine, aspartic acid, beta-cyano alanine, and allo-threonine side
chains; R.sup.2 represents CH.sub.3SCH.sub.2CH.sub.2--, iso-butyl,
n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and
cyclohexylmethyl radicals; and R.sup.3 represents alkyl,
cyclohexyl, isobutyl, isoamyl, and n-butyl radicals; and R.sup.4
represents methyl, phenyl and substituted phenyl radicals wherein
the substituents are selected from halo, alkoxy, hydroxy, nitro and
amino substituents.
Another family of compounds of particular interest within Formula I
are compounds embraced by Formula IV:
##STR00004## wherein: R represents hydrogen, alkoxycarbonyl,
aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl,
aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl,
heterocyclylcarbonyl, heterocyclyloxycarbonyl,
heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl,
alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl,
heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and
mono- and disubstituted aminocarbonyl and mono- and disubstituted
aminoalkanoyl radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroaralkyl, heterocycloalkyl, heterocycloalkyalkyl radicals, or
where said aminoalkanoyl radical is disubstituted, said
substituents along with the nitrogen atom to which they are
attached form a heterocycloalkyl or heteroaryl radical; R'
represents hydrogen and radicals as defined for R.sup.3 or R and R'
together with the nitrogen to which they are attached represent
heterocycloalkyl and heteroaryl radical; R.sup.1 represents
hydrogen, --CH.sub.2SO.sub.2NH.sub.2, --CH.sub.2CO.sub.2CH.sub.3,
--CO.sub.2CH.sub.3, --CONH.sub.2, --CH.sub.2C(O)NHCH.sub.3,
--C(CH.sub.3).sub.2(SH), --C(CH.sub.3).sub.2(SCH.sub.3),
--C(CH.sub.3).sub.2(S[O]CH.sub.3),
--C(CH.sub.3).sub.2(S[O].sub.2CH.sub.3), alkyl, haloalkyl, alkenyl,
alkynyl and cycloalkyl radicals, and amino acid side chains
selected from asparagine, S-methyl cysteine and the sulfoxide (SO)
and sulfone (SO.sub.2) derivatives thereof, isoleucine,
allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine,
ornithine, histidine, norleucine, glutamine, threonine, glycine,
allo-threonine, serine, aspartic acid, beta-cyano alanine and
valine side chains; R.sup.1' and R.sup.1'' independently represent
hydrogen and radicals as defined for R.sup.1, or one of R.sup.1'
and R.sup.1'', together with R.sup.1 and the carbon atoms to which
R.sup.1, R.sup.1' and R.sup.1'' are attached, represent a
cycloalkyl radical; R.sup.2 represents alkyl, aryl, cycloalkyl,
cycloalkylalkyl and aralkyl radicals, which radicals are optionally
substituted with a group selected from alkyl and halogen radials,
--NO.sub.2, --C.ident.N, CF.sub.3, --OR.sup.9 and --SR.sup.9,
wherein R.sup.9 represents hydrogen and alkyl radicals; R.sup.3
represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl,
alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl,
heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl,
aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein
said substituents are selected from alkyl, aryl, aralkyl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,
heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the
case of a disubstituted aminoalkyl radical, said substituents along
with the nitrogen atom to which they are attached, form a
heterocycloalkyl or a heteroaryl radical; and R.sup.4 represents
radicals as defined by R.sup.3.
A more preferred family of compounds within Formula IV consists of
compounds wherein R represents an arylalkanoyl, heteroaroyl,
aryloxyalkanoyl, aryloxycarbonyl, alkanoyl, aminocarbonyl,
mono-substituted aminoalkanoyl, or disubstituted aminoalkanoyl, or
mono-or dialkylaminocarbonyl radical; R' represents hydrogen and
radicals as defined for R.sup.3 or R and R' together with the
nitrogen to which they are attached represent a heterocycloalkyl or
heteroaryl radical; R.sup.1, R.sup.1' and R.sup.1'' independently
represent hydrogen and alkyl radicals having from 1 to about 4
carbon atoms, alkenyl, alkynyl, aralkyl radicals, and radicals
represented by the formula --CH.sub.2C(O)R'' or --C(O)R'' wherein
R'' represents R.sup.38, --NR.sup.38R.sup.39 and OR.sup.38 wherein
R.sup.38 and R.sup.39 independently represent hydrogen and alkyl
radicals having from 1 to about 4 carbon atoms; R.sup.2 represents
alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are
optionally substituted with halogen radicals and radicals
represented by the formula --OR.sup.9 and --SR.sup.9 wherein
R.sup.9 represents hydrogen and alkyl radicals; and R.sup.3 and
R.sup.4 independently represent alkyl, alkenyl, alkoxyalkyl,
cycloalkyl, cycloalkylalkyl, heterocycloalkyl,
heterocycloalkylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl
radicals.
Of highest interest are compounds of Formula IV
wherein:
R represents an arylalkanoyl, aryloxycarbonyl, aryloxyalkanoyl,
alkanoyl, aminocarbonyl, mono-substituted aminoalkanoyl, or
disubstituted aminoalkanoyl, or mono-or dialkylaminocarbonyl
radical; R' represents hydrogen and radicals as defined for R.sup.3
or R and R' together with the nitrogen to which they are attached
represent a heterocycloalkyl or heteroaryl radical; R.sup.1,
R.sup.1' and R.sup.1'' independently represent hydrogen, methyl,
ethyl, benzyl, phenylpropyl and propargyl radicals; R.sup.2
represents CH.sub.3SCH.sub.2CH.sub.2--, iso-butyl, n-butyl, benzyl,
4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;
R.sup.3 represents alkyl, cyclohexyl, isobutyl, isoamyl and n-butyl
radicals; and R.sup.4 represents methyl, phenyl and substituted
phenyl radicals wherein the substituents are selected from halo,
alkoxy, amino and nitro substituents.
As utilized herein, the term "alkyl", alone or in combination,
means a straight-chain or branched-chain alkyl radical containing
from 1 to about 10 carbon atoms, preferably from 1 to about 8
carbon atoms, more preferably 1-5 carbon atoms. Examples of such
radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and
the like. The term "alkenyl", alone or in combination, means a
straight-chain or branched-chain hydrocarbon radial having one or
more double bonds and containing from 2 to about 18 carbon atoms,
preferably from 2 to about 8 carbon atoms, more preferably from 2
to about 5 carbon atoms. Examples of suitable alkenyl radicals
include ethenyl, propenyl, alkyl, 1,4-butadienyl and the like. The
term "alkynyl", alone or in combination, means a straight-chain or
branched chain hydrocarbon radical having one or more triple bonds
and containing from 2 to about 10 carbon atoms, more preferably
from 2 to about 5 carbon atoms. Examples of alkynyl radicals
include ethynyl, propynyl, (propargyl), butynyl and the like. The
term "alkoxy", alone or in combination, means an alkyl ether
radical wherein the term alkyl is as defined above. Examples of
suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy,
isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the
like. The term "cycloalkyl", alone or in combination, means a
saturated or partially saturated monocyclic, bicyclic or tricyclic
alkyl radical wherein each cyclic moiety contains from about 3 to
about 8 carbon atoms, more preferably from about 3 to about 6
carbon atoms, and is cyclic. Examples of such cycloalkyl radicals
include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the
like. The term "cycloalkylalkyl" means an alkyl radical as defined
above which is substituted by a cycloalkyl radical as defined
above. The term "aryl", alone or in combination, means a phenyl or
naphthyl radical which optionally carries one or more substituents
selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano,
haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, heterocycloalkyl,
amido, mono and dialkyl substituted amino, mono and dialkyl
substituted amido and the like, such as phenyl, p-tolyl,
4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl,
4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the
like. The terms "aralkyl" and "aralkoxy", alone or in combination,
means an alkyl or alkoxy radical as defined above in which at least
one hydrogen atom is replaced by an aryl radical as defined above,
such as benzyl, benzyloxy, 2-phenylethyl, dibenzylmethyl,
hydroxyphenylmethyl, methylphenylmethyl, and the like. The term
"aralkoxy carbonyl", alone or in combination, means a radical of
the formula --C(O)--O--aralkyl in which the term "aralkyl" has the
significance given above. Examples of an aralkoxycarbonyl radical
are benzyloxycarbonyl and methylphenylmethoxycarbonyl. The term
"aryloxyll means a radical of the formula aryl--O-- in which the
term aryl has the significance given above. The term "alkanoyl",
alone or in combination, means an acyl radical derived from an
alkanecarboxylic acid, examples of which include acetyl, propionyl,
butyryl, valeryl, 4-methylvaleryl, and the like. The term
"cycloalkylcarbony", means an acyl group derived from a monocyclic
or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl,
cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a
benz-fused monocyclic cycloalkanecarboxylic acid which is
optionally substituted by, for example, alkanoylamino, such as
1,2,3,4-tetrahydro-2-naphthoyl,
2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl. The term "aralkanoyl"
means an acyl radical derived from an aryl-substituted
alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl
(hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl,
4-chlorohydrocinnamoyl,
4-aminohydrocinnamoyl,4-methoxyhydrocinnamoyl, and the like. The
term "aroyl" means an acyl radical derived from an aromatic
carboxylic acid. Examples of such radicals include aromatic
carboxylic acids, an optionally substituted benzoic or naphthoic
acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl,
4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2
naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl,
3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl,
3-(benzyloxyformamido)-2-naphthoyl, and the like. The terms
"heterocyclyl" and "heterocycloalkyl" alone or in combination, mean
a saturated or partially unsaturated monocyclic, bicyclic or
tricyclic heterocycle which contains one or more heteroatoms
selected from nitrogen, oxygen and sulphur, which is optionally
substituted on one or more carbon atoms by halogen, alkyl, alkoxy,
hydroxy, oxo, aryl, aralkyl and the like, and/or on a secondary
nitrogen atom (i.e., --NH--) by hydroxy, alkyl, aralkoxycarbonyl,
alkanoyl, phenyl or phenylalkyl and/or on a tertiary nitrogen atom
(i.e.=N--) by oxido and which is attached via a carbon atom.
Heterocycloalkyl and heterocyclyl also includes benz-fused
monocyclic cycloalkyl groups having at least one heteroatom.
Heterocycloalkyl and heterocyclyl in addition to sulfur and
nitrogen also includes sulfones, sulfoxides and N-oxides of
tertiary nitrogen containing heterocycloalkyl groups. The term
"heteroaryl", alone or in combination, means an aromatic
monocyclic, bicyclic, or tricyclic heterocycle which contains the
heteroatoms and is optionally substituted as defined above with
respect to the definitions of aryl and heterocycloalkyl. Examples
of such heterocycloalkyl and heteroaryl groups are pyrrolidinyl,
piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl,
imidazolyl (e.g., imidazol 4-yl, 1-benzyloxycarbonylimidazol-4-yl,
etc.), pyrazolyl, pyridyl, (e.g., 2-(1-piperidinyl)pyridyl and
2-(4-benzyl piperazin-1-yl-1-pyridinyl), pyrazinyl, pyrimidinyl,
furyl, thienyl, triazolyl, oxazolyl, thiazolyl, indolyl (e.g.,
2-indolyl, etc.), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl,
1-oxido-2-quinolinyl, etc.), isoquinolinyl (e.g., 1-isoquinolinyl,
3-isoquinolinyl, etc.), tetrahydroquinolinyl (e.g.,
1,2,3,4-tetrahydro-2-quinolyl, etc.),
1,2,3,4-tetrahydroisoquinolinyl (e.g.,
1,2,3,4-tetrahydro-1-oxoisoquinolinyl, etc.), quinoxalinyl,
.beta.-carbolinyl, 2-benzofurancarbonyl, 1-, 2-,4- or
5-benzimidazolyl, and the like. The term "cycloalkylalkoxycarbonyl"
means an acyl group derived from a cycloalkylalkoxycarboxylic acid
of the formula cycloalkylalkyl--O--COOH wherein cycloalkylalkyl has
the significance given above. The term "aryloxyalkanoyl" means an
acyl radical of the formula aryl--O--alkanoyl wherein aryl and
alkanoyl have the significance given above. The term
"heterocycloalkoxycarbonyll, means an acyl group derived from
heterocyclyl--O--COOH wherein heterocyclyl is as defined above. The
term "heterocycloalkylalkanoyl" is an acyl radical derived from a
heterocycloalkyl-substituted alkane carboxylic acid wherein
heterocycloalkyl has the significance given above. The term
"heterocycloalkylalkoxycarbonyl" means an acyl radical derived from
a heterocycloalkyl-substituted alkane--O--COOH wherein heterocyclyl
has the significance given above. The term "heteroaryloxycarbonyl"
means an acyl radical derived from a carboxylic acid represented by
heteroaryl--O--COOH wherein heteroaryl has the significance given
above. The term "aminocarbonyl" alone or in combination, means an
amino-substituted carbonyl (carbamoyl) group wherein the amino
group can be a primary; secondary or tertiary amino group
containing substituents selected from alkyl, aryl, aralkyl,
cycloalkyl, cycloalkylalkyl radicals and the like. The term
"aminoalkanoyl" means an acyl group derived from an
amino-substituted alkanecarboxylic acid wherein the amino group can
be a primary, secondary or tertiary amino group containing
substituents selected from alkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl radicals and the like. The term "halogen" means
fluorine, chlorine, bromine or iodine. The term "haloalkyll" means
an alkyl radical having the significance as defined above wherein
one or more hydrogens are replaced with a halogen. Examples of such
haloalkyl radicals include chloromethyl, 1-bromoethyl,
fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl
and the like. The term "leaving group" generally refers to groups
readily displaceable by a nucleophile, such as an amine, a thiol or
an alcohol nucleophile. Such leaving groups are well known in the
art. Examples of such leaving groups include, but are not limited
to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides,
triflates, tosylates and the like. Preferred leaving groups are
indicated herein where appropriate. The term "amino acid side
chain" means the side chain group, including the stereochemistry of
the carbon to which it is attached, attached to the naturally
occurring amino acid which distinguishes the amino acid from
glycine. For example, the amino acid side chain of alanine is
methyl, of histidine is imidazolylmethyl and phenylalanine is
benzyl, and the attachment of such side chains to the compound of
this invention retain the naturally occurring stereochemistry of
the carbon to which it is attached. The following example
illustrates the definitions:
##STR00005##
Procedures for preparing the compounds of Formula I are set forth
below. It should be noted that the general procedure is shown as it
relates to preparation of compounds having the specified
stereochemistry, for example, wherein the absolute stereochemistry
about the hydroxyl group is designated as (R). However, such
procedures are generally applicable to those compounds of opposite
configuration, e.g., where the stereochemistry about the hydroxyl
group is (S). In addition, the compounds having the (R)
stereochemistry can be utilized to produce those having the (S)
stereochemistry. For example, a compound having the (R)
stereochemistry can be inverted to the (S) stereochemistry using
well-known methods.
Preparation of Compounds of Formula I
The compounds of the present invention represented by Formula I
above can be prepared utilizing the following general procedure.
This procedure is schematically shown in the following Schemes I
and II:
##STR00006## a) amine b) sulfonyl chloride R.sup.4SO.sub.2Cl (or
anhydride)+acid scavenger c) deprotection d) coupling e)
coupling.
##STR00007## a) amine b) sulfonyl chloride R.sup.4SO.sub.2Cl (or
anhydride)+acid scavenger c) deprotection d) coupling e)
coupling.
An N-protected chloroketone derivative of an amino acid having the
formula:
##STR00008## wherein P represents an amino protecting group, and
R.sup.2 is as defined above, is reduced to the corresponding
alcohol utilizing an appropriate reducing agent. Suitable amino
protecting groups are well known in the art and include
carbobenzoxy, t-butoxycarbonyl, and the like. A preferred amino
protecting group is carbobenzoxy. A preferred N-protected
chloroketone is N-benzyloxycarbonyl-L-phenylalanine chloromethyl
ketone. A preferred reducing agent is sodium borohydride. The
reduction reaction is conducted at a temperature of from
-10.degree. C. to about 25.degree. C., preferably at about
0.degree. C., in a suitable solvent system such as, for example,
tetrahydrofuran, and the like. The N-protected chloroketones are
commercially available, e.g., such as from Bachem, Inc., Torrance,
Calif. Alternatively, the chloroketones can be prepared by the
procedure set forth in S. J. Fittkau, J. Prakt. Chem., 315, 1037
(1973), and subsequently N-protected utilizing procedures which are
well known in the art.
The halo alcohol can be utilized directly, as described below, or,
preferably, is then reacted, preferably at room temperature, with a
suitable base in a suitable solvent system to produce an
N-protected amino epoxide of the formula:
##STR00009## wherein P and R.sup.2 are as defined above. Suitable
solvent systems for preparing the amino epoxide include ethanol,
methanol, isopropanol, tetrahydrofuran, dioxane, and the like
including mixtures thereof. Suitable bases for producing the
epoxide from the reduced chloroketone include potassium hydroxide,
sodium hydroxide, potassium t-butoxide, DBU and the like. A
preferred base is potassium hydroxide.
Alternatively, a protected amino epoxide can be prepared, such as
in co-owned and co-pending PCT patent application Ser. No.
PCT/US93/04804 which is incorporated herein by reference, starting
with an L-amino acid which is reacted with a suitable
amino-protecting group in a suitable solvent to produce an
amino-protected L-amino acid ester of the formula:
##STR00010## wherein P.sup.3 represents carboxyl-protecting group,
e.g., methyl, ethyl, benzyl, tertiary-butyl and the like; R.sup.2
is as defined above; and P.sup.1 and P.sup.2 independently are
selected from amine protecting groups, including but not limited
to, arylalkyl, substituted arylalkyl, cycloalkenylalkyl and
substituted cycloalkenylalkyl, allyl, substituted allyl, acyl,
alkoxycarbonyl, aralkoxycarbonyl and silyl. Examples of arylalkyl
include, but are not limited to benzyl, orthomethylbenzyl, trityl
and benzhydryl, which can be optionally substituted with halogen,
alkyl of C.sub.1-C.sub.8, alkoxy, hydroxy, nitro, alkylene, amino,
alkylamino, acylamino and acyl, or their salts, such as phosphonium
and ammonium salts. Examples of aryl groups include phenyl,
naphthalenyl, indanyl, anthracenyl, durenyl, 9-(9-phenylfluorenyl)
and phenanthrenyl, cycloalkenylalkyl or substituted
cycloalkylenylalkyl radicals containing cycloalkyls of
C.sub.6-C.sub.10. Suitable acyl groups include carbobenzoxy,
t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl,
butyryl, acetyl, tri-fluoroacetyl, tri-chloroacetyl, phthaloyl and
the like.
Additionally, the .[.P.sup.1 and/or p.sup.2.]. .Iadd.P.sup.1 and/or
P.sup.2 .Iaddend.protecting groups can form a heterocyclic ring
with the nitrogen to which they are attached, for example,
1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl
and the like and where these heterocyclic groups can further
include adjoining aryl and cycloalkyl rings. In addition, the
heterocyclic groups can be mono-, di- or tri-substituted, e.g.,
nitrophthalimidyl. The term silyl refers to a silicon atom
optionally substituted by one or more alkyl, aryl and aralkyl
groups.
Suitable silyl protecting groups include, but are not limited to,
trimethylsilyl, triethylsilyl, tri-isopropylsilyl,
tert-butyldimethylsilyl, dimethylphenylsilyl,
1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and
diphenylmethylsilyl. Silylation of the amine functions to provide
mono- or bis-disilylamine can provide derivatives of the
aminoalcohol, amino acid, amino acid esters and amino acid amide.
In the case of amino acids, amino acid esters and amino acid
amides, reduction of the carbonyl function provides the required
mono- or bis-silyl aminoalcohol. Silylation of the aminoalcohol can
lead to the N,N,O--tri-silyl derivative. Removal of the silyl
function from the silyl ether function is readily accomplished by
treatment with, for example, a metal hydroxide or ammonium flouride
reagent, either as a discrete reaction step or in situ during the
preparation of the amino aldehyde reagent. Suitable silylating
agents are, for example, trimethylsilyl chloride,
tert-butydimethylsilyl chloride, phenyldimethylsilyl chlorie,
diphenylmethylsilyl chloride or their combination products with
imidazole or DMF. Methods for silylation of amines and removal of
silyl protecting groups are well known to those skilled in the art.
Methods of preparation of these amine derivatives from
corresponding amino acids, amino acid amides or amino acid esters
are also well known to those skilled in the art of organic
chemistry including amino acid/amino acid ester or aminoalcohol
chemistry.
Preferably P.sup.1 and P.sup.2 are independently selected from
aralkyl and substituted aralkyl. More preferably, each of P.sup.1
and P.sup.2 is benzyl.
The amino-protected L-amino acid ester is then reduced, to the
corresponding alcohol. For example, the amino-protected L-amino
acid ester can be reduced with diisobutylaluminum hydride at
-78.degree. C. in a suitable solvent such as toluene. Preferred
reducing agents include lithium aluminium hydride, lithium
borohydride, sodium borohydride, borane, lithium
tri-ter-butoxyaluminum hydride, borane/THF complex. Most
preferably, the reducing agent is diisobutylaluminum hydride
(DiBAL-H) in toluene. The resulting alcohol is then converted, for
example, by way of a Swern oxidation, to the corresponding aldehyde
of the formula:
##STR00011## wherein .[.p.sup.1, P.sup.2 and R.sup.2.].
.Iadd.P.sup.1, P.sup.2 and R.sup.2 .Iaddend.are as defined above.
Thus, a dichloromethane solution of the alcohol is added to a
cooled (-75 to -68.degree. C.) solution of oxalyl chloride in
dichloromethane and DMSO in dichloromethane and stirred for 35
minutes.
Acceptable oxidizing reagents include, for example, sulfur
trioxide-pyridine complex and DMSO, oxalyl chloride and DMSO,
acetyl chloride or anhydride and DMSO, trifluoroacetyl chloride or
anhydride and DMSO, methanesulfonyl chloride and DMSO or
tetrahydrothiaphene-S-oxide, toluenesulfonyl bromide and DMSO,
trifluoromethanesulfonyl anhydride (triflic anhydride) and DMSO,
phosphorus pentachloride and DMSO, dimethylphosphoryl chloride and
DMSO and isobutylchloroformate and DMSO. The oxidation conditions
reported by Reetz et al [Angew Chem., 99, p. 1186, (1987)], Angew
Chem. Int. Ed. Engl., 26, p. 1141, 1987) employed oxalyl chloride
and DMSO at -78.degree. C.
The preferred oxidation method described in this invention is
sulfur trioxide pyridine complex, triethylamine and DMSO at room
temperature. This system provides excellent yields of the desired
chiral protected amino aldehyde usable without the need for
purification i.e., the need to purify kilograms of intermediates by
chromatography is eliminated and large scale operations are made
less hazardous. Reaction at room temperature also eliminated the
need for the use of low temperature reactor which makes the process
more suitable for commercial production.
The reaction may be carried out under .[.and.]. .Iadd.an
.Iaddend.inert atmosphere such as nitrogen or argon, or normal or
dry air, under atmospheric pressure or in a sealed reaction vessel
under positive pressure. Preferred is a nitrogen atmosphere.
Alternative amine bases include, for example, tri-butyl amine,
tri-isopropyl amine, N-methylpiperidine, N-methyl morpholine,
azabicyclononane, diisopropylethylamine,
2,2,6,6-tetramethylpiperidine, N,N-dimethylaminopyridine, or
mixtures of these bases. Triethylamine is a preferred base.
Alternatives to pure DMSO as solvent include mixtures of DMSO with
non-protic or halogenated solvents such as tetrahydrofuran, ethyl
acetate, toluene, xylene, dichloromethane, ethylene dichloride and
the like. Dipolar aprotic co-solvents include acetonitrile,
dimethylformamide, dimethylacetamide, acetamide, tetramethyl urea
and its cyclic analog, N-methylpyrrolidone, sulfolane and the like.
Rather than N,N-dibenzylphenylalaninol as the aldehyde precursor,
the phenylalaninol derivatives discussed above can be used to
provide the corresponding N-monosubstituted .[.[either P.sup.1 or
P.sup.2=H].]. .Iadd.either P.sup.1 or P.sup.2=H .Iaddend.or
N,N-disubstituted aldehyde.
In addition, hydride reduction of an amide or ester derivative of
the corresponding alkyl, benzyl or cycloalkenyl nitrogen protected
phenylalanine, substituted phenylalanine or cycloalkyl analog of
phenyalanine derivative can be carried out to provide the
aldehydes. Hydride transfer is an additional method of aldehyde
synthesis under conditions where aldehyde condensations are
avoided, cf, Oppenauer Oxidation.
The aldehydes of this process can also be prepared by methods of
reducing protected phenylalanine and phenylalanine analogs or their
amide or ester derivatives by, e.g., sodium amalgam with HCl in
ethanol or lithium or sodium or potassium or calcium in ammonia.
The reaction temperature may be from about -20.degree. C. to about
45.degree. C., and preferably from .[.abut.]. .Iadd.about
.Iaddend.5.degree. C. to about 25.degree. C. Two additional methods
of obtaining the nitrogen protected aldehyde include oxidation of
the corresponding alcohol with bleach in the presence of a
catalytic amount of 2,2,6,6-tetramethyl-1-pyridyloxy free radical.
In a second method, oxidation of the alcohol to the aldehyde is
accomplished by a catalytic amount of tetrapropylammonium
perruthenate in the presence of N-methylmorpholine-N-oxide.
Alternatively, an acid chloride derivative of a protected
phenylalanine or phenylalanine derivative as disclosed above can be
reduced with hydrogen and a catalyst such as Pd on barium carbonate
or barium sulphate, with or without an additional catalyst
moderating agent such as sulfur or a thiol (Rosenmund
Reduction).
The aldehyde resulting from the Swern oxidation is then reacted
with a halomethyllithium reagent, which reagent is generated in
situ by reacting an alkyllithium or arylithium compound with a
dihalomethane represented by the formula X.sup.1CH.sub.2X.sup.2
wherein X.sup.1 and X.sup.2 independently represent I, Br or Cl.
For example, a solution of the aldehyde and chloroiodomethane in
THF is cooled to -78.degree. C. and a solution of n-butyllithium in
hexane is added. The resulting product is a mixture of
diastereomers of the corresponding amino-protected epoxides of the
formulas:
##STR00012## The diastereomers can be separated e.g., by
chromatography, or, alternatively, once reacted in subsequent steps
the diastereomeric products can be separated. For compounds having
the (S) stereochemistry, a D-amino acid can be utilized in place of
the L-amino acid.
The addition of chloromethylithium or bromomethylithium to a chiral
amino aldehyde is highly diastereoselective. Preferably, the
chloromethyllithium or bromomethylithium is generated in-situ from
the reaction of the dihalomethane and n-butyllithium. Acceptable
methyleneating halomethanes include chloroiodomethane,
bromochloromethane, dibromomethane, diiodomethane,
bromofluoromethane and the like. The sulfonate ester of the
addition product of, for example, hydrogen bromide to formaldehyde
is also a methyleneating agent. Tetrahydrofuran is the preferred
solvent, however alternative solvents such as toluene,
dimethoxyethane, ethylene dichloride, methylene chloride can be
used as pure solvents or as a mixture. Dipolar aprotic solvents
such as acetonitrile, DMF, N-methylpyrrolidone are useful as
solvents or as part of a solvent mixture. The reaction can be
carried out under an inert atmosphere such as nitrogen or argon.
For n-butyl lithium can be substituted other organometalic reagents
reagents such as methyllithium, tert-butyl lithium, sec-butyl
lithium, phenyllithium, phenyl sodium and the like. The reaction
can be carried out at temperatures of between about -80.degree. C.
to 0.degree. C. but preferably between about -80.degree. C. to
-20.degree. C. The most preferred reaction temperatures are between
-40.degree. C. to -15.degree. C. Reagents can be added singly but
multiple additions are preferred in certain conditions. The
preferred pressure of the reaction is atmospheric however a
positive pressure is valuable under certain conditions such as a
high humidity environment.
Alternative methods of conversion to the epoxides of this invention
include substitution of other charged methylenation precurser
species followed by their treatment with base to form the analogous
anion. Examples of these species include trimethylsulfoxonium
tosylate or triflate, tetramethylammonium halide,
methyldiphenylsulfoxonium halide wherein halide is chloride,
bromide or iodide.
The conversion of the aldehydes of this invention into their
epoxide derivative can also be carried out in multiple steps. For
example, the addition of the anion of thioanisole prepared from,
for example, a butyl or aryl lithium reagent, to the protected
aminoaldehyde, oxidation of the resulting protected aminosulfide
alcohol with well known oxidizing agents such as hydrogen peroxide,
tert-butyl hypochlorite, bleach or sodium periodate to give a
sulfoxide. Alkylation of the sulfoxide with, for example, methyl
iodide or bromide, methyl tosylate, methyl mesylate, methyl
triflate, ethyl bromide, isopropyl bromide, benzyl chloride or the
like, in the presence of an organic or inorganic base
Alternatively, the protected aminosulfide alcohol can be alkylated
with, for example, the alkylating agents above, to provide a
sulfonium salts that are subsequently converted into the subject
epoxides with tert-amine or mineral bases.
The desired epoxides formed, using most preferred conditions,
diastereoselectively in ratio amounts of at least about an 85:15
ratio (S:R). The product can be purified by chromatography to give
the diastereomerically and enantiomerically pure product but it is
more conveniently used directly without purification to prepare
retroviral protease inhibitors. The foregoing process is applicable
to mixtures of optical isomers as well as resolved compounds. If a
particular optical isomer is desired, it can be selected by the
choice of starting material, e.g., L-phenylalanine,
D-phenylalanine, L-phenylalaninol, D-phenylalaninol,
D-hexahydrophenylalaninol and the like, or resolution can occur at
intermediate or final steps. Chiral auxiliaries such as one or two
equivilants of camphor sulfonic acid, citric acid, camphoric acid,
2-methoxyphenylacetic acid and the like can be used to form salts,
esters or amides of the compounds of this invention. These
compounds or derivatives can be crystallized or separated
chromatographically using either a chiral or achiral column as is
well known to those skilled in the art.
The amino epoxide is then reacted, in a suitable solvent system,
with an equal amount, or preferably an excess of, a desired amine
of the formula: R.sup.3NH.sub.2 wherein R.sup.3 is hydrogen or is
as defined above. The reaction can be conducted over a wide range
of temperatures, e.g., from about 10.degree. C. to about
100.degree. C., but is preferably, but not necessarily, conducted
at a temperature at which the solvent begins to reflux. Suitable
solvent systems include protic, non-protic and dipolar aprotic
organic solvents such as, for example, those wherein the solvent is
an alcohol, such as methanol, ethanol, isopropanol, and the like;
ethers such as tetrahydrofuran, dioxane and the like, and toluene,
N,N-dimethylformamide, dimethyl sulfoxide, and mixtures thereof. A
preferred solvent is isopropanol. Exemplary amines corresponding to
the formula R.sup.3NH.sub.2 include benzyl amine, isobutylamine,
n-butyl amine, isopentyl amine, isoamylamine, cyclohexanemethyl
amine, naphthylene methyl amine and the like. The resulting product
is a 3-(N-protected amino)-3-(R.sup.2)-1-(NHR.sup.3)-propan-2-ol
derivative (hereinafter referred to as an amino alcohol) can be
represented by the formulas:
##STR00013## wherein P, P.sup.1, P.sup.2, R.sup.2 and R.sup.3 are
as described above. Alternatively, a haloalcohol can be utilized in
place of the amino epoxide.
The amino alcohol defined above is then reacted in a suitable
solvent with a sulfonyl chloride (R.sup.4SO.sub.2Cl) or sulfonyl
anhydride in the presence of an acid scavenger. Suitable solvents
in which the reaction can be conducted include methylene chloride,
tetrahydrofuran. Suitable acid scavengers include triethylamine,
pyridine. Preferred sulfonyl chlorides are methanesulfonyl chloride
and benzenesulfonyl chloride. The resulting sulfonamide derivative
can be represented, depending on the epoxide utilized by the
formulas
##STR00014## wherein P, P.sup.1, P.sup.2; R.sup.2, R.sup.3 and
R.sup.4 are as defined above. These intermediates are useful for
preparing inhibitor compounds of the present invention and are also
active inhibitors of retroviral proteases.
The sulfonyl halides of the formula R.sup.4SO.sub.2X can be
prepared by the reaction of a suitable Grignard or alkyl lithium
reagent with sulfuryl chloride, or sulfur dioxide followed by
oxidation with a halogen, preferably chlorine. Also, thiols may be
oxidized to sulfonyl chlorides using chlorine in the presence of
water under carefully controlled conditions. Additionally, sulfonic
acids may be converted to sulfonyl halides using reagents such as
PCl.sub.5, and also to anhydrides using suitable dehydrating
reagents. The sulfonic acids may in turn be prepared using
procedures well known in the art. Such sulfonic acids are also
commercially available. In place of the sulfonyl halides, sulfinyl
halides (R.sup.4SOX) or sulfenyl halides (R.sup.4SX) can be
utilized to prepare compounds wherein the --SO.sub.2-- moiety is
replaced by an --SO-- or --S-- moiety, respectively.
Following preparation of the sulfonamide derivative, the amino
protecting group P or P.sup.1 and P.sup.2 amino protecting groups
are removed under conditions which will not affect the remaining
portion of the molecule. These methods are well known in the art
and include acid hydrolysis, hydrogenolysis and the like. A
preferred method involves removal of the protecting group, e.g.,
removal of a carbobenzoxy group, by hydrogenolysis utilizing
palladium on carbon in a suitable solvent system such as an
alcohol, acetic acid, and the like or mixtures thereof. Where the
protecting group is a t-butoxycarbonyl group, it can be removed
utilizing an inorganic or organic acid, e.g., HCl or
trifluoroacetic acid, in a suitable solvent system, e.g., dioxane
or methylene chloride. The resulting product is the amine salt
derivative. Following neutralization of the salt, the amine is then
reacted with an amino acid or corresponding derivative thereof
represented by the formula (PN[CR.sup.1'R.sup.1''].sub.t
CH(R.sup.1)COOH) wherein t, R.sup.1, R.sup.1' and R.sup.1'' are as
defined above, to produce the antiviral compounds of the present
invention to having the formula:
##STR00015## wherein t, P, R.sup.1, R.sup.1', R.sup.1'', R.sup.2,
R.sup.3 and R.sup.4 are as defined above. Preferred protecting
groups in this instance are a benzyloxycarbonyl group or a
t-butoxycarbonyl group. Where t is O and R.sup.1 is alkyl, alkenyl,
alkynyl, cycloalkyl, --CH.sub.2SO.sub.2NH.sub.2,
--CH.sub.2CO.sub.2CH.sub.3, --CO.sub.2CH.sub.3, --CONH.sub.2,
--CH.sub.2C(O)NHCH.sub.3, --C(CH.sub.3).sub.2(SH),
--C(CH.sub.3).sub.2(SCH.sub.3), --C(CH.sub.3).sub.2[S(O)CH.sub.3],
--C(CH.sub.3).sub.2[S(O.sub.2)CH.sub.3], or an amino acid side
chain, such materials are well known and many are commercially
available from Sigma-Aldrich.
Where the amine is reacted with a derivative of an amino acid,
e.g., when t=1, so that the amino acid is a .beta.-amino acid, such
.beta.-amino acids can be prepared according to the procedure set
forth in a co-owned, copending patent application, U.S. Ser. No.
07/853,561 or the following procedures.Iadd...Iaddend.
Various methods have been proposed for the preparation of chiral
.beta.-amino acids. See, for example, Chemistry and Biochemistry of
Amino Acids, Vol. 4, Chapter 5, pp. 250-57, B. Weinstein, Ed.,
Dekker, N.Y. (1975). Furukawa et al, Chem. Pharm. Bull., 25, 1319
(1977), disclose asymmetric synthesis of .beta.-amino acids by
addition of chiral amines to carbon-carbon double bonds having
nitrile or ester groups in the .alpha.-position. However, optical
purities of the .beta.-amino acids thus produced range from 2 to
19%. Furukawa et al also report that optically active .beta.-amino
acids have been produced with optical purities ranging from 2 to
28% by reacting chiral Schiff bases with Reformsky reagent.
Terentev et al, Dohl. Ahad. Nauh SSR, 163,674 (1965) disclose
synthesis of .beta.-aminobutyric acids involving addition of chiral
amines to crotonic acid with optical purities ranging from
7-9%.
Brown et al, Tetrahedron Lett., Vol. 28, No. 19, pp 2179-2182
(1987), disclose a method of preparing optically active
disubstituted .beta.-amino acids which involves asymmetric
catalytic hydrogenation of N-substituted .alpha.-(aminoalkyl)
acrylates. In order to verify the stereochemistry of the product,
Curtius rearrangement was effected on the monomethyl ester of
optically enriched RR-anti-2,3-dimethylsuccinic acid and trapping
of the incipient isocyanate derivative with tertiary alcohol,
namely, t-butyl alcohol, to give the corresponding R-enriched
.beta.-amino acid.
Ninomita et al, Tetrahedron Lett., Vol. 30, 2152-2157 (1975)
studied the Curtius rearrangement utilizing benzoic acid,
diphenylphosphoryl azide and triethylamine followed by treatment
with various alcohols and found that t-butyl alcohol gives yields
superior to benzyl alcohol, ethanol and phenol.
Utilization of a primary or secondary alcohol to trap an isocyanate
derivative of a chiral mono-substituted succinate, and, in
particular, in a Curtius rearrangement of a chiral mono-substituted
succinate, to produce chiral .beta.-amino acids significantly
increases the overall yield. The resulting carbamate-protected
.beta.-amino esters are then saponified to produce the
corresponding carbamate-protected .beta.-amino acids which are then
deprotected to produce .beta.-amino acids possessing the same
absolute configuration as naturally-occurring (L)-amino acids.
The overall reaction sequence can be shown as follows:
##STR00016## wherein R.sup.1, R.sup.1', R.sup.1'', and P.sup.3 are
as defined above and P.sup.4OH are preferably represents radicals
derived from primary and secondary alcohols.
This process can also be used in the asymetric synthesis of
.beta.-amino acids represented by the formula:
##STR00017## wherein R.sup.1, R.sup.1' and R.sup.1'' are as defined
above. Such compounds are formed by Curtius rearrangement of
2(R)-substituted succinates represented by the formula
##STR00018## wherein R.sup.1, R.sup.1', R.sup.1'' and P.sup.3 are
as defined above, to afford the isocyanate derivative:
##STR00019## Using 2(S)-substituted succinates, 2(S)-substituted
.beta.-amino acids can also be prepared stereospecifically.
Curtius rearrangement involves pyrolysis of acyol azides
##STR00020## to yield isocyanates (R--N.dbd.C.dbd.O) which can be
subsequently hydrolyzed to give amines. See March, Advanced Organic
Chemistry, p. 1005, 2nd ed (1977). As a general rule, Curtius
rearrangement is a concerted reaction and therefore proceeds with
retention of configuration of the starting materials. Determination
of specific reaction conditions for effecting Curtius
rearrangements of various succinates is within the skill of one in
the art familiar with such reactions. In the method of the present
invention, Curtius rearrangement to afford the desired isocyante is
preferably effected by treating a 2-substituted succinate with one
equivalent of diphenoxyphosphoryl azide (PhO).sub.2PON.sub.3 and
triethylamine to form the acyl azide followed by heating in an
inert solvent, such as in warm toluene, preferably at about
80.degree. C. for about three hours, to afford the isocyante
derivative.
Suitable primary and secondary alcohols include those represented
by the formula P.sup.4OH where P.sup.4 .[.representes.].
.Iadd.represents .Iaddend.substituted and unsubstituted alkyl,
cycloalkyl, aralkyl and aryl radicals, as well as suitable
equivalents such as, for example, silyl radicals. Preferably, the
primary and secondary alcohols are those wherein P.sup.4 represents
substituted and unsubstituted, straight chain as well as branched
chain, alkyl radicals having from 1 to about 12 carbon atoms,
substituted and unsubstituted cycloalkyl radicals having from 4 to
about 7 carbon atoms, and substituted and unsubstituted aryl,
alkaryl and aralkyl radicals. Examples of such suitable alcohols
include benzyl alcohol, isopropyl alcohol, 4-methoxybenzyl alcohol,
2-trimethylsilylethanol, fluorenyl methanol and benzhydrol.
Preferred alcohols are benzyl alcohol and 4-methoxybenzyl alcohol.
Other primary and secondary alcohols suitable for use in the
practice of the present invention will be readily apparent to those
skilled in the art.
The ester derivative is then saponified by any one of numerous
well-known procedures, such as by treatment with aqueous lithium
hydroxide/THF (tetrahydrofuran), preferably for three hours at
0.degree. C. The resultant product is the corresponding
carbamate-protected .beta.-amino acids. These are subsequently
deprotected by any one of several well-known procedures, such as by
acid catalyzed hydrolysis or by hydrogenolysis, to produce the
corresponding deprotected .beta.-amino acids. Alternatively, the
carbamate-protected .beta.-amino acid can be coupled to the
amine
##STR00021## followed by deprotection and incorporation of R and
R'.
The N-protecting group can be subsequently removed, if desired,
utilizing the procedures described above, and then reacted with a
carboxylate represented by the formula:
##STR00022## wherein R is as defined above and L is an appropriate
leaving group such as a halide. Preferably, where R.sup.1 is a side
chain of a naturally occurring .alpha.-amino acid, R is a
2-quinoline carbonyl group derived from
N-hydroxysuccinimide-2-quinoline carboxylate, i.e., L is hydroxy
succinimide. A solution of the free amine (or amine acetate salt)
and about 1.0 equivalent of the carboxylate are mixed in an
appropriate solvent system and optionally treated with up to five
equivalents of a base such as, for example, N-methylmorpholine, at
about room temperature. Appropriate solvent systems include
tetrahydrofuran, methylene chloride or N,N-dimethylformamide, and
the like, including mixtures thereof.
Alternatively, the protected amino alcohol from the epoxide opening
can be further protected at the newly introduced amino group with a
protecting group P' which is not removed when the first protecting
P is removed. One skilled in the art can choose appropriate
combinations of P and P'. One suitable choice is when P is Cbz and
P' is Boc. The resulting compound represented by the formula:
##STR00023## can be carried through the remainder of the synthesis
to provide a compound of the formula:
##STR00024## and the new protecting group P' is selectively
removed, and following deprotection, the resulting amine reacted to
form the sulfonamide derivative as described above. This selective
deprotection and conversion to the sulfonamide can be accomplished
at either the end of the synthesis or at any appropriate
intermediate step if desired.
The thiocarbonyl compounds of this invention are really prepared by
methods well known to those skilled in the art, for example, by
treatment of a carbonyl compound with Lawesson's reagent
(2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide)
which is an article of commerce. Phosphoruspentasulfide may also be
used or one can treat an amine of this invention with a pre-formed
thiocarbonyl reagent such as thiocarbonylchlorid in the presence of
base.
In place of the sulfonyl halides, sulfinyl halides (RSOCl) and
sulfenyl halides (RSCl) can be utilized to prepare compounds
wherein the --SO.sub.2-- moiey is replaced by --SO-- or --S--,
respectively.
It is contemplated that for preparing compounds of the Formulas
having R.sup.6, the compounds can be prepared following the
procedure set forth above and, prior to coupling the sulfonamide
derivative or analog thereof, e.g. coupling to the amino acid
PNH(CH.sub.2).sub.tCH(R.sup.1)COOH, carried through a procedure
referred to in the art as reductive amination. Thus, a sodium
cyanoborohydride and an appropriate aldehyde or ketone can be
reacted with the sulfonamide derivative compound or appropriate
analog at room temperature in order to reductively aminate any of
the compounds of Formulas I-IV. It is also contemplated that where
R.sup.3 of the amino alcohol intermediate is hydrogen, the
inhibitor compounds of the present invention wherein R.sup.3 is
alkyl, or other substituents wherein the .alpha.-C contains at
least one hydrogen, can be prepared through reductive amination of
the final product of the reaction between the amino alcohol and the
amine or at any other stage of the synthesis for preparing the
inhibitor compounds.
Contemplated equivalents of the general formulas set forth above
for the antiviral compounds and derivatives as well as the
intermediates are compounds otherwise corresponding thereto and
having the same general properties, such as tautomers thereof as
well as compounds, wherein one or more of the various R groups are
simple variations of the substituents as defined therein, e.g.,
wherein R is a higher alkyl group than that indicated. In addition,
where a substituent is designated as, or can be, a hydrogen, the
exact chemical nature of a substituent which is other than hydrogen
at that position, e.g., a hydrocarbyl radical or a halogen,
hydroxy, amino and the like functional group, is not critical so
long as it does not adversely affect the overall activity and/or
synthesis procedure.
The chemical reactions described above are generally disclosed in
terms of their broadest application to the preparation of the
compounds of this invention. Occasionally, the reactions may not be
applicable as described to each compound included within the
disclosed scope. The compounds for which this occurs will be
readily recognized by those skilled in the art. In all such cases,
either the reactions can be successfully performed by conventional
modifications known to those skilled in the art, e.g., by
appropriate protection of interfering groups, by changing to
alternative conventional reagents, by routine modification of
reaction conditions, and the like, or other reactions disclosed
herein or otherwise conventional, will be applicable to the
preparation of the corresponding compounds of this invention. In
all preparative methods, all starting materials are known or
readily preparable from known starting materials.
Without further elaboration, it is believed that one skilled in the
art can, using the preceding description, utilize the present
invention to its fullest extent. The following preferred specific
embodiments are, therefore, to be construed as merely illustrative,
and not limitative of the remainder of the disclosure in any way
whatsoever.
All reagents were used as received without purification. All proton
and carbon NMR spectra were obtained on either a Varian VXR-300 or
VXR-400 nuclear magnetic resonance spectrometer.
The following Examples 1 through 9 illustrate preparation of
intermediates. These intermediates are useful in preparing the
inhibitor compounds of the present invention as illustrated in
Examples 10-16. In addition, the intermediates of Examples 2-6 are
also retroviral protease inhibitors and inhibit, in particular, HIV
protease.
EXAMPLE 1A
##STR00025##
Preparation of N[3(S)-benzyloxycarbonylamino-2
(R)-hydroxy-4-phenylbutyl]-N-isoamylamine
Part A:
To a solution of 75.0 g (0.226 mol) of
N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a
mixture of 807 mL of methanol and 807 mL of tetrahydrofuran at
-2.degree. C., was added 13.17 g (0.348 mol, 1.54 equiv.) of solid
sodium borohydride over one hundred minutes. The solvents were
removed under reduced pressure at 40.degree. C. and the residue
dissolved in ethyl acetate (approx. 1 L). The solution was washed
sequentially with 1M potassium hydrogen sulfate, saturated sodium
bicarbonate and then saturated sodium chloride solutions. After
drying over anhydrous magnesium sulfate and filtering, the solution
was removed under reduced pressure. To the resulting oil was added
hexane (approx. 1 L) and the mixture warmed to 60.degree. C. with
swirling. After cooling to room temperature, the solids were
collected and washed with 2 L of hexane. The resulting solid was
recrystallized from hot ethyl acetate and hexane to afford 32.3 g
(43% yield) of
N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol, mp
150-151.degree. C. and M+Li.sup.+=340.
Part B:
To a solution of 6.52 g (0.116 mol, 1.2 equiv.) of potassium
hydroxide in 968 mL of absolute ethanol at room temperature, was
added 32.3 g (0.097 mol) of
N-CBZ-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol. After stirring for
fifteen minutes, the solvent was removed under reduced pressure and
the solids dissolved in methylene chloride. After washing with
water, drying over magnesium sulfate, filtering and stripping, one
obtains 27.9 g of a white solid. Recrystallization from hot ethyl
acetate and hexane afforded 22.3 g (77% yield) of
N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp
102-103.degree. C. and MH.sup.+298.
Part C:
A solution of N-benzyloxycarbonyl
3(S)-amino-1,2-(S)-epoxy-4-phenylbutane (1.00 g, 3.36 mmol) and
isoamylamine (4.90 g, 67.2 mmol, 20 equiv.) in 10 mL of isopropyl
alcohol was heated to reflux for 1.5 hours. The solution was cooled
to room temperature, concentrated in vacuo and then poured into 100
mL of stirring hexane whereupon the product crystallized from
solution. The product was isolated by filtration and air dried to
give 1.18 g, 95% of
N=[[3(S)-phenylmethylcarbamoyl)amino-2(R)-hydroxy-4-phenylbutyl]N-[(3-met-
hylbutyl)]amine mp 108.0-109.5.degree. C., MH.sup.+ m/z=371.
EXAMPLE 1B
##STR00026##
Preparation of
N,N-dibenzyl-3(S)-amino-1,2-(S)-epoxy-4-phenylbutane
Step A:
A solution of L-phenylalanine (50.0 g, 0.302 mol), sodium hydroxide
(24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605 mol) in
water (500 ml) was heated to 97.degree. C. Benzyl bromide (108.5
ml, 0.912 mol) was then slowly added (addition time .about.25 min).
The mixture was then stirred at 97.degree. C. for 30 minutes. The
solution was cooled to room temperature and extracted with toluene
(2.times.250 ml). The combined organic layers were then washed with
water, brine, dried over magnesium sulfate, filtered and
concentrated to give an oil product. The crude product was then
used in the next step without purification.
Step B:
The crude benzylated product of the above step was dissolved in
toluene (750 ml) and cooled to -55.degree. C. A 1.5M solution of
DIBAL-H in toluene (443.9 ml, 0.666 mol) was then added at a rate
to maintain the temperature between -55.degree. to -50.degree. C.
(addition time -1 hour). The mixture was stirred for 20 minutes at
-55.degree. C. The reaction was quenched at -55.degree. C. by the
slow addition of methanol (37 ml). The cold solution was then
poured into cold (5.degree. C.) 1.5 N HCl solution (1.8 L). The
precipitated solid (approx. 138 g) was filtered off and washed with
toluene. The solid material was suspended in a mixture of toluene
(400 ml) and water (100 ml) The mixture was cooled to 5.degree. C.,
treated with 2.5 N NaOH (186 ml) and then stirred at room
temperature until the solid was dissolved. The toluene layer was
separated from the aqueous phase and washed with water and brine,
dried over magnesium sulfate, filtered and concentrated to a volume
of 75 ml (89 g). Ethyl acetate (25 ml) and hexane (25 ml) were then
added to the residue upon which the alcohol product began to
crystallize. After 30 min., an additional 50 ml hexane was added to
promote further crystallization. The solid was filtered off and
washed with 50 ml hexane to give approximately 35 g of material. A
second crop of material could be isolated by refiltering the mother
liquor The solids were combined and recrystallized from ethyl
acetate (20 ml) and hexane (30 ml) to give, in 2 crops,
approximately 40 g (40% from L-phenylalanine) of analytically pure
alcohol product. The mother liquors were combined and concentrated
(34 g). The residue was treated with ethyl acetate and hexane which
provided an additional 7 g (.about.7% yield) of slightly impure
solid product. Further optimization in the recovery from the mother
liquor is probable.
Alternatively, the alcohol was prepared from L-phenylalaninol.
L-phenylalaninol (176.6 g, 1.168 mol) was added to a stirred
solution of potassium carbonate (484.6 g, 3.506 mol) in 710 mL of
water. The mixture was heated to 65.degree. C. under a nitrogen
atmosphere. A solution of benzyl bromide (400 g, 2.339 mol) in 3A
ethanol (305 mL) was added at a rate that maintained the
temperature between 60-68.degree. C. The biphasic solution was
stirred at 65.degree. C. for 55 min and then allowed to cool to
10.degree. C. with vigorous stirring. The oily product solidified
into small granules. The product was diluted with 2.0 L of tap
water and stirred for 5 minutes to dissolve the inorganic by
products. The product was isolated by filtration under reduced
pressure and washed with water until the pH is 7. The crude product
obtained was air dried overnite to give a semi-dry solid (407 g)
which was recrystallized from 1.1 L of ethyl acetate/heptane (1:10
by volume). The product was isolated by filtration (at -8.degree.
C.), washed with 1.6 L of cold (-10.degree. C.) ethyl
acetate/heptane (1:10 by volume) and air-dried to give 339 g (88%
yield) of .beta.S-2-[Bis(phenylmethy)amino]benzene-propanol, mp
71.5-73.0.degree. C. More product can be obtained from the mother
liquor if necessary. The other analytical characterization was
identical to compound prepared as described above. Step C:
A solution of oxalyl chloride (8.4 ml, 0.096 mol) in
dichloromethane (240 ml) was cooled to -74.degree. C. A solution of
DMSO (12.0 ml, 0.155 mol) in dichloromethane (50 ml) was then
slowly added at a rate to maintain the temperature at -74.degree.
C. (addition time .about.1.25 hr). The mixture was stirred for 5
min. followed by addition of a solution of the alcohol (0.074 mol)
in 100 ml of dichloromethane (addition time -20 min., temp.
-75.degree. C. to -68.degree. C.). The solution was stirred at
-78.degree. C. for 35 minutes. Triethylamine (41.2 ml, 0.295 mol)
was then added over 10 min. (temp. -78.degree. to -68.degree. C.)
upon which the ammonium salt precipitated. The cold mixture was
stirred for 30 min. and then water (225 ml) was added. The
dichloromethane layer was separated from the aqueous phase and
washed with water, brine, dried over magnesium sulfate, filtered
and concentrated. The residue was diluted with ethyl acetate and
hexane and then filtered to further remove the ammonium salt. The
filtrate was concentrated to give the desired aldehyde product. The
aldehyde was carried on to the next step without purification.
Temperatures higher than -70.degree. C. have been reported in the
literature for the Swern oxidation. Other Swern modifications and
alternatives to the Swern oxidations are also possible.
Alternatively, the aldehyde was prepared as follows. (200 g, 0.604
mol) was dissolved in triethylamine (300 mL, 2.15 mol). The mixture
was cooled to 12.degree. C. and a solution of sulfur
trioxide/pyridine complex (380 g, 2.39 mol) in DMSO (1.6 L) was
added at a rate to maintain the temperature between 8-17.degree. C.
(addition time -1.0 h). The solution was stirred at ambient
temperature under a nitrogen atmosphere for 1.5 hour at which time
the reaction was complete by TLC analysis (33% ethyl
acetate/hexane, silica gel). The reaction mixture was cooled with
ice water and quenced with 1.6 L of cold water (10-15.degree. C.)
over 45 minutes. The resultant solution was extracted with ethyl
acetate (2.0 L), washed with 5% citric acid (2.0 L), and brine (2.2
L), dried over MgSO.sub.4 (280 g) and filtered. The solvent was
removed on a rotary evaporator at 35-40.degree. C. and then dried
under vaccuum to give 198.8 g of
.alpha.S-[Bis-(phenylmethyl)amino]-benzenepropanaldehyde as a pale
yellow oil (99.9%). The crude product obtained was pure enough to
be used directly in the next step without purification. The
analytical data of the compound were consistent with the published
literature. [.alpha.].sub.D25=-92.9.degree. (c 1.87,
CH.sub.2Cl.sub.2); .sup.1H NMR (400 MHz, CDCl.sub.3)
.differential., 2.94 and 3.15 (ABX-System, 2H, J.sub.AB=13.9 Hz,
J.sub.AX=7.3 Hz and J.sub.BX=6.2 Hz), 3.56 (t, 1H, 7.1 Hz), 3.69
and 3.82 (AB-System, 4H, J.sub.AB=13.7 Hz), 7.25 (m, 15 H) and 9.72
(s, 1H); HRMS calcd for (M+1) C.sub.23H.sub.24NO 330.450, found:
330.1836. Anal. Calcd. for C.sub.23H.sub.23ON: C, 83.86; H, 7.04;
N, 4.25. Found: C, 83.64; H, 7.42; N, 4.19. HPLC on chiral
stationary phase:(S,S) Pirkle-Whelk--O 1 column (250.times.4.6 mm
I.D.), mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-rate:
1.5 ml/min, detection with UV detector at 210 nm. Retention time of
the desired S-isomer: 8.75 min., retention time of the
R-enanatiomer 10.62 min.
Step D:
A solution of .alpha.S-[BiS(phenylmethyl)amino]
benzene-propanaldehyde (191.7 g, 0.58 mol) and chloroiodomethane
(56.4 mL, 0.77 mol) in tetrahydrofuran (1.8 L) was cooled to -30 to
-35.degree. C. (colder temperature such as -70.degree. C. also
worked well but warmer temperatures are more readily achieved in
large scale operations) in a stainless steel reactor under a
nitrogen atmosphere. A solution of n-butyllithium in hexane (1.6 M,
365 mL, 0.58 mol) was then added at a rate that maintained the
temperature below -25.degree. C. After addition the mixture was
stirred at -30 to -35.degree. C. for 10 minutes. More additions of
reagents were carried out in the following manner: (1) additional
chloroiodomethane (17 mL) was added, followed by n-butyllithium
(110 mL) at <-25.degree. C. After addition the mixture was
stirred at -30 to -35.degree. C. for 10 minutes. This was repeated
once. (2) Additional chloroiodomethane (8.5 mL, 0.11 mol) was
added, followed by n-butyllithium (55 mL, 0.088 mol) at
<-25.degree. C. After addition, the mixture was stirred at -30
to -35.degree. C. for 10 minutes. This was repeated 5 times. (3)
Additional chloroiodomethane (8.5 mL, 0.11 mol) was added, followed
by n-butyllithium (37 mL, 0.059 mol) at <-25.degree. C. After
addition, the mixture was stirred at -30 to -35.degree. C. for 10
minutes. This was repeated once. The external cooling was stopped
and the mixture warmed to ambient temp. over 4 to 16 hours when TLC
(silica gel, 20% ethyl acetate/hexane) indicated that the reaction
was completed. The reaction mixture was cooled to 10.degree. C. and
quenched with 1452 g of 16% ammonium chloride solution (prepared by
dissolving 232 g of ammonium chloride in 1220 mL of water), keeping
the temperature below 23.degree. C. The mixture was stirred for 10
minutes and the organic and aqueous layers were separated. The
aqueous phase was extracted with ethyl acetate (2.times.500 mL).
The ethyl acetate layer was combined with the tetrahydrofuran
layer. The combined solution was dried over magnesium sulfate (220
g), filtered and concentrated on a rotary evaporator at 65.degree.
C. The brown oil residue was dried at 70.degree. C. in vacuo (0.8
bar) for 1 h to give 222.8 g of crude material. (The crude product
weight was >100%. Due to the relative instability of the product
on silica gel, the crude product is usually used directly in the
next step without purification). The diastereomeric ratio of the
crude mixture was determined by proton NMR: (2S)/(2R): 86:14. The
minor and major epoxide diastereomers were characterized in this
mixture by tlc analysis (silica gel, 10% ethyl acetate/hexane),
Rf=0.29 & 0.32, respectively. An analytical sample of each of
the diastereomers was obtained by purification on silica-gel
chromatography (3% ethyl acetate/hexane) and characterized as
follows:
N,N,.alpha.S-Tris(phenylmethyl)-2S-oxiranemethanamine; .sup.1H NMR
(400 MHz, CDCl.sub.3) .differential. 2.49 and 2.51 (AB-System, 1H,
J.sub.AB=2.82), 2.76 and 2.77 (AB-System, 1H, J.sub.AB=4.03), 2.83
(m, 2H), 2.99 & 3.03 (AB-System, 1H, J.sub.AB=10.1 Hz), 3.15
(m, 1H), 3.73 & 3.84 (AB-System, 4H, J.sub.AB=14.00), 7.21 (m,
15H); .sup.13C NMR (400 MHz,CDCl.sub.3) .differential. 139.55,
129.45, 128.42, 128.14, 128.09, 126.84, 125.97, 60.32, 54.23,
52.13, 45,99, 33.76; HRMS calcd for C.sub.24H.sub.26NO (M+1)
344.477, found 344.2003.
N,N,.alpha.S-Tris(phenylmethyl)-2R-oxiranemethanamine; .sup.1H NMR
(300 MHz, CDCl.sub.3) .differential. 2.20 (m, 1H), 2.59 (m, 1H),
2.75 (m, 2H), 2.97 (m, 1H), 3.14 (m, 1H), 3.85 (AB-System, 4H),
7.25 (m, 15H).HPLC on chiral stationary phase: Pirkle-Whelk--O 1
column (250.times.4.6 mm I.D.), mobile phase: hexane/isopropanol
(99.5:0.5, v/v), flow-rate: 1.5 ml/min, detection with UV detector
at 210 nm. Retention time of (8): 9.38 min., retention time of
enanatiomer of (4): 13.75 min.
Alternatively, a solution of the crude aldehyde 0.074 mol and
chloroiodomethane (7.0 ml, 0.096 mol) in tetrahydrofuran (285 ml)
was cooled to -78.degree. C., under a nitrogen atmosphere. A 1.6 M
solution of n-butyllithium in hexane (25 ml, 0.040 mol) was then
added at a rate to maintain the temperature at -75.degree. C.
(addition time -15 min.). After the first addition, additional
chloroiodomethane (1.6 ml, 0.022 mol) was added again, followed by
n-butyllithium (23 ml, 0.037 mol), keeping the temperature at
-75.degree. C. The mixture was stirred for 15 min. Each of the
reagents, chloroiodomethane (0.70 ml, 0.010 mol) and n-butyllithium
(5 ml, 0.008 mol) were added 4 more times over 45 min. at
-75.degree. C. The cooling bath was then removed and the solution
warmed to 22.degree. C. over 1.5 hr. The mixture was poured into
300 ml of saturated aq. ammonium chloride solution. The
tetrahydrofuran layer was separated. The aqueous phase was
extracted with ethyl acetate (1.times.300 ml). The combined organic
layers were washed with brine, dried over magnesium sulfate,
filtered and concentrated to give a brown oil (27.4 g). The product
could be used in the next step without purification. The desired
diastereomer can be purified by recrystallization at a subsequent
step. The product could also be purified by chromatography.
Alternatively, a solution of
.alpha.S-[Bis(phenylmethyl)amino]benzene-propanaldehyde (178.84 g,
0.54 mol) and bromochloromethane (46 mL, 0.71 mol) in
tetrahydrofuran (1.8 L) was cooled to -30 to -35.degree. C. (colder
temperature such as -70.degree. C. also worked well but warmer
temperatures are more readily achieved in large scale operations)
in a stainless steel reactor under a nitrogen atmosphere. A
solution of n-butyllithium in hexane (1.6 M, 340 mL, 0.54 mol) was
then added at a rate that maintained the temperature below
-25.degree. C. After addition the mixture was stirred at -30 to
-35.degree. C. for 10 minutes. More additions of reagents were
carried out in the following manner: (1) additional
bromochloromethane (14 mL) was added, followed by n-butyllithium
(102 mL) at <-25.degree. C. After addition the mixture was
stirred at -30 to -35.degree. C. for 10 minutes. This was repeated
once. (2) Additional bromochloromethane (7 mL, 0.11 mol) was added,
followed by n-butyllithium (51 mL, 0.082 mol) at <-25.degree. C.
After addition the mixture was stirred at -30 to -35.degree. C. for
10 minutes. This was repeated 5 times. (3) Additional
bromochloromethane (7 mL, 0.11 mol) was added, followed by
n-butyllithium (51 mL, 0.082 mol) at <-25.degree. C. After
addition the mixture was stirred at -30 to -35.degree. C. for 10
minutes. This was repeated once. The external cooling was stopped
and the mixture warmed to ambient temp. over 4 to 16 hours when TLC
(silica gel, 20% ethyl acetate/hexane) indicated that the reaction
was completed The reaction mixture was cooled to 10.degree. C. and
quenched with 1452 g of 16% ammonium chloride solution (prepared by
dissolving 232 g of ammonium chloride in 1220 mL of water), keeping
the temperature below 23.degree. C. The mixture was stirred for 10
minutes and the organic and aqueous layers were separated. The
aqueous phase was extracted with ethyl acetate (2.times.500 mL).
The ethyl acetate layer was combined with the tetrahydrofuran
layer. The combined solution was dried over magnesium sulfate (220
g), filtered and concentrated on a rotary evaporator at 65.degree.
C. The brown oil residue was dried at 70.degree. C. in vacuo (0.8
bar) for 1 h to give 222.8 g of crude material.
EXAMPLE 2
##STR00027##
Preparation of
N-[[3S-(phenylmethylcarbamoyl)aminol-2R-hydroxy-4-phenyl]-1-[(2-methylpro-
pyl)amino-2-(1,1-dimethylethoxyl)carbonyl]butane
To a solution of 7.51 g (20.3 mmol) of
N-[[3S-(phenylmethylcarbamoyl)amino]-2R-hydroxy-4-phenylbutyl]-N-(2-methy-
lpropyl)]amine in 67 mL of anhydrous tetrahydrofuran was added 2.25
g (22.3 mmol) of triethylamine. After cooling to 0.degree. C., 4.4
g (20.3 mmol) of di-tert-butyldicarbonate was added and stirring
continued at room temperature for 21 hours. The volatiles were
removed in vacuo, ethyl acetate added, then washed with 5% citric
acid, saturated sodium bicarbonate, brine, dried over magnesium
sulfate, filtered and concentrated to afford 9.6 g of crude
product. Chromatography on silica gel using 30% ethyl
acetate/hexane afforded 8.2 g of pure
N-[[3S-(phenylmethylcarbamoyl)amino]-2R-hydroxy-4-phenyl]-1-[(2-methylpro-
pyl)amino-2-(1,1-dimethylethoxyl)carbonyl]butane, mass spectum
m/e=477 (M+Li).
EXAMPLE 3A
##STR00028##
Preparation of phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)
(methylsulfonyl)amino]-1S-(phenylmethyl)-propyl]carbamate
To a solution of
N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]
N-isoamylamine (2.0 gm, 5.2 mmol) and triethylamine (723 uL, 5.5
mmol) in dichloromethane (20 mL) was added dropwise methanesulfonyl
chloride (400 uL, 5.2 mmol). The reaction mixture was stirred for 2
hours at room temperature, then the dichloromethane solution was
concentrated to ca. 5 mL and applied to a silica gel column (100
gm). The column was eluted with chloroform containing 1% ethanol
and 1% methanol. The phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)
(methylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate was
obtained as a white solid Anal. Calcd for
C.sub.24H.sub.34N.sub.2O.sub.5S: C, 62.31; H, 7.41; N, 6.06. Found:
C, 62.17; H, 7.55; N, 5.97.
EXAMPLE 3B
##STR00029##
Preparation of phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)amino]-1S-(phenylmethyl)-propyl]carbamate
From the reaction of
N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]
N-isoamylamine (1.47 gm, 3.8 mmol), triethylamine (528 uL, 3.8
mmol) and benzenesulfonyl chloride (483 uL, 3.8 mmol) one obtains
phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-carbamate. Column
chromotography on silica gel eluting with chloroform containing 1%
ethanol afforded the pure product. Anal. Calcd for
C.sub.29H.sub.36N.sub.2O.sub.5S: C, 66.39; H, 6.92; N, 5.34. Found:
C, 66.37; H, 6.93; N, 5.26.
EXAMPLE 4
##STR00030##
Preparation of Phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)
(n-propanesulfonyl)amino]-1S-(phenylmethyl)-propyl]carbamate
To a solution of
N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]
N-isoamylamine (192 mg, 0.5 mmol) and triethylamine (139 uL, 1.0
mmol) in dichloromethane (10 mL) was added dropwise trimethylsilyl
chloride (63 uL, 0.5 mmol). The reaction was allowed to stir for 1
hour at room temperature, cooled to 0.degree. C. with an ice bath
and then n-propanesulfonyl chloride (56 uL, 0.5 mmol) was added
dropwise. The reaction mixture was stirred for 1.5 hours at room
temperature, then diluted with ethyl acetate (50 mL) and washed
sequentially with 1N HCl, water, saturated sodium bicarbonate
solution, and saturated sodium chloride solution (25 mL each). The
organic solution was dried over magnesium sulfate, filtered and
concentrated to an oil. The oil was stirred with methanol (10 mL)
for 16 hours, concentrated and the residue chromatographed on
silica gel (50 gm) eluting with 10% ethyl acetate in hexane (450
mL), then with 1:1 ethyl acetate/hexane. The phenylmethyl
[2R-hydroxy-3-[(3-methylbutyl)
(n-propanesulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate was
recrystallized from ethyl ether/hexane to afford a white solid
Anal. Calcd. for C.sub.26H.sub.38N.sub.2O.sub.5S: C, 63.64; H,
7.81; N, 5.71. Found: C, 63.09; H, 7.74; N, 5.64.
EXAMPLE 5
##STR00031## The procedure described in Example 2 was used to
prepare phenylmethyl [2S-hydroxy-3-[(3-methylbutyl)
(methylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate.
To a solution of
N[3(S)-benzyloxycarbonylamino-2(S)-hydroxy-4-phenylbutyl]
N-isoamylamine (192 mg, 0.5 mmol) and triethylamine (139 uL, 0.55
mmol) in dichloromethane (8 mL) was added dropwise methanesulfonyl
chloride (39 uL, 0.55 mmol). The reaction mixture was stirred for
16 hours at room temperature, then the dichloromethane solution was
applied to a silica gel column (50 gm). The column was eluted with
dichloromethane containing 2.5% methanol. The phenylmethyl
[2S-hydroxy-3-[(3-methylbutyl)
(methylsulfonyl)amino]-1S-(phenylmethyl) propyl]carbamate was
obtained as a white solid Anal. Calcd. for
C.sub.24H.sub.34N.sub.2O.sub.5S .diamond. 0.2 H.sub.2O: C, 61.83;
H, 7.44; N, 6.01. Found: C, 61.62; H, 7.40; N, 5.99.
EXAMPLE 6
Following the procedures of the previous Examples 1-5, the
intermediate compounds set forth in Tables 1A and 1B were
prepared.
TABLE-US-00001 TABLE 1A ##STR00032## Entry R.sup.3 R.sup.4 1
isoamyl p-fluorophenyl 2 isoamyl p-nitrophenyl 3 isoamyl
o-nitrophenyl 4 isoamyl 13-naphthyl 5 isoamyl 2-thienyl 6 isoamyl
benzyl 7 isobutyl p-fluorophenyl 8 p-fluorobenzyl phenyl 9
4-pyridylmethyl phenyl 10 cyclohexylmethyl phenyl 11 allyl phenyl
12 propyl phenyl 13 cyclopropylmethyl phenyl 14 methyl phenyl 15
propargyl phenyl 16 isoamyl p-chlorophenyl 17 isoamyl
p-methoxyphenyl 18 isoamyl m-nitrophenyl 19 isoamyl
m-trifluoromethylphenyl 20 isoamyl o-methoxycarbonylphenyl 21
isoamyl p-acetamidophenyl 22 isobutyl phenyl 23 --CH.sub.2Ph --Ph
24 ##STR00033## --Ph 25 ##STR00034## --Ph 26 ##STR00035## --Ph 27
##STR00036## --Ph 28 ##STR00037## --Ph 29 --CH.sub.2CH.dbd.CH.sub.2
--Ph 30 ##STR00038## --Ph 31 ##STR00039## --Ph 32
--CH.sub.2CH.sub.2Ph --Ph 33 --CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH
--Ph 34 --CH.sub.2CH.sub.2N(CH.sub.3).sub.2 --Ph 35 ##STR00040##
--Ph 36 --CH.sub.3 --Ph 37 --CH.sub.2CH.sub.2CH.sub.2SCH.sub.3 --Ph
38 --CH.sub.2CH.sub.2CH.sub.2S(O).sub.2CH.sub.3 --Ph 39
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00041## 40
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 --CH.sub.2CH.sub.2CH.sub.3 41
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 --CH.sub.3 42
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00042## 43
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00043## 44
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00044## 45
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00045## 46
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00046## 47
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00047## 48
--CH.sub.2CH.sub.2CH.sub.3 ##STR00048## 49
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3 ##STR00049## 50
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 --CF.sub.3 51
--CH.sub.2CH(CH.sub.3).sub.2 --CH.sub.3 52
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 --CH.sub.2Cl 53
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00050## 54
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00051## 55
--CH.sub.2CH(CH.sub.3).sub.2 --CH.dbd.CH.sub.2 56
--CH.sub.2--CH)CH.sub.3)(CH.sub.2CH.sub.3) ##STR00052##
##STR00053## MASS MEASUREMENT Entry R.sup.3 R.sup.4 MOL FORM CALC
FOUND 1 ##STR00054## ##STR00055## C.sub.29H.sub.36N.sub.2O.sub.5S
531 531 2 ##STR00056## C.sub.29H.sub.36N.sub.2O.sub.6S 541 541 3
##STR00057## C.sub.30H.sub.36N.sub.2O.sub.6S 555.2529 555.2582 4
##STR00058## 5 ##STR00059## 6 ##STR00060##
C.sub.28H.sub.33N.sub.2O.sub.5SF 529.2172 521.2976 7 ##STR00061## 8
##STR00062## C.sub.29H.sub.36N.sub.2O.sub.5S.sub.2 563 (M + Li) 563
9 ##STR00063## C.sub.29H.sub.36N.sub.2O.sub.6S.sub.2 573 (M + H)
573 10 ##STR00064## C.sub.29H.sub.36N.sub.2O.sub.7S.sub.2 595 (M +
Li) 595
TABLE-US-00002 TABLE 1B ##STR00065## Entry R R.sup.3 1 ##STR00066##
--CH.sub.2Ph 2 ##STR00067## --CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 3
##STR00068## --CH.sub.2CH(CH.sub.3).sub.2 4 ##STR00069##
--CH.sub.2CH(CH.sub.3).sub.2 5 ##STR00070##
--CH.sub.2CH(CH.sub.3).sub.2 6 ##STR00071##
--CH.sub.2CH(CH.sub.3).sub.2 7 ##STR00072##
--CH.sub.2CH(CH.sub.3).sub.2 8 ##STR00073##
--CH.sub.2CH(CH.sub.3).sub.2 9 ##STR00074##
--CH.sub.2CH.sub.2(CH.sub.3).sub.2
TABLE-US-00003 TABLE 1C ##STR00075## Mass Determination X R.sup.8
FORMULA Calc Found H ##STR00076## C.sub.27H.sub.33N.sub.3O.sub.5S
512.2219 (M + H) 521.2267 OCH.sub.3 ##STR00077##
C.sub.28H.sub.35N.sub.3O.sub.6S 548.2407 (M + Li) 548.2434 F
##STR00078## C.sub.27H.sub.32N.sub.3O.sub.5SF 530 (M + H) 530 Cl
##STR00079## C.sub.27H.sub.32N.sub.3O.sub.5SCl 546 (M + H) 546
NO.sub.2 ##STR00080## C.sub.22H.sub.32N.sub.4O.sub.2S 557 (M + H)
557 OH ##STR00081## C.sub.27H.sub.33N.sub.3O.sub.6S 528 (M + H) 528
OCH.sub.3 ##STR00082## C.sub.28H.sub.35N.sub.3O.sub.6S 542.2325 (M
+ H) 542.2362 OCH.sub.3 ##STR00083##
C.sub.28H.sub.35N.sub.3O.sub.6S 548.2407 (M + Li) 548.2393
OCH.sub.3 ##STR00084## C.sub.27H.sub.34N.sub.4O.sub.6S 543 (M + H)
543 OCH.sub.3 ##STR00085## C.sub.29H.sub.36O.sub.6N.sub.2S 547.2454
(M + Li) 547.2475 OCH.sub.3 tert-Butyl
C.sub.26H.sub.38N.sub.2O.sub.6S 513.2611 513.2593 (M + Li)
OCH.sub.3 ##STR00086## C.sub.28H.sub.35N.sub.3O.sub.7S 564 (M + Li)
564 OCH.sub.3 ##STR00087## C.sub.28H.sub.35N.sub.3O.sub.7S 564 (M +
Li) 564
The following Examples 7-9 illustrate preparation of .beta.-amino
acid intermediates. These intermediates can be coupled to the
intermediate compounds of Examples 1-6 to produce inhibitor
compounds of the present invention containing .beta.-amino
acids.
EXAMPLE 7
A. Preparation of 4(4-methoxybenzyl)itaconate
##STR00088##
A 5 L three-necked round bottomed flask equipped with constant
pressure addition funnel, reflux condenser, nitrogen inlet, and
mechanical stirrer was charged with itaconic anhydride (660.8 g,
5.88 mol) and toluene (2300 mL). The solution was warmed to reflux
and treated with 4-methoxybenzyl alcohol (812.4 g, 5.88 mol)
dropwise over a 2.6 h period. The solution was maintained at reflux
for an additional 1.5 h and then the contents were poured into
three 2 L erlenmeyer flasks to crystallize. The solution was
allowed to cool to room temperature whereupon the desired
mono-ester crystallized. The product was isolated by filtration on
a Buchner funnel and air dried to give 850.2 g, 58% of material
with mp 83-85.degree. C., a second crop, 17% was isolated after
cooling of the filtrate in an ice bath. .sup.1H NMR (CDCl.sub.3)
300 MHz 7.32(d, J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz, 2H), 6.49(s, 1H),
5.85(s, 1H), 5.12(s, 2H), 3.83(s, 3H), 3.40(s, 2H).
B. Preparation of Methyl 4(4-methoxybenzyl) itaconate
##STR00089##
A 5 L three-necked round bottomed flask equipped with reflux
condenser, nitrogen inlet, constant pressure addition funnel and
mechanical stirrer was charged with 4(4-methoxybenzyl) itaconate
(453.4 g, 1.81 mol) and treated with
1,5-diazabicyclo[4.3.0]non-5-ene (275.6 g, 1.81 mol), (DBN),
dropwise so that the temperature did not rise above 15.degree. C.
To this stirring mixture was added a solution of methyl iodide
(256.9 g, 1.81 mol) in 250 mL of toluene from the dropping funnel
over a 45m period. The solution was allowed to warm to room
temperature and stirred for an additional 3.25 h.
The precipitated DBN hydroiodide was removed by filtration, washed
with toluene and the filtrate poured into a separatory funnel. The
solution was washed with sat. aq. NaHCO.sub.3 (2.times.500 mL),
0.2N HCl (1.times.500 mL), and brine (2.times.500 mL), dried over
anhyd. MgSO.sub.4, filtered, and the solvent removed in vacuo. This
gave a clear colorless oil, 450.2 g, 94% whose NMR was consistent
with the assigned structure. .sup.1H NMR (CDCl.sub.3 300 MHz
7.30(d, J=8.7 Hz, 2H), 6.90(d, J=8.7 Hz, 2H), 6.34(s, 1H), 5.71(s,
1H), 5.09(s, 2H), 3.82(s, 3H), 3.73(s, 3H), 3.38(s, 2H). .sup.13C
NMR (CDCl.sub.3) 170.46, 166.47, 159.51, 133.55, 129.97, 128.45,
127.72, 113.77, 66.36, 55.12, 51.94, 37.64.
C. Preparation of Methyl 4(4-methoxybenzyl)
2(R)-methylsuccinate
##STR00090##
A 500 mL Fisher-Porter bottle was charged with methyl
4(4-methoxybenzyl) itaconate (71.1 g, 0.269 mol), rhodium (R,R)
DIPAMP catalyst (204 mg, 0.269 mmol, 0.1 mol %) and degassed
methanol (215 mL). The bottle was flushed 5 times with nitrogen and
5 times with hydrogen to a final pressure of 40 psig. The
hydrogenation commenced immediately and after ca. lh the uptake
began to taper off, after 3 h the hydrogen uptake ceased and the
bottle was flushed with nitrogen, opened and the contents
concentrated on a rotary evaporator to give a brown oil that was
taken up in boiling iso-octane (ca. 200 mL, this was repeated
twice), filtered through a pad of celite and the filtrate
concentrated in vacuo to give 66.6 g, 93% of a clear colorless oil,
.sup.1H NMR (CDCl3 300 MHz 7.30(d, J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz,
2H), 5.08(s, 2H), 3.82(s, 3H), 3.67(s, 3H), 2.95(ddq, J=5.7, 7.5,
8.7 Hz, 1H), 2.79(dd, J=8.1, 16.5 Hz, 1H), 2.45(dd, J=5.7, 16.5 Hz,
1H), 1.23(d, J=7.5 Hz, 3H).
D. Preparation of Methyl 2(R)-methylsuccinate
A 3 L three-necked round-bottomed flask equipped with a nitrogen
inlet, mechanical stirrer, reflux condenser and constant pressure
addition funnel was charged with methyl 4(4-methoxybenzyl)
2(R)-methylsuccinate (432.6 g, 1.65 mol) and toluene (1200 mL). The
stirrer was started and the solution treated with trifluoroacetic
acid (600 mL) from the dropping funnel over 0.25 h. The solution
turned a deep purple color and the internal temperature rose to
45.degree. C. After stirring for 2.25 h the temperature was
27.degree. C. and the solution had acquired a pink color. The
solution was concentrated on a rotary evaporator. The residue was
diluted with water (2200 mL) and sat. aq. NaHCO.sub.3 (1000 mL).
Additional NaHCO.sub.3 was added until the acid had been
neutralized. The aqueous phase was extracted with ethyl acetate
(2.times.1000 mL) to remove the by-products and the aqueous layer
was acidified to pH=1.8 with conc. HCl. This solution was extracted
with ethyl acetate (4.times.1000 mL), washed with brine, dried over
anhyd. MgSO.sub.4, filtered and concentrated on a rotary evaporator
to give a colorless liquid 251 g, >100% that was vacuum
distilled through a short path apparatus cut 1: bath temperature
120.degree. C. @ >1 mm, bp 25-29.degree. C.; cut 2: bath
temperature 140.degree. C. @ 0.5 mm, bp 95-108.degree. C., 151 g,
[.alpha.].sub.d @ 25.degree. C.=+1.38.degree. C.(c=15.475, MeOH),
[.alpha.].sub.d=+8.48.degree. C. (neat); cut 3: bath temperature
140.degree. C., bp 108.degree. C., 36 g, [.alpha.].sub.d @
25.degree. C.=+1.49.degree. C.(c=15.00, MeOH),
[.alpha.].sub.d=+8.98.degree. C. (neat). Cuts 2 and 3 were combined
to give 189 g, 78% of product, .sup.1H NMR (CDCl.sub.3) 300 MHz
11.6(brs, 1H), 3.72(s, 3H), 2.92(ddq, J=15.7, 6.9, 8.0 Hz, 1H),
2.81(dd, J=8.0, 16.8 Hz, 1H), 2.47(dd, J=5.7, 16.8 Hz, 1H), 1.26(d,
J=6.9 Hz, 3H).
E. Preparation of Methyl Itaconate
##STR00091##
A 50 mL round bottomed flask equipped with reflux condenser,
nitrogen inlet and magnetic stir bar was charged with methyl
4(4-methoxybenzyl) itaconate (4.00 g, 16 mmol), 12 mL of touluene
and 6 mL of trifluoroacetic acid. The solution was kept at room
temperature for 18 hours and then the volatiles were removed in
vacuo. The residue was taken up in ethyl acetate and extracted
three times with saturated aqueous sodium bicarbonate solution. The
combined aqueous extract was acidified to pH=1 with aqueous
potassium bisulfate and then extracted three times with ethyl
acetate. The combined ethyl acetate solution was washed with
saturated aqueous sodium chloride, dried over anhydrous magnesium
sulfate, filtered, and concentrated in vacuo. The residue was then
vacuum distilled to give 1.23 g, 75% of pure product, by 85-87 @
0.1 mm. .sup.1H NMR (CDCl.sub.3) 300 MHz 6.34(s, 1H), 5.73(s, 2H),
3.76(s, 3H) 3.38(s, 2H). .sup.13C NMR (CDCl.sub.3) 177.03, 166.65,
129.220, 132.99, 52.27, 37.46.
F. Curtius Rearrangement of Methyl 2(R)-methylsuccinate:
Preparation of Methyl N-Moz-.alpha.-methyl .beta.-alanine.
##STR00092##
A 5 L four necked round bottomed flask equipped with a nitrogen
inlet, reflux condenser, mechanical stirrer, constant pressure
addition funnel, and thermometer adapter was charged with methyl
2(R)-methylsuccinate (184.1 g, 1.26 mol), triethylamine (165.6 g,
218 mL, 1.64 mol, 1.3 equivalents), and toluene (1063 mL). The
solution was warmed to 85.degree. C. and then treated dropwise with
a solution of diphenylphosphoryl azide (346.8 g, 1.26 mol) over a
period of 1.2 h. The solution was maintained at that temperature
for an additional 1.0h and then the mixture was treated with
4-methoxybenzyl alcohol (174.1 g, 1.26 mol) over a 0.33 h period
from the dropping funnel. The solution was stirred at 88.degree. C.
for an additional 2.25 h and then cooled to room temperature. The
contents of the flask were poured into a separatory funnel and
washed with sat. aq. NaHCO.sub.3 (2.times.500 mL), 0.2N HCl
(2.times.500 mL), brine (1.times.500 mL), dried over anhyd.
MgSO.sub.4, filtered, and concentrated in vacuo to give 302.3 g,
85% of the desired product as a slightly brown oil. .sup.1H NMR
(CDCl.sub.3) 300 MHz 7.32(d, J=8.4 Hz, 2H), 6.91(d, J=8.4 Hz, 2H),
5.2(brm, 1H), 5.05(s, 2H), 3.83(s, 3H), 3.70(s, 3H), 3.35(m, 2H),
2.70(m, 2H), 1.20(d, J=7.2 Hz, 3H).
G. Hydrolysis of Methyl N-Moz-.alpha.-methyl .beta.-alanine:
Preparation of .alpha.-methyl .beta.-alanine Hydrochloride
##STR00093##
A 5 L three-necked round bottomed flask equipped with a reflux
condenser, nitrogen inlet and mechanical stirrer was charged with
methyl N-Moz-.alpha.-methyl .beta.-alanine (218.6 g, 0.78 mol),
glacial acetic acid (975 mL) and 12N hydrochloric acid (1960 mL).
The solution was then heated to reflux for 3 h. After the solution
had cooled to room temperature (ca. 1 h) the aqueous phase was
decanted from organic residue (polymer) and the aqueous phase
concentrated on a rotary evaporator. Upon addition of acetone to
the concentrated residue a slightly yellow solid formed that was
slurried with acetone and the white solid was isolated by
filtration on a Buchner funnel. The last traces of acetone were
removed by evacuation to give 97.7 g, 90% of pure product, mp
128.5-130.5.degree. C. [.alpha.].sub.d @ 25.degree. C.=9.0.degree.
C. (c=2.535, Methanol). .sup.1H NMR (D.sub.2O) 300 MHz 3.29(dd,
J=8.6, 13.0 Hz, 1H), 3.16(dd, J=5.0, 13.0 m Hz, 1H), 2.94(ddq,
J=7.2, 5.0, 8.6 Hz, 1H), 1.30(d,J=7.2 Hz, 3H); .sup.13C NMR
(D.sub.2O) 180.84, 44.56, 40.27, 17.49.
H. Preparation of N-Boc .alpha.-Methyl .beta.-Alanine
##STR00094##
A solution of a-methyl b-alanine hydrochloride (97.7 g, 0.70 mol)
in water (1050 mL) and dioxane (1050 mL) the pH was adjusted to 8.9
with 2.9N NaOH solution. This stirring solution was then treated
with di-tert-butyl pyrocarbonate (183.3 g, 0.84 mol, 1.2
equivalents) all at once. The pH of the solution was maintained
between 8.7 and 9.0 by the periodic addition of 2.5N NaOH solution.
After 2.5 h the pH had stabilized and the reaction was judged to be
complete. The solution was concentrated on a rotary evaporator (the
temperature was maintained at <40.degree. C.). The excess
di-tert-butyl pyrocarbonate was removed by extraction with
dichloromethane and then the aqueous solution was acidified with
cold 1N HCl and immediately extracted with ethyl acetate
(4.times.1000 mL). The combined ethyl acetate extract was washed
with brine, dried over anhyd. MgSO.sub.4, filtered and concentrated
on a rotary evaporator to give a thick oil 127.3 g, 90% crude yield
that was stirred with n-hexane whereupon crystals of pure product
formed, 95.65 g, 67%, mp 76-78.degree. C., [.alpha.].sub.d @
25.degree. C.=-11.8.degree. C. (c=2.4, EtOH). A second crop was
obtained by concentration of the filtrate and dilution with hexane,
15.4 g, for a combined yield of 111.05 g, 78%. .sup.1H NMR (acetone
D.sub.6) 300 MHz 11.7 (brs, 1H), 6.05 (brs 1H), 3.35 (m, 1H), 3.22
(m, 1H), 2.50 (m, 1H), 1.45(s, 9H), 1.19 (d, J=7.3 Hz, 3H);
.sup.13C NMR (acetone D.sub.6) 177.01, 79.28, 44.44, 40.92, 29.08,
15.50. Elemental analysis calcd. for C.sub.9H.sub.17NO.sub.4: C,
53.19, H, 8.42; N, 6.89. Found: C, 53.36; H, 8.46; N, 6.99.
I. Preparation of N-4-Methoxybenzyloxycarbonyl .alpha.-Methyl
.beta.-Alanine
A solution of N-4-methoxybenzyloxycarbonyl .alpha.-methyl
.beta.-alanine methyl ester (2.81 g, 10.0 mmol) in 30 mL of 25%
aqueous methanol was treated with lithium hydroxide (1.3
equivalents) at room temperature for a period of 2 h. The solution
was concentrated in vacuo and the residue taken up in a mixture of
water and ether and the phases separated and the organic phase
discarded. The aqueous phase was acidified with aqueous potassium
hydrogen sulfate to pH=1.5 and then extracted three times with
ether. The combined ethereal phase was washed with saturated
aqueous sodium chloride solution, dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo to give 2.60 g, 97% of
N-4-Methoxybenzyloxycarbonyl .alpha.-methyl .beta.-alanine
(N-Moz-AMBA) which was purified by recrystallization from a mixture
of ethyl acetate and hexane to give 2.44 g, 91% of pure product, mp
96-97.degree. C., MH+=268. .sup.1H NMR (D.sub.6-acetone/300 MHz)
1.16 (3H, d, J=7.2Hz), 2.70 (1H, m), 3.31 (2H, m), 3.31 (3H, s),
4.99 (2H, s), 6.92 (2H, 4, J=8.7 Hz), 7.13 (2H, d, J=8.7 Hz).
EXAMPLE 8
Following generally the procedure of Example 7, the .beta.-amino
acids set forth in Table 1 were prepared.
TABLE-US-00004 TABLE 2 ##STR00095## Entry R.sup.1 R.sup.1'
R.sup.1'' 1 --CH.sub.3 H H 2 --CH(CH.sub.3).sub.2 H H 3
--C(CH.sub.3).sub.3 H H 4 H H H 5 H --CH.sub.3 H 6 H --CH.sub.3
--CH.sub.3 7 H H --CO.sub.2CH.sub.3 8 H H --CONH.sub.2 9
--CH.sub.2CH.sub.3 H H 10 --CH.sub.2CH(CH.sub.3).sub.2 H H 11
--CH.sub.2C.sub.6H.sub.5 H H 12 ##STR00096## H H 13 ##STR00097## H
H 14 --CH.sub.2COOH H H 15 H --CH(CH.sub.3).sub.2 H 16 H
--CH.sub.2CH(CH.sub.3).sub.2 H 17 H ##STR00098## H 18 H
##STR00099## H 19 H ##STR00100## H 20 H ##STR00101## H 21 H
--(CH.sub.2).sub.3CH(C.sub.6H.sub.5).sub.2 H
EXAMPLE 9
Utilizing generally the procedure set forth in Example 7, the
following .beta.-amino acid compounds were prepared.
##STR00102##
EXAMPLE 10A
##STR00103##
Preparation of 4-Pyridinecarboxamide,
N-[2R-hydroxy-3-[[(4-methoxyyhenyl)sulfonyl](2-methylpropyl)amino]-1S-(-p-
henylmethyl)propyl]
To a solution of 231 mg (0.57 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]
amino-1S-(phenylmethyl)propylamine in 3 mL of methylene chloride at
0 C, was added 288 mg(2.85 mmol) of triethylamine and then 112
mg(0.63 mmol) of isonicotinoyl chloride hydrochloride. After 19
hours at room temperature, the solvent was removed, ethyl acetate
added, then washed with saturated sodium bicarbonate, brine, dried
with magnesium sulfate, filtered and concentrated to afford 290 mg
of crude product. This was chromatographed on silica gel using 3-5%
isopropanol/methylene chloride as eluent to afford 190 mg of the
desired compound; mass spectrum calc. for
C.sub.27H.sub.34N.sub.3O.sub.5S (M+H) 512.2219; found 512.2280.
EXAMPLE 10B
##STR00104##
Preparation of Benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(-p-
henylmethyl)propyl]-2,6-dimethyl
To a solution of 83 mg (0.55 mmol) of 2,6-dimethylbenzoic acid and
125 mg (0.82 mmol) of N-hydroxybenzotriazole in 3 mL of anhydrous
DMF at 0 C was added 117 mg (0.61 mmol) of
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. After
2 hours at 0 C, 203 mg (0.50 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyllsulfonyl]amino-1S-(phenylm-
ethyl)propylamine was added. After 22 hours at room temperature,
the solvent was removed in vacuo, ethyl acetate added, then washed
with saturated sodium bicarbonate, brine, dried over magnesium
sulfate, filtered and concentrated to afford 300 mg of crude
product. Chromatography on silica gel using 20-50% ethyl
acetate/hexane afforded 37 mg of the desired product; mass spectrum
calcd for C.sub.30H.sub.38N.sub.2O.sub.5S (M+H) 539.2580; found
539.2632.
EXAMPLE 10C
##STR00105##
Preparation of Benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyl)propyl]-2-methyl.
Part A. Preparation of 4-Nitro-2-methylbenzoic Acid.
A mixture of 1.0 g(3.8 mmol) of 2-iodo-nitrotoluene, 2.1 g(15.2
mmol) potassium carbonate and 27 mg(0.038 mmol) of palladium(II)
dichloride bis(triphenylphosphine) in a mixture of 5 mL of water
and 10 mL of N,N-dimethylformamide. This was placed in a
Fisher/Porter bottle under 15 psig of carbon monoxideand heated at
70 C for 16 hours. The solution became homogeneous when heated. The
reaction was cooled, diethyl ether and water was added, the organic
layer separated and discarded. The aqueous layer was acidified with
iN hydrohloric acid, extracted with ethyl acetate, washed with
water, brine, dried over magnesium sulfate, filtered and
concentrated to yield 0.5 g of crude material. This dissolved in
ethyl acetate, hexane added and the resulting brown solid
discarded. The filtrate was concentrated, and then recrystallized
fom diethyl ether/hexane to afford 215 mg of
4-nitro-2-methylbenzoic acid, m/e=182(M+H).
Part B. Preparation of Benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyl)propyl]-2-methyl-4-nitro.
To a solution of 181 mg(1.0 mmol) of 4-nitro-2-methylbenzoic acid
and 230 mg(1.5 mmol) N-hydroxybenzotriazole in 3 mL of anhydrous
N,N-dimethylformamide at 0 C, was added 211 mg(1.1 mmol) of
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. After
stirring at 0 C for 1 hour, 406 mg(1 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]amino-1S-(phenylm-
ethyl)propylamine was added. After 17 hours at room temperature,
the solvent was removed under reduced pressure, ethyl acetate
added, washed with 5% citric acid, saturated sodium bicarbonate,
brine, dried with magnesium sulfate, filtered and concentrated to
yield 0.55 g of crude product. This was chromatographed on silica
gel using 20-50% ethyl acetate/hexane as eluent to afford 0.49 g of
the desired benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyl)propyl]-2-methyl-4-nitro, m/e=570(M+H).
Part C. Preparation of Benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyl)propyl]-2-methyl-4-amino.
A solution of 400 mg(0.70 mmol) of benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyl)propyl]-2-methyl-4-nitro from part B in 20 mL of
methanol was hydrogenated over 0.2 g of 10% palladium on carbon
catalyst under 50 psig of hydrogen for 2.5 hours. The catalyst was
removed by filtration and the solution concentrated to afford 370
mg of the desired benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyllpropyl]-2-methyl-4-amino, m/e=540(M+H).
Part D. Preparation of Benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyl)propyl]-2-methyl-4-dimethylamino.
A solution of 0.17 g(0.31 mmol) of benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyl)propyl]-2-methyl-4-amino from part C in 5 mL of methanol
and 0.20 mL of 37% aqueous formaldehyde was hydrogenated over 90 mg
of 10% palladium on carbon under 15 psig of hydrogen for 16 hours.
The catalyst was removed by filtration, the solvents removed under
reduced pressure to afford 0.16 g of crude material. Chromatography
on silica gel using 50% ethyl acetate as eluent afforded 0.12 g of
the desired benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(ph-
enylmethyl)propyl]-2-methyl-4-dimethylamino, m/e=568 (M+H).
EXAMPLE 10D
##STR00106##
Preparation of Benzamide,
N-[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]1S-(phe-
nylmethyl)propyl]-2-methyl.
To a solution of 500 mg(1 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1S-(phenylm-
ethyl)propylamine in 2 mL of methylene chloride and 2 mL of
N,N-dimethylformamide, was added 0.42 mL of triethylamine, followed
by 0.12 mL of ortho-toluoyl chloride. After 17 hours, the solvent
was removed under reduced pressure, the residue dissolved in ethyl
acetate, was with 5% citric acid, saturated sodium bicarbonate and
brine, dried over anhydrous magnesium sulfate, filtered and
concentrated to afford 490 mg of crude material. This was
chromatographed over 100 g of silica gel using 20-50% ethyl
acetate/hexane as eluent to afford 232 mg of the desired product,
m/e=511(M+H).
EXAMPLE 11A
##STR00107##
Preparation of
N1-[2R-hydroxy-3-[(3-methylbutyl)(methyl-sulfonyl)amino]1S-(phenylmethyl)-
propyl]1-2S-[(2-quinolinylcarbonyl)amino]butanediamide
Part A:
A solution of phenylmethyl
[2R-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1S-(phenylmethyl)pro-
pyl]carbamate prepared as in Example 3 (100 mg) in methanol (10 mL)
was hydrogenated over 10% palladium on carbon for 2 hours, filtered
through diatomaceous earth and concentrated to give the product as
an oil.
Part B:
A solution of N--CBZ-L-asparagine (61 mg, 0.23 mmol) and
N-hydroxybenzotriazole (33 mg, 0.22 mmol) in DMF (2 mL) was cooled
to 0.degree. C. with an ice bath and then EDC (42 mg, 0.22 mmol)
was added. The solution was stirred for 30 minutes at 0.degree. C.
and then the product of Part A (69 mg, 0.21 mmol) in DMF (2 mL) was
added. After 30 minutes at 0.degree. C. the reaction was allowed to
warm to room temperature and stir for 16 hours. The reaction
mixture was then poured into a 50% saturated aqueous solution of
sodium bicarbonate (100 mL) and the resulting white precipitate
collected by suction filtration, washed with water and dried in
vacuo. The phenylmethyl [3-amino-1S-[[2R-hydroxy-3-[(3-methylbutyl)
(methylsulfonyl)amino]-1S-(phenylmethyl)amino]carbonyl]-3-oxopropyl]carba-
mate was obtained as a white solid Anal. Calcd. for
C.sub.28H.sub.40N.sub.4O.sub.7S. 0.5 H.sub.2O: C, 57.42; H, 7.06;
N, 9.57. Found: C, 57.72; H, 7.21; N, 9.24.
Part C:
A solution of phenylmethyl
[3-amino-1S-[[2R-hydroxy-3-[(3-methylbutyl)
(methylsulfonyl)amino]-1S-(phenylmethyl)amino]carbonyl]-3-oxopropyl]carba-
mate (135 mg, 0.23) in methanol (15 mL) was hydrogenated over 10%
palladium on carbon for 6 hours, filtered through diatomaceous
earth and concentrated to give the product as an oil.
Part D:
To a solution of the product from Part C (101 mg, 0.23 mmol) in DMF
(5 mL) was added 2-quinoline carboxylic acid N-hydroxysuccinimide
ester (67 mg, 0.25 mmol). The reaction was stirred at room
temperature for 16 hours, then poured into a 50% saturated solution
of sodium bicarbonate (60 mL). The resulting solid was collected by
suction filtration washed with water and dried in vacuo. The
N1-[2R-hydroxy-3-[(3-methylbutyl)
(methylsulfonyl)-amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbony-
l)amino]butanediamide was obtained as a white solid Anal. Calcd.
for C.sub.30H.sub.39N.sub.5O.sub.6S. 0.1 H.sub.2O: C, 58.52; H,
6.71; N, 11.37. Found: C, 58.34; H, 6.35; N, 11.13.
EXAMPLE 11B
##STR00108##
Preparation of
N1-[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)-
propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide.
Part A:
The CBZ protected compound phenylmethyl
[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)pro-
pyl]carbamate (200 mg, 0.38 mmol) was deprotected by hydrogenation
over 10% palladium on carbon and the resulting product obtained as
an oil.
Part B:
The free amine from Part A was coupled with N-CBZ-L-asparagine (109
mg, 0.41 mmol) in the presence of N-hydroxybenzotriazole (63 mg,
0.41 mmol) and EDC (77 mg, 0.40 mmol) to give phenylmethyl
[3-amino-1S-[[2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)amino]-1S-(phenylmethyl)amino]carbonyl]-3-oxopropyl]carba-
mate as a white solid Anal. Calcd. for
C.sub.33H.sub.42N.sub.4O.sub.7S: C, 62.05; H, 6.63; N, 8.77. Found:
C, 61.86; H, 6.60; N, 8.64.
Part C:
The product of Part B (110 mg, 0.17) was deprotected by
hydrogenation over 10% palladium on carbon to give the product as
an oil.
Part D:
The resulting free amine was coupled with 2-quinoline carboxylic
acid N-hydroxysuccinimide ester (45 mg, 0.17 mmol) to give
N1-[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)-
propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide as a white
solid Anal. Calcd for C.sub.35H.sub.41N.sub.5O.sub.6S: C, 63.71; H,
6.26; N, 10.61. Found: C, 63.59; H, 6.42; N, 10.42.
EXAMPLE 12A
##STR00109##
Preparation of
2S-[[(dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)(methyl-
sulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutanamide
Part A:
To a solution of N-CBZ-L-tert-leucine (100 mg, 0.38 mmol) and
N-hydroxybenzotriazole (52 mg, 0.34 mmol) in DMF (3 mL) was added
EDC (65 mg, 0.34 mmol). The solution was stirred for 60 minutes at
room temperature and then the product of Example 10, Part A (105
mg, 0.32 mmol) in DMF (2 mL) was added. The reaction was stirred
for 16 hours at room temperature, then poured into a 50% saturated
solution of sodium bicarbonate (50 mL). The aqueous mixture was
extracted twice with ethyl acetate (25 mL). The combined ethyl
acetate layers were washed with water (25 mL) and dried over
magnesium sulfate. Filtration and concentration produced an oil
which was chromatographed on silica gel (50 gm) eluting with 2.5%
methanol in dichloromethane. The phenylmethyl
[1S-[[[2R-hydroxy-3-[(3-methylbutyl)-(methylsulfonyl)amino]-1S-(phenylmet-
hyl)propyl]amino]-carbonyl]-2,2-dimethylpropyl]carbamate was
obtained as a gummy solid Anal. Calcd. for
C.sub.30H.sub.45N.sub.3O.sub.6S .diamond. 2.2 H.sub.2O: C, 58.55;
H, 8.09; N, 6.83. Found: C, 58.38; H, 7.77; N, 7.10.
Part B:
A solution of phenylmethyl [1S-[[[2R-hydroxy-3-[(3-methylbutyl)
(methylsulfonyl)amino]-1S-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimeth-
ylpropyl]carbamate (100 mg, 0.17 mmol) in methanol (10 mL) was
hydrogenated over 10% palladium on carbon for 2 hours. The reaction
was filtered through diatomaceous earth and concentrated to an
oil.
Part C:
N,N-dimethylglycine (20 mg, 0.19 mmol), N-hydroxybenzotriazole (28
mg, 0.18 mmol) and EDC (35 mg, 0.18 mmol) were stirred in DMF (4
mL) at room temperature for 40 minutes. The product from Part B in
DMF (4 mL) was added and the reaction mixture stirred for 16 hours,
then poured into a 50% saturated sodium bicarbonate solution (50
mL). The aqueous mixture was extracted three times with
dichloromethane (30 mL) which in turn were washed with water (30
mL) and dried over magnesium sulfate. Filtration and concentration
afforded an oil. The oil was chromatographed on silica gel (50 gm)
eluting initially with 2.5% methanol in dichloromethane (400 mL)
and then with 5% methanol in dichloromethane. The
2S-[[(dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)(methyl-
sulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutanamide was
obtained as a white solid Anal. Calcd. for
C.sub.26H.sub.46N.sub.4O.sub.5S .diamond. 0.5 CH.sub.2Cl.sub.2: C,
56.04; H, 8.34; N, 9.87. Found: C, 56.06; H, 8.36; N, 9.70.
EXAMPLE 12B
##STR00110##
Preparation of
2S-[[(dimethylamino)acetyllamino]N-[2R-hydroxy-3-[(3-methyl-butyl)(phenyl-
sulfonyl)amino]-1S-(phenylmethyl)-propyl]-3,3-dimethylbutaneamide
Part A:
To a solution of N-CBZ-L-tert-leucine (450 mg, 1.7 mmol) and
N-hydroxybenzotriazole (260 mg, 1.7 mmol) in DMF (10 mL) was added
EDC (307 mg, 1.6 mmol). The solution was stirred for 60 minutes at
room temperature and then the product of Example 11, Part A (585
mg, 1.5 mmol) in DMF (2 mL) was added. The reaction was stirred for
16 hours at room temperature, then poured into a 50% saturated
solution of sodium bicarbonate (200 mL). The aqueous mixture was
extracted thrice with ethyl acetate (50 mL). The combined ethyl
acetate layers were washed with water (50 mL) and saturated NaCl
solution (50 mL), then dried over magnesium sulfate. Filtration and
concentration produced an oil which was chromatographed on silica
gel (50 gm) eluting with 20% ethyl acetate in hexane. The
phenylmethyl [1S-[[[2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimeth-
ylpropyl]carbamate was obtained as a solid Anal. Calcd for
C.sub.35H.sub.47N.sub.3O.sub.6S: C, 65.91; H, 7.43; N, 6.59. Found:
C, 65.42; H, 7.24; N, 6.55.
Part B:
A solution of phenylmethyl [1S-[[[2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)-amino]-1S-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimet-
hylpropyl]carbamate (200 mg, 0.31 mmol) in methanol (15 mL) was
hydrogenated over 10% palladium on carbon for 2 hours. The reaction
was filtered through diatomaceous earth and concentrated to an
oil.
Part C:
The resulting free amine from part B (150 mg, 0.3 mmol) was
combined with diisopropylethylamine (114 uL, 0.33 mmol) in
dichloromethane (5 mL). To this was added bromoacetyl chloride (27
uL, 0.33 mmol) dropwise. The reaction was stirred for 30 minutes at
room temperature, then diluted with dichloromethane (30 mL) and
extracted with 1 N HCl, water, and then saturated NaCl solution (25
mL each). The organic solution was dried over MgSO.sub.4 and
concentrated to a solid. The
2S-[[bromoacetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)a-
mino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide was
sufficiently pure for use in the next step. This material can also
be prepared by substituing bromoacetic anhydride for bromoacetyl
chloride, or one can use chloroacetyl chloride or chloracetic
anhydride.
Part D:
The product from part C was dissolved in dichloromethane (5 mL) and
diisopropylethylamine (114 uL, 0.66 mmol) and dimethylamine
hydrochloride (53 mg, 0.66 mmol) were added. The reaction was
stirred for 18 hours then concentrated under a stream of nitrogen
to about 1 mL. The residue was chromatographed on silica gel (50
gm) using 2% methanol in dichloromethane. The
2S-[[(dimethylamino)-acetyl]
amino]-N-[2R-hydroxy-3-[(3methylbutyl)-(phenylsulfonyl)amino]-1S-(phenylm-
ethyl) propyl]-3,3-dimethylbutaneamide was obtained as a solid.
Anal, Calcd for C.sub.31H.sub.48N.sub.4O.sub.5S: C, 63.24; H, 8.22;
N, 9.52. Found: C, 63.03; H, 8.01; N, 9.40.
EXAMPLE 12C
##STR00111##
Preparation of
2S-[[(methylamino)acetyl]aminol]-N-[2R-hydroxy-3-[(3-methyl-butyl)
(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide
2S-[[bromoacetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)a-
mino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide (103 mg,
0.16 mmol) and 40% aqueous methylamine (42 uL, 0.49 mmol) were
combined in ethanol (2 mL) and stirred at room temperature for 24
hours. The reaction mixture was concentrated to dryness and
triturated with ether. The solid material was removed by filtration
and the filtrate concentrated to an oil. The oil was
chromatographed on silica (50 gm) using 4% methanol in
dichloromethane. The
2S-[[(methylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)(phenylsu-
lfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide was
obtained as a solid. Anal. Calcd for
C.sub.30H.sub.46N.sub.4O.sub.5S: C, 62.69; H, 8.07; N, 9.75. Found:
C, 62.38; H, 8.14; N, 9.60.
EXAMPLE 12D
##STR00112##
Preparation of Pentanamide,
2S-[[(Dimethylamino))acetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)phenyl-
sulfonyl)amino]-1S-(phenylmethyl)propyl]3S-methyl--
Part A:
To a solution the amine product of Example 11, Part A; (2.79 g, 7.1
mmol) in 27 mL of dioxane was added (2.3 g, 7.1 mmol) of
N-t-butylcarbonyl-L-isoleucine-N-hydroxysuccinamide ester, and the
reaction was stirred under nitrogen atmosphere for 16 hours. The
contents of the reaction were concentrated in vacuo, and the
residue dissolved in ethyl acetate, washed with potassium hydrogen
sulfate (5% aqueous), saturated sodium bicarbonate, and saturated
sodium chloride. The organic layer was dried over magnesium
sulfate, filtered and concentrated to yield 4.3 grams of crude
material which was chromatographed using 3:1 ethyl acetate: hexane
to obtain 3.05 g, 72% yield of Pentanamide,
2S-[[(1,1-dimethylethoxy)carbonyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)-
phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3-methyl-.
Part B
(3.05 g, 5.0 mmol) of the product from Part A; was dissolved in 20
mL of 4N HCl in dioxane and stirred under nitrogen atmosphere for
1.5 hours. The contents were concentrated in vacuo, and chased with
diethyl ether. The crude hydrochloride salt was pumped on at 1 mm
Hg until dry to yield 2.54 g of product as its hydrochloride
salt.
Part C:
(2.54 g, 5.0 mmol) of amine hydrochloride was dissolved in 50 mL of
tetrahydrofuran and to this was added (1.01 g, 10 mmol) of
4-methyl-morpholine, at which time a precipitate forms. To this
suspension was added chloroacetic anhydride (0.865 g, 5.0 mmol) and
stirred for 40 minutes. The contents were concentrated in vacuo,
and the residue partitioned in ethyl acetate (200 mL) and 5%
KHSO.sub.4. The organic layer was washed with saturated sodium
bicarbonate, and saturated sodium chloride, dried over magnesium
sulfate, filtered and concentrated to yield the crude product.
Purification by silica gel chromatography using an eluant of 1:1
ethyl acetate; hexanes yielded 1.89 grams of pure
chloroacetamide.
Part D:
To a solution of chloroacetamide (1.89 g, 3.2 mmol) from Part C, in
25 mL of tetrahydrofuran was added 4.0 mL of 50% aqueous
dimethylamine and the solution was stirred for 1 hour. The solution
was concentrated in vacuo and the residue was dissolved in ethyl
acetate and washed with water. The organic layer was dried over
magnesium sulfate, filtered and concentrated to yield the crude
product which was purified by crystallization from ethyl acetate
and isooctane to yield 1.80 g, (88% yield), mp.=121-122 C, HRes.
MS. calc. 589.3424, found 589.3405.
EXAMPLE 12E
##STR00113##
Preparation of Pentanamide,
2S-[[(Methylamino)acetyl]amino]N-[2R-hydroxy-3-[(3-methylbutyl)(phenylsul-
fonyl)amino]-1S-(phenylmethyl)propyl]-3S-methyl--
To a solution of the chloroacetamide of Example 12D, Part C, (2.36
g, 4.0 mmol) in tetrahydrofuran (25 mL) was added 3 mL of aqueous
methylamine 40 wt %, and the reaction stirred for 1 hour. The
contents were concentrated and the residue was partitioned between
ethyl acetate (100 mL) and water (100 mL). The organic layer was
dried over magnesium sulfate, filtered and concentrated to yield
the crude product, which was purified by recrystallization from
ethyl acetate heptane; (M+H).sub.575. HRes.found 575.3267.
EXAMPLE 12F
##STR00114##
Preparation of Pentanamide,
2S-[[(Dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(4-met-
hoxyphenylsulfonyl)amino]-1S-(phenylmethyl) propyl]-3S-methyl--
Part A:
To a solution of
2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenylsulfonyl)amino]1-S-propylam-
ine (1.70 g, 4.18 mmol) in 40 mL of dichloromethane was added
N-carbobenzyloxy-L-isoleucine-N-hydroxysuccinamide ester (1.51 g,
4.18 mmol) and the solution stirred under nitrogen atmosphere for
16 hours. The contents were concentrated in vacuo and the residue
was redissolved in ethyl acetate. The ethyl acetate solution was
washed with an aqueous solution of 5% KHSO.sub.4, saturated sodium
bicarbonate, and saturated sodium chloride, dried over magnesium
sulfate, filtered, and concentrated to yield 2.47 g of crude
product. The product was purified by silica gel chromatography
using 1 2:1 hexane:ethyl acetate eluant to yield 2.3 g. (84% yield)
of Pentanamide,
2-[(carbobenzyloxy)amino]-N-[2-hydroxy-3-[(3-methylpropyl)(4-methoxypheny-
lsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl-,[4-(R*,S*,S*,)].
Part B:
(1.18 g, 1.8 mmol) of the product from Part A was dissolved in 50
mL of methanol, and to this was added 250 mg of 10% Palladium on
Carbon while under a stream of nitrogen. The suspension was
hydrogenated using 50 psig of hydrogen for 20 hours. The contents
were purged with nitrogen and filtered through celite, and
concentrated in vacuo to yield 935 mg of Pentanamide,
2S-(amino)-N-[2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl)amin-
o]-1-S-(phenylmethyl)propyl]-3S-methyl-, which was used without
further purification.
Part C:
(0.935 g, 1.8 mmol) of the amine from Part B was dissolved in 15 mL
of dioxane and to this was added (190 mg, 1.85 mmol) of
4-methylmorpholine followed by (0.315 g, 1.8 mmol) of chloroacetic
anhydride. The reaction mixture was stirred under nitrogen
atmosphere for 3 hours, concentrated in vacuo, and redissolved in
ethyl acetate. The ethyl acetate solution was washed with 50 mL of
5% agueous KHSO.sub.4, saturated NaHCO.sub.3, and saturated NaCl
solution, dried over MgSO.sub.4, filtered and concentrated to yield
613 mg, (68% yield) of Pentanamide,
2S-[(chloroacetyl)amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(4-methoxypheny-
lsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methyl-, after
purification by silica gel chromatography using 1:1 hexane:ethyl
acetate.
Part D:
To a solution of the chloroacetamide from Part C; (673 mg, 1.10
mmol) in 20 mL of tetrahydrofuran was added 5 mL of 50 wt % aqueous
dimethylamine and the solution was stirred for 1 hour. The reaction
was concentrated and the residue was redissolved in 50 mL of ethyl
acetate and washed with 25 mL of water. The ethyl acetate layer was
dried over magnesium sulfate, filtered and concentrated to yield a
crude solid which was purified by silica gel column chromatography
using an eluant of 97:3 dichloromethane:methanol to provide 400 mg
of Pentanamide,
2S-[[Dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(4-meth-
oxyphenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methyl-.
EXAMPLE 13A
##STR00115##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-dimethylaminophenyl)sulfonyl](2-methylpropyl)amino]-1S-
-(phenylmethyl)propyl]-, phenylmethyl ester
To a solution of 100 mg (0.19 mmol) of carbamic acid,
[2R-hydroxy-3-[[(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-1S-(pheny-
lmethyl)propyl]-, phenylmethyl ester in 1 mL of pyridine was added
53 .mu.L of triethylamine and 120 .mu.L (p.95 mmol) of 40% aqueous
dimethylamine. After heating for 24 hours at 100 C, the solution
was cooled, ethyl acetate added, then washed with 5% citric acid,
saturated sodium bicarbonate, dried over magnesium sulfate,
filtered and concentrated. The resulting solid was recrystallized
from ethyl acetate/hexane to afford 10 mg of the desired product;
mass spectrum m/e=540 (M+H).
EXAMPLE 13B
##STR00116##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylopropyl)amino]-1S-(phe-
nylmethyl)propyl]-, 3-pyridylmethyl ester
Part A:
A solution of
N-benzyloxycarbonyl-3S-amino-1,2-S-epoxy-4-phenylbutane (50 g,
0.168 mol) and isobutylamine (246 g, 3.24 mol) in 650 mL of
isopropyl alcohol was refluxed for 1.25 hours. The solution was
cooled to room temperature, concentrated in vacuo and then poured
into 1 L of stirring hexane whereupon the product crystallized from
solution, was collected and air dried to give 57.6 g of
N-[3S-benzyloxycarbonylamino-2R-hydroxy-4-phenyl]-N-isobutylamine,
mp 108-109.5 C, mass spectrum m/e=371 (M+H).
Part B:
The amine from part A (1.11 g, 3.0 mmol) and triethylamine (324 mg,
3.20 mmol) in 20 mL of methylene chloride was treated with 715
mg(3.46 mmol) of 4-methoxybenzenesulfonyl chloride. The solution
was stirred at room temperature for 6 hours, concentrated,
dissolved in ethyl acetate, then washed with 1N potassium hydrogen
sulfate, saturated sodium bicarbonate, brine, dried over magnesium
sulfate, filtered and concentrated to afford a clear oil. This was
recrystallized from diethyl ether to afford 1.27 g of carbamic
acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, phenylmethyl ester, mp 97-101 C, mass spectrum
m/e=541 (M+H).
Part C:
A solution of 930 mg (3.20 mmol) of the product of part B in 30 mL
of methanol was hydrogenated in the presence of 70 mg of a 10%
palladium on carbon catalyst under 40 psig for 17 hours, the
catalyst was removed by filtration, and the solution concentrated
to afford 704 mg of
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propylamine, mass spectrum m/e=407 (M+H), which was used
directly in the next step without purification.
Part D:
To a solution of 2.5 g (22.9 mmol) of 3-pyridylcarbinol in 100 mL
of anhydrous acetonitrile was added 8.8 g (34.4 mmol) of
N,N'-disuccinimidyl carbonate and 5.55 mL (68.7 mmol) of pyridine.
The solution was stirred for 1 hour and then concentrated in vacuo.
The residue was dissolved in ethyl acetate, then washed with
saturated sodium bicarbonate, brine, dried over magnesium sulfate,
filtered and concentrated to afford 5.3 g of
N-Hydroxysuccinimide-3-pyridylmethyl carbonate, mass spectrum
m/e=251 (M+H), which was used directly in the next step without
purification.
Part E:
To a solution of the amine from part C (2.87 g, 7.0 mmol) and 1.38
mL of triethylamine in 24 mL of anhydrous methylene chloride was
added a solution of 1.65 g (6.6 mmol) of
N-hydroxysuccinimide-3-pyridyl carbonate from part D in 24 mL of
methylene chloride, The solution was stirred for 1 hour, 100 mL of
methylene chloride added, then washed with saturated sodium
bicarbonate, brine, dried over sodium sulfate, filtered and
concentrated to afford 3.69 g of crude product. Chromatography on
silica gel using 2% methanol/methylene chloride to afford 3.27 g of
carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-
-(phenylmethyl)propyl]-, 3-pyridylmethyl ester, mass spectrum
m/e=548 (M+Li).
EXAMPLE 13C
##STR00117##
Preparation of Carbamic acid,
[2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)pr-
opyl]-, 3-pyridylmethyl ester
Part A:
A solution of
N-benzyloxycarbonyl-3S-amino-1,2-S-epoxy-4-phenylbutane (50 g,
0.168 mol) and isobutylamine (246 g, 3.24 mol) in 650 mL of
isopropyl alcohol was refluxed for 1.25 hours. The solution was
cooled to room temperature, concentrated in vacuo and then poured
into 1 L of stirring hexane whereupon the product crystallized from
solution, was collected and air dried to give 57.6 g of
N-[3S-benzyloxycarbonylamino-2R-hydroxy-4-phenyl]-N-isobutylamine,
mp 108-109.5 C, mass spectrum m/e=371 (M+H).
Part B:
The amine from part A (0.94 g, 2.5 mmol) and triethylamine (288
mg,2.85 mmol) in 20 mL of methylene chloride was treated with 461
mg(2.61 mmol) of benzenesulfonyl chloride. The solution was stirred
at room temperature for 16 hours, concentrated, dissolved in ethyl
acetate, then washed with 1N potassium hydrogen sulfate, saturated
sodium bicarbonate, brine, dried over magnesium sulfate, filtered
and concentrated to afford a clear oil. This was recrystallized
from diethyl ether and hexane to afford 0.73 g of carbamic acid,
[2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)pr-
opyl]-, phenylmethyl ester, mp 95-99 C, mass spectrum m/e=511
(M+H).
Part C:
A solution of 500 mg of carbamic acid,
[2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)pr-
opyl]-, phenylmethyl ester in 20 mL of methanol was hydrogenated in
the presence of 250 mg of a 10% palladium on carbon catalyst under
40 psig for 3 hours, the catalyst was removed by filtration, and
the solution concentrated to afford 352 mg of
[2R-hydroxy-3-[(phenylsulfonyl])2-methylpropyl)amino]-1S-(phenylmethyl)pr-
opylamine, mass spectrum m/e=377 (M+H), which was used directly in
the next step without purification.
Part D:
To a solution of 1.24 mmol of 5-norbornene-2,3-dicarboximido
carbonochloridate (Henklein, P., et. al., Synthesis 1987, 166-167)
in 1 mL of anhydrous methylene chloride, was added a solution of 43
.mu.L (2.44 mmol) of 3-pyridylcarbinol and 129 4 .mu.L (1.6 mmol)
of pyridine in 1 mL of methylene chloride at 0.degree. C. under a
nitrogen atmosphere. After 4 hours at room temperature, 150 mg (0.4
mmol) of
[2R-hydroxy-3-[(phenylsulfonyl])2-methylpropyl)amino]-1S-(phenylmethyl)pr-
opylamine from Part C above was added and 100 .mu.L of pyridine.
After stirring for 15 hours at room temperature, ethyl acetate was
added, then washed with 1N hydrochloric acid, saturated sodium
bicarbonate, brine, dried over magnesium sulfate, filtered and
concentrated to afford 175 mg of crude product. Chromatography over
silica gel using 1% methanol/methylene chloride tp afford 69 mg of
pure carbamic acid,
[2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)pr-
opyl]-, 3-pyridylmethyl ester, mass spectrum m/e=512.2267 (M+H);
calcd for C.sub.27H.sub.33N.sub.3O.sub.5S, 512.2219.
EXAMPLE 13D
##STR00118##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)-propyl]-, 3-pyridylmethyl ester, N-oxide
To a solution of 211 mg (0.39 mmol) of carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-pyridylmethyl ester in 5 mL of methylene
chloride at 0 C was added 500 mg of 50% 3-chloroperbenzoic acid.
After stirring at room temperature for 1 hour, ethyl acetate was
added, the solution washed with saturated sodium bicarbonate, 0.2N
ammonium hydroxide solution and brine, dried over magnesium
sulfate, filtered and concentrated to afford 200 mg of crude
product. This was chromatographed on C18 reverse phase material
using 20-40% acetonitrile/water, then 100% acetonitrile to afford
90 mg of the desired product, which was then recrystallized from
ethyl acetate/isooctane to yield 34 mg of pure carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-pyridylmethyl ester, N-oxide; mass spectrum
m/e=564 (M+Li).
EXAMPLE 13E
##STR00119##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl]-(2-methylpropyl)amino]-1S-(phe-
nylmethyl)propyl]-, 3-pyridylmethyl ester
Part A:
A solution of 0.98 g (1.85 mmol) of carbamic acid,
[2R-hydroxy-3-[[(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-1S-(pheny-
lmethyl)propyl]-phenylmethyl ester in 3.8 mL of anhydrous DMF was
added to 22 mg (7.4 mmol) of 80% sodium hydride in 2 mL of DMF. To
this mixture was added 0.40 g (3.7 mmol) of benzyl alcohol. After 2
hours, the solution was cooled to 0 C, water added, and then ethyl
acetate. The organic layer was washed with 5% cirtic acid,
saturated sodium bicarbonate and brine, dried over magnesium
sulfate, filtered and concentrated to afford 0.90 g of crude
material. This was chromatographed on basic alumina using 3%
methanol/methylene chloride to afford 0.70 g of
2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]
amino-1S-(phenylmethyl)propylamine, cyclic carbamate; mass spectrum
m/e=509(M+H).
Part B:
To a solution of 0.65 g (1.28 mmol) of the cyclic carbamate from
part A in 15 mL of ethanol, was added 2.6 mL (6.4 mmol) of 2.5N
sodium hydroxide solution. After 1 hour at reflux, 4 mL of water
was added and the solution refluxed for an additional eight hours.
The volatiles were removed, ethyl acetate added, and washed with
water, brine, dried over magnesium sulfate, filtered and
concentrated to afford 550 mg of
crude2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1S-(ph-
enylmethyl)propylamine.
Part C:
A solution of crude
2R-hydroxy-3-[(2-methylpropyl)(4-benzyloxyphenyl)sulfonyl]amino-1S-(pheny-
lmethyl)propylamine in 10 mL of ethanol was hydrogenated in the
presence of 500 mg of a 10% palldium on carbon catalyst under 50
psig of hydrogen for 2 hours. The catalyst was removed by
filtration and the solvent removed in vacuo to afford 330 mg of
2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)
sulfonyl]amino-1S-(phenylmethyl)propylamine, mass spectrum m/e=393
(M+H).
Part D:
To a solution of 320 mg (0.82 mmol) of the amine from part C in 6
mL of DMF, was added 192 mg (0.76 mmol) of
N-hydroxysuccinimide-3-pyridylmethyl carbonate. After 15 hours at
room temperature, the DMF was removed in vacuo, ethyl acetate
added, washed with water, brine, dried with magnesium sulfate,
filtered and concentrated to afford 390 mg of crude material.
Chromatogrpahy on silica gel using 50-80% ethyl acetate/hexane
afforded 180 mg of carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-
1S-(phenylmethyl)propyl]-,3-pyridylmethyl ester, mass spectrum
m/e=528(M+H)
EXAMPLE 13F
##STR00120##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxy-phenyl)sulfonyl](2-methylpropyl)amino]-1S-(phe-
nylmethyl)-propyl]-, 5pyrimidylmethyl ester
To a solution of 9.5 mg (0.09 mmol) of 5-pyrimidylcarbinol in 1 mL
of anhydrous acetonitrile at room temperature, was added 24 mg
(0.09 mmol) of N,N'-disuccinimidyl carbonate and 19.1 .mu.L (0.24
mmol) of pyridine. After stirring for 5 hours, 32 mg (0.08 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]amino-1S-(phenylm-
ethyl)propylamine was added and the solution stirred for 48 hours.
After concentration in vacuo, methylene chloride was added, then
washed with a 1:1 mixture of saturated sodium bicarbonate and
brine, dried over magnesium sulfate, filtered and concentrated to
give 27 mg of crude product. Chromatography on silica gel using 2%
methanol/methylene chloride afforded 22 mg of the desired product,
mass spectrum m/e=543(M+H).
EXAMPLE 13G
##STR00121##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-aminopyridyl)methyl ester.
Part A. Prepartion of Ethyl 6-Aminonicotinate.
To a suspension of 1.3 g(9.4 mmol) 6-aminonicotinic acid in 100 mL
of ethanol, was bubbled in dry hydrochloric acid at 0 C, then the
solution was refluxed until all the solids dissolved. The solvents
were removed under reduced pressure, the residue dissolved in ethyl
acetate, washed with saturated sodium bicarbonate, brine and
concentrated to afford 1.37 g of a white solid, m/e=166(M+H).
Part B. Preparation of Ethyl
6-(tert-Butyloxycarbonylamino)nicotinate.
A mixture of 848 mg(5.1 mmol) of ethyl 6-aminonicotinate from part
A, 1.11 g(5.1 mmol) of di-tert-butylpyrocarbonate and 0.71 mL(5.1
mmol) of triethylamine in 10 mL of anhydrous toluene was refluxed
for 15 hours. The solution was cooled, ethyl acetate added, washed
with saturated sodium bicarbonate, brine, dried over anhydrous
magnesium sulfate, filtered and concentrated to afford 1.28 g of
the desired ethyl 6-(tert-butyloxycarbonylamino)nicotinate,
m/e=267(M+H), which was used directly in the next step.
Part C. Preparation of
6-(tert-Butyloxycarbonylamino)-3-pyridylmethanol.
To 4.6 mL(4.6 mmol) of a 1M solution of lithium aluminum hydride in
diethyl ether at -40 C under a nitrogen atmosphere, was added a
solution of 618 mg(2.3 mmol) of ethyl
6-(tert-butyloxycarbonylamino)nicotinate from part B in 40 mL of
anhydrous tetrahydrofuran. After the addition, this was warmed to
room temperature, stirred for 3 hours, cooled to 0 C, and 145 .mu.L
of water, 145 .mu.L of 20% sodium hydroxide solution and 290 .mu.L
of water were successively added. To the resulting mixture was
added 50 mL of tetrahydrofuran and stirring continued for 30
minutes. Anhydrous magnesium sulfate was added, the solids removed
via filtration and the filtrate concentrated under reduced pressure
to afford 460 mg of the desired product, m/e=224(M+), which was
used directly in the next step.
Part D. Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-[(6-tert-butyloxycarbonylamino)pyridyl]methyl
ester.
To a solution of 336 mg (1.5 mmol) of
6-(tert-butyloxycarbonylamino)-3-pyridylmethanol from part C in 14
mL of anhydrous acetonitrile at room temperature under a nitrogen
atmosphere, was added 384 mg(1.5 mmol) of N,N'-disuccinimidyl
carbonate and 364 .mu.L(4.5 mmol) of anhydrous pyridine. After 4
hours, 406 mg(1 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]amino-1S-(phenylm-
ethyl)propylamine was added and stirring continued for 19 hours.
The solvent was removed under reduced pressure, ethyl acetate
added, washed with saturated sodium bicarbonate, brine, dried over
magnesium sulfate, filtered and concentrated to afford 702 mg of
crude product. Chromatography on silica gel using 1%
methanol/methylene chloride as eluent afforded 170 mg of the
desired carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-[(6-tert-butyloxycarbonylamino)pyridyl]methyl
ester, m/e=663(M+Li).
Part E. Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methyipropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-aminopyridyl)methyl ester.
To 5 mL of 4N hydrochloric acid in dioxane at room temperature, was
added 150 mg(0.23 mmol) of carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-[(6-tert-butyloxycarbonylamino)pyridyl]methyl
ester from part D. After stirring at room temperature for 28 hours,
the solvent was removed under reduced pressure, the resulting
solids triturated with diethyl ether, then dissolved in ethyl
acetate and saturated sodium bicarbonate solution, separated, the
organic layer washed with brine, dried with magnesium sulfate,
filtered and concentrated. The residue was chromatographed on
silica gel using 2.5% methanol/methylene chloride to yield 59 mg of
the desired carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-aminopyridyl)methyl ester,
m/e=557(M+H).
EXAMPLE 13H
##STR00122##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-aminopyridyl)methyl ester.
Part A. Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-
1S-(phenylmethyl)propyl]-,
3-[(6-tert-butyloxycarbonylamino)pyridyl]methyl ester.
To a solution of 505 mg (2.25 mmol) of
6-(tert-butyloxycarbonylamino)-3-pyridylmethanol from in 20 mL of
anhydrous acetonitrile at room temperature under a nitrogen
atmosphere, was added 576 mg(2.25 mmol) of N,N'-disuccinimidyl
carbonate and 546 .mu.l(6.75 mmol) of anhydrous pyridine. After 1
hour, 837 mg(1.87 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1S-(phen-
ylmethyl)propylamine was added and stirring continued for 3 hours.
The solvent was removed under reduced pressure, ethyl acetate
added, washed with saturated sodium bicarbonate, brine, dried over
magnesium sulfate, filtered and concentrated to afford 1.37 g of
crude product. Chromatography on silica gel using 1%
methanol/methylene chloride as eluent afforded 830 mg of material
which was identified as a mixture of the desired carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-[(6-tert-butyloxycarbonylamino)pyridyl]methyl
ester and the cyclic carbamate derived from the
2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1S-(phenylm-
ethyl)propylamine. The mixture was very difficult to separate, so
was used as is in the next step.
Part B. Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-aminopyridyl)methyl ester.
To 830 mg of the mixture from part A, was added 50 mL of a 1:1
mixture of trifluoroacetic acid and methylene chloride. After 2.5
hours at room temperature, the solvent was removed under reduced
pressure, ethyl acetate added, washed with saturated sodium
bicarbonate, dried over magnesium sulfate, filtered and
concentrated to afford 720 mg of crude material. This was
chromatgraphed on silica gel using 5% methanol/ethyl acetate as
eluent to yield 220 mg of product, which was recrystallized from
methylene chloride/diethyl ether to afford 108 mg of the desired
carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-aminopyridyl)methyl ester,
m/e=549(M+Li).
EXAMPLE 13I
##STR00123##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]1S-(pheny-
lmethyl)propyl]-, 3-(6-hydroxypyridyl)methyl ester.
Part A. Preparation of tert-Butyldimethylsilyl
6-(tert-butyldimethylsiloxy)nicotinate.
To a solution of 5.0 g(35.9 mmol) of 6-hydroxynicotinic acid in 200
mL of anhydrous N,N-dimethylformamide at room temperature, was
added 8.56 g (125 mmol) of imidazole and then 13.5 g(89 mmol) of
tert-butyldimethylsilyl chloride. After 20 hours, the solvent was
removed under reduced pressure, ethyl acetate added, washed with
water, 5% citric acid, saturated sodium bicarbonate, brine, dried
over anhydrous magnesium sulfate, filtered and concentrated to
afford 10.5 g of crude material, m/e=368(M+H).
Part B. Preparation of
3-(6-tert-butyldimethylsiloxy)pyridylcarbinol.
To 11 mL of 1M solution of lithium aluminum hydride in diethyl
ether at -35 C under a nitrogen atmosphere, was added a solution of
2.0 g(5.46 mmol) of product from part A in 20 mL of anhydrous
diethyl ether. After 30 minutes, the reaction was warmed to 0 C and
stirred for 40 minutes. The solution was then quenched by the
careful addition of 0.42 mL of water, 0.42 mL of 20% sodium
hydroxide solution, and 0.84 mL of ater. Ethyl acetate was added,
the precipate filtered and the organic phase concentrated to yield
0.93 g of crude 3-(6-tert-butyldimethylsiloxy)pyridylcarbinol,
which was used directly in the next step.
Part C. Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 3-(6-hydroxypyridyl)methyl ester.
To a solution of 860 mg(3.6 mmol) of material from part B in 15 mL
of anhydrous acetonitrile, was added 919 mg(3.6 mmol) of
N,N'disuccinimidyl carbonate and 0.87 mL of pyridine. After 1 hour,
1.42 g(3.5 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]amino-1S-(phenylm-
ethyl)propylamine was added. After 14 hours at room temperature,
the solvent was removed under reduced pressure, the residue
dissolved in ethyl acetate, washed with 5% citric acid, saturated
sodium bicarbonate, brine, dried over magnesium sulfate, filtered
and concentrated to afford 2.1 g of crude material. This was
directly deprotected by dissolving in 40 mL of 80% acetic
acid/water and stirring for 2 hours. The solvents were removed
under reduced pressure, the residue dissolved in ethyl acetate,
washed with saturated sodium bicarbonate, brine, dried over
magnesium sulfate, filtered and concentrated to afford 1.7 g of
crude product. This was chromatographed on silica gel using 50-100%
ethyl acetate/hexane to provide a fraction of 0.19 g of fairly pure
material, which was further purified by reverse phase
chromatography using 15-40% acetonitrile/water(0.05%
trifluoroacetic acid) to provide 120 mg of the desired carbamic
acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)aminon]-1S-(phe-
nylmethyl)propyl]-, 3-(6-hydroxypyridyl)methyl ester,
m/e=558(M+H)
EXAMPLE 13J
##STR00124##
Preparation of Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyyl], 5-pyrimidylmethyl ester.
To a solution of 237 mg (2.15 mmol) of 5-pyrimidylcarbinol in 24 mL
of anhydrous acetonitrile, was added 602 mg is (2.35 mmol) of
N,N'-disuccinimidyl carbonate and then 0.47 mL of pyridine. After
stirring for 4.5 hours, 766 mg(196 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1-(phenylme-
thyl)propyl amine was added. After stirring for 19 hours, the
solvent was removed under reduced pressure, ethyl acetate added,
washed with 5% citric acid, saturated sodium bicarbonate, brine,
dried over anhydrous magnesium sulfate, filtered and concentrated
to afford 1.0 g of crude material. Chromatography on silica gel
using 50-100% ethyl acetate/hexane as eluent afforded 450 mg of the
desired carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)propyl]-, 5-pyrimidylmethyl ester, m/e=529(M+H).
EXAMPLE 14
##STR00125##
Preparation of phenylmethyl[3-amino-1S-[[2R-hydroxy-3-[(3-propyl)
(phenylsulfonyl)amino]-1S-(phenylmethyl)amino]-carbonyl]-3-oxopropyl]carb-
amate
Phenylmethyl[2R-hydroxy-3-[(3-propyl)(phenylsulfonyl)amino]-1S-(phenylmet-
hyl)propyl]-carbamate (200 mg, 0.40 mmol) was deprotected by
hydrogenation over 10% palladium on carbon and the resulting free
amine was coupled with N-CBZ-L-asparagine (157 mg,0.42 mmol) in the
presence of N-hydroxybenzotriazole (114 mg, 0.84 mmol) and EDC (130
mg, 0.67 mmol) to give phenylmethyl
[3-amino-1S-[[2R-hydroxy-3-[(3-propyl)(phenylsulfonyl)amino]-1S-(phenylme-
thyl)amino]carbonyl]-3-oxopropyl]carbamate as a solid. Anal. Calcd
for C.sub.31H.sub.38N.sub.4O.sub.7S.0.2H.sub.2O: C,60.61; H,6.30;
N,9.12. Found: C,60.27; H,6.16; N,8.93.
EXAMPLE 15A
##STR00126##
Preparation of
N1-[2R-hydroxy-3-[(3-methylbutyl)(phenyl-sulfonyl)amino]-N4-methyl-1S-(ph-
enylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide
Part A:
N2-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-asparagine was
prepared from Boc-L-aspartic acid alpha-benzyl ester(1.0 g, 3.09
mmol), methylamine.HCl (209 mg, 3.09 mmol), EDC(711 mg, 3.7 mmol),
1-hydroxybenzotriazole (627 mg, 4.63 mmol), and N-methylmorpholine
(0.7 mL, 6.3 mmol), in DMF (20 mL). After stirring overnight at
r.t., the reaction mixture was diluted with ethyl acetate, washed
with water, sat. sodium bicarbonate, 5% citric acid, brine, dried
over magnesium sulfate and concentrated to an oil. The oil was
taken up in 20 mL dry ethanol, and hydrogenated in the presence of
10% w/w of 10% Pd on C at atmospheric pressure and room temperature
overnight. The mixture was filtered through Celite and concentrated
to a white solid foam, 670 mg.
Part B:
A solution of phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate (310 mg,
0.59 mmol) in methanol (10 mL) was hydrogenated over 10% palladium
on carbon for 3 h., filtered through diatomaceous earth and
concentrated to give the product as an oil (214 mg) This free amine
(208 mg, 0.53 mmol) was coupled with
N2-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-asparagine (137 mg,
0.56 mmol) in the presence of N-hydroxybenzotriazole (102 mg, 0.76
mmol) and EDC (130 mg, 0.67 mmol) to yield 290 mg of
N1[2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)amino]-N4-methyl-1S-(phenylmethyl)propyl]-2S-[(1,1-dimeth-
ylethoxy-carbonyl) amino]butane diamide.
Part C:
N1[2R-hydroxy-3-[(3-methylbutyl)
(phenyl-sulfonyl)amino]-N4-methyl-1S-(phenylmethyl)propyl]-2S-[(1,1-dimet-
hylethoxycarbonyl)-amino]butane diamide(270 mg, 0.43 mmol) was
stirred in 4N HCl in dioxane (5 mL) at r.t. for 0.5 h. Solvent and
excess reagent were evaporated to dryness. The product was dried in
vacuo. This material (125 mg, 0.225 mmol) was then reacted with
2-quinoline carboxylic acid N-hydroxysuccimide ester (61 mg, 0.225
mmol), N-methylmorpholine (50 uL, 0.45 mmol) in methylene chloride
(2 mL) for 3 h. The product N1 [2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)amino]-N4-methyl-1S-(phenylmethyl)propyl]-2S-[(2-quinolin-
ykarbonyl)-amino]butane diamide was purified by silica gel
chromatography. Anal. Calcd for
C.sub.36H.sub.43N.sub.5O.sub.6S.0.2H.sub.2O: C,63.83; H,6.45;
N,10.34. Found: C,63.64; H,6.40; N,10.34.
EXAMPLE 15B
Following the procedures set forth above, the following compound
was also prepared:
##STR00127##
Preparation of Carbamic acid,
[3-[[2-hydroxy-3-[(3-methylbutyl)(phenylsutonyl)amino]-1-(phenylmethyl)pr-
opyl]amino]-2-methyl-3-oxopropyl]- (4-methoxyohenyl)methyl ester,
[1S-[1R*(S*),2S*]--
Thus, 4.10 g, (7.8 mmol), of Carbamic acid,
[2R-hydroxy-3-[(3-methylbutyl)
(phenylsulphonyl)amino]-1S-(phenylmethyl) propyl]-, phenylmethyl
ester, [R-(R*,S*)]- was hydrogenated in a solution of methanol and
ethanol using catalytic Pd/C 10% at 50 psig hydrogen for 3 hours.
The catalyst was filtered and the solvents removed in vacuo to
yield 3.0 grams of free amine.
In a separate flask, 2.09 g, (7.8 mmol), of N-Moz-AMBA was added to
10 mL of dimethylformamide and 1.58 g, (1.5 equiv.), of
N-hydroxybenzoltriazole and the solution was cooled to 5 degrees C.
To this solution was added 1.49 g, (7.8 mmol), of EDC and the
solution stirred for 30 min. To this was added the free amine in 10
mL of dimethylformamide, and the reaction was stirred for 20 hours.
The solvent was removed by evaporation and the crude material was
partitioned between ethyl acetate and saturated aqueous sodium
bicarbonate. The ethyl acetate layer was washed with 5% potassium
hydrogen sulfate and brine, dried over magnesium sulfate, filtered
and concentrated to yield 2.58 grams of pure product after
recrystallization from ethyl acetate, ether, and hexanes. 52%
yield.
EXAMPLE 16A
##STR00128##
Preparation of Carbamic acid,
[2R-hydroxy-3-[(4-methoxyyhenylsulfonyl)
(2-methylpronyl)amino]-1S-(phenylmethyl)propyl-,
3-S-tetrahydrofuran-3-yl-ester
To a solution of 406 mg (1.0 mmol) of
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl) propylamine in 5.0 mL of dichloromethane containing 150
mg(1.Smmol) of triethylamine was added 280 mg (1.22 mmol) of
N-succinimidyl-3-(S)-tetrahydrofuranyl carbonate and the reacton
mixture was stirred for 2 hours, an additional 136 mg (0.3 mmol) of
amine was added to the mixture and the solution stirred another 2
hours. The contents were diluted with 50 mL of ethyl acetate and
washed with 5% aqueous citric acid, saturated sodium bicarbonate,
and brine, then dried over magnesium sulfate, filtered and
concentrated to yield 330 mg of crude product. Purification by
silica gel chromatography using an eluant of 1:1 to 2:1 ethyl
acetate/hexanes gradient provided Carbamic acid,
[2R-hydroxy-3-[(4-methoxyphenylsulfonyl) (2-methylpropyl)
amino]-1S-(phenylmethyl)propyl-, 3-S-tetrahydrofuran-3-yl-ester as
a white solid. m/z=521 (M+H) calc. 521.2311 obs. 521.2311.
EXAMPLE 16B
##STR00129##
Preparation of Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3-S-tetrahydrofuran-3-yl-ester
To a solution of 435 mg (1.0 mmol) of
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl) propylamine in 3.0 mL of dimethylformamide was added 225
mg (0.98 mmol) of N-succinimidyl-3-(S)-tetrahydrofuranyl carbonate
and the solution was stirred overnight. The mixture was diluted
with 50 mL of ethyl acetate and washed with 5% aqueous citric acid,
saturated sodium bicarbonate, and brine, dried over magnesium
sulfate, filtered and concentrated to yield 515 mg of crude
product. Purificaton by silica gel chromatography using and eluant
of 1:1 ethyl acetate :hexanes provided 315 mg of Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)(2-methylpropyl)amino]-1S-(phenyl-
methyl)propyl-, 3-S-tetrahydrofuran-3-yl-ester, as a white solid.
m.p=HRMS calc. 507.2165, obs. 507.2155.
EXAMPLE 16C
##STR00130##
Preparation of Carbamic acid,
[2R-hydroxy-3-[(4-methoxyyphenylsulfonyl)
(2-methylpronyl)amino]-1S-(phenylmethyl)propyl-,
3-S-tetrahydrothiophen-3-yl-ester
To a solution of 215 mg (2.0 mmol) of 3-S-hydroxythiophene, 415
.mu.L of anhydrous pyridine,and 2 mL of dry acetonitrile was added
512 mg (2.0 mmol) of N,N'-Dimethylsuccinimidyl carbonate and this
suspension was stirred for 45 minutes. To this clear solution was
added a solution of 700 mg (1.7 mmol) of
[2R-hydroxy-3-[[(4-methoxyyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phe-
nylmethyl)propylamine in 2.0 mL of acetonitrile and stirred for 12
hours. the contents were concentrated, and the residue was
partitioned between ethyl acetate and 5% aqueous potassium hydrogen
sulfate. The organic layer was washed with saturated sodium
bicarbonate and then brine, dried over sodium sulfate, filtered and
concentrated to yield 780 mg of crude material. Purificaton by
silica gel chromatograpy using an eluant of 10:10:1 ethyl acetate:
hexane:methanol provided 520 mg of Carbamic acid,
[2R-hydroxy-3-[(4-methoxyphenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3-S-tetrahydrothiophen-3-yl-ester, as a crystalline white solid.
m.p.=162-3.degree. C., m/z=553 (M+H).
EXAMPLE 16D
##STR00131##
Preparation of Carbamic acid,
[2R-hydroxy-3-[(4-methoxyphenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3(S)-1,1-dioxotetrahydrothiophen-3-yl-ester
To a solution of 270 mg (0.5 mmol) of Carbamic acid,
[2R-hydroxy-3-[(4-methoxyphenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3-S-tetrahydrothiophen-3-yl-ester in 30 mL of dichloromethane was
added 400 mg (1.2 mmol) of m-chloroperbenzoic acid (50 wt %) and
the mixture was stirred for 12 hours. The contents were diluted
with 10 mL of 10% aqueous sodium metabisulfite and stirred for 30
minutes. The organic layer was washed with saturated sodium
bicarbonate, dried over sodium sulfate, filtered and concentrated
to yield 290 mg of crude product. Purification by silica gel
chromatography using an eluant of 10:10:1 ethyl
acetate:hexane:methanol provided 260 mg of Carbamic acid,
[2R-hydroxy-3-[(4-methoxyphenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3(S)-1,1-dioxotetrahydrothiophen-3-yl-ester, as a white crystalline
solid. m.p.=69.degree. C., m/z=569 (M+H).
EXAMPLE 16E
##STR00132##
Preparation of Carbamic acid,
[2R-hydroxy-3-[(4-hydroxythenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3-S-tetrahydrothiophen-3-yl-ester
To a solution of 125 mg (1.2 mmol) of 3-S-hydroxythiophene, 250
.mu.L of anhydrous pyridine,and 1 mL of dry acetonitrile was added
307 mg (1.2 mmol) of N,N'-Dimethylsuccinimidyl carbonate and this
suspension was stirred for 45 minutes. To this clear solution was
added a solution of 445 mg (1.0 mmol)
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl) propylamine in 1.0 mL of acetonitrile and stirred for 12
hours. the contents were concentrated, and the residue was
partitioned between ethyl acetate and 5% aqueous potassium hydrogen
sulfate. The organic layer was washed with saturated sodium
bicarbonate and then brine, dried over sodium sulfate, filtered and
concentrated to yield 460 mg of crude material. Purificaton by
silica gel chromatograpy using an eluant of 10:10:1 ethyl acetate:
hexane:methanol provided 235 mg of Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3-S-tetrahydrothiophen-3-yl-ester, as a crystalline white solid.
m.p.=184-85.degree. C., m/z=529 (M+Li).
EXAMPLE 16F
##STR00133##
Preparation of Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)
(2-methyl-ronyl)amino]-1S-(phenylmethyl)propyl-,
3(S)-1,1-dioxotetrahydrothionhen-3-yl-ester
To a solution of 125 mg (0.24 mmol) of Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3-S-tetrahydrothiophen-3-yl-ester in 30 mL of dichloromethane was
added 240 mg (0.7 mmol) of m-chloroperbenzoic acid (50 wt %) and
the mixture was stirred for 12 hours. The contents were diluted
with 5 mL of 10% aqueous sodium metabisulfite and stirred for 30
minutes. The organic layer was washed with saturated sodium
bicarbonate, dried over sodium sulfate, filtered and concentrated
to yield 110 mg of crude product. Purification by silica gel
chromatography using an eluant of 1:1 to 2:1 ethyl
acetate:hexane:methanol provided 100 mg of Carbamic acid,
[2R-hydroxy-3-[(4-hydroxyphenylsulfonyl)
(2-methylpropyl)amino]-1S-(phenylmethyl)propyl-,
3(S)-1,1-dioxotetrahydrothiophen-3-yl-ester, as a white crustalline
solid, m.p.=190-1.degree. C., m/z=561 (M+Li).
EXAMPLE 17A
Carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](methylpropyl)amino]-1S-(phenyl-
methyl)propyl]-,5-(thiazolyl)methyl ester can be prepared according
to the following procedures.
##STR00134##
To a solution of 172 mg (1.5 mmol) of 5-hydroxymethylthiazole in 14
mL of anhydrous acetonitrile at room temperatures under a nitrogen
atmosphere, is added 384 mg (1.5 mmol) of N,N'-disuccinimidyl
carbonate and 364 .mu.L (4.5 mmol) of anhydrous pyridine. After
about 4 hourse, 406 mg (1 mmol) of 2R-hydroxy-3-[(2-methylpropyl)
(4-methoxyphenyl)sulfonyl]amino-1S-(phenylmethyl)propylamine is
added and stirring would be continued for approximately 19 hours.
The solvent would be removed under reduced pressure, ethyl acetate
added, washed with saturated sodium bicarbonate, brine, dried over
magnesium sulfate, filtered and concentrated to afford crude
product. The desired carbamic acid,
[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-
-(phenylmethyl)propyl]-,5-(thiazolyl)methyl ester could be isolated
in pure form through chromatography on silica gel using 50-100%
ethyl acetate/hexane as eluent.
EXAMPLE 17B
Carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](methylpropyl)amino]-1S-(phenyl-
methyl)propyl]-,5-(thiazolyl)methyl ester can be prepared according
to the following procedure
##STR00135##
To a solution of 482 mg (4.3 mmol) of 5-(hydroxymethyl)thiazole in
48 mL of anhydrous acetonitrile, is added 1.2 g (4.7 mmol) of
N,N'-disuccinimidyl carbonate and then 0.94 mL of pyridine. After
stirring for about 4 to 5 hours, 1.53 g (3.92 mmol) of
2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1S-(phenylm-
ethyl)propylamine is added. After stirring for approximately 19
hours, the solvent would be removed under reduced pressure, theyl
acetate added, washed with 5% citric acid, saturated sodium
bicarbonate, brine, dried over anhydrous magnesium sulfate,
filtered and concentrated to afford crude product. The desired
carbamic acid,
[2R-hydroxy-3-[[(4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phen-
ylmethyl)pro,5-(thiazolyl)methyl ester could be isolated in pure
form through chromatography on silica gel using 50-100% ethyl
acetate/hexane as eluent.
EXAMPLE 18
Following the procedures of Examples 1-16, the compounds shown in
Tables 3, 5A and 5B were prepared and in Tables 4 through 17 can be
prepared.
TABLE-US-00005 TABLE 3 ##STR00136## Entry No. R R.sup.1 R.sup.3
R.sup.4 1 Cbz t-Butyl i-Amyl Methyl 2 N,N-Dimethylglycine t-Butyl
i-Amyl Methyl 3 Cbz i-Propyl i-Amyl Phenyl 4 Cbz sec-Butyl i-Amyl
Phenyl 5 Cbz CH.sub.2C(O)NH.sub.2 n-Propyl Phenyl 6 N-Methylglycine
t-Butyl i-Amyl Phenyl 7 Cbz t-Butyl i-Butyl Phenyl 8
N,N-Dimethylglycine t-Butyl i-Amyl Phenyl 9 N-Methylglycine t-Butyl
i-Amyl Phenyl 10 N,N-Dimethylglycine t-Butyl i-Butyl (4-OCH.sub.3)
Phenyl 11 N-Methylglycine t-Butyl i-Butyl (4-OCH.sub.3) Phenyl
TABLE-US-00006 TABLE 4 ##STR00137## Entry No. R R.sup.3 R.sup.4 1
Cbz' CH.sub.3 n-Butyl 2 Cbz i-Butyl CH.sub.3 3 Cbz i-Butyl n-Butyl
4 Qb i-Butyl n-Butyl 5 Cbz i-Propyl n-Butyl 6 Q i-Propyl n-Butyl 7
Cbz C.sub.6H.sub.5 n-Butyl 8 Cbz ##STR00138## n-Butyl 9 Cbz
##STR00139## n-Butyl 10 Q ##STR00140## n-Butyl 11 Cbz ##STR00141##
n-Butyl 12 Cbz i-Butyl n-Propyl 13 Cbz i-Butyl
--CH.sub.2CH(CH.sub.3).sub.2 14 Cbz ##STR00142## n-Butyl 15 Cbz
##STR00143## i-Propyl 16 Cbz ##STR00144##
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 17 Cbz i-Butyl
--CH.sub.2CH.sub.3 18 Cbz i-Butyl --CH(CH.sub.3).sub.2 19 Cbz
i-Butyl ##STR00145## 20 Q -Butyl ##STR00146## 21 Cbz ##STR00147##
--(CH.sub.2).sub.2CH(CH.sub.3).sub.2 22 Cbz
--(CH.sub.2).sub.2CH(CH.sub.3).sub.2 --CH(CH.sub.3).sub.2 23 Q
i-Butyl --CH(CH.sub.3).sub.2 24 Cbz i-Butyl --C(CH.sub.3).sub.3 25
Q i-Butyl --C(CH.sub.3).sub.3 26 Cbz ##STR00148##
--C(CH.sub.3).sub.3 27 Q ##STR00149## --C(CH.sub.3).sub.3 28 Cbz
--(CH.sub.2).sub.2CH(CH.sub.3).sub.2 --C(CH.sub.3).sub.3 29 Q
--(CH.sub.2).sub.2CH(CH.sub.3).sub.2 --C(CH.sub.3).sub.3 30 Cbz
--CH.sub.2C.sub.6H.sub.5 --C(CH.sub.3).sub.3 31 Q
--CH.sub.2C.sub.6H.sub.5 --C(CH.sub.3).sub.3 32 Cbz
--(CH.sub.2).sub.2C.sub.6H.sub.5 --C(CH.sub.3).sub.3 33 Cbz
--(CH.sub.2).sub.2C.sub.6H.sub.5 --C(CH.sub.3).sub.3 34 Cbz n-Butyl
--C(CH.sub.3).sub.3 35 Cbz n-Pentyl --C(CH.sub.3).sub.3 36 Cbz
n-Hexyl --C(CH.sub.3).sub.3 37 Cbz ##STR00150## --C(CH.sub.3).sub.3
38 Cbz --CH.sub.2C(CH.sub.3).sub.3 --C(CH.sub.3).sub.3 39 Q
--CH.sub.2C(CH.sub.3).sub.3 --C(CH.sub.3).sub.3 40 Cbz ##STR00151##
--C(CH.sub.3).sub.3 41 Cbz --CH.sub.2C.sub.6H.sub.5OCH.sub.3(para)
--C(CH.sub.3).sub.3 42 Cbz ##STR00152## --C(CH.sub.3).sub.3 43 Cbz
##STR00153## --C(CH.sub.3).sub.3 44 Cbz
--(CH.sub.2).sub.2C(CH.sub.3).sub.3 --C(CH.sub.3).sub.3 45 Q
--(CH.sub.2).sub.2C(CH.sub.3).sub.3 --C(CH.sub.3).sub.3 46 Cbz
--(CH.sub.2).sub.4OH --C(CH.sub.3).sub.3 47 Q --(CH.sub.2).sub.4OH
--C(CH.sub.3).sub.3 48 Q ##STR00154## --C(CH.sub.3).sub.3 49 Q
##STR00155## --C(CH.sub.3).sub.3 50 Cbz
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 51 ##STR00156##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 52 ##STR00157##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 53 ##STR00158##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 54 ##STR00159##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 55 ##STR00160##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 56 ##STR00161##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 57 ##STR00162##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 58 ##STR00163##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 59 ##STR00164##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 60 ##STR00165##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 61 ##STR00166##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 62 ##STR00167##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 63 ##STR00168##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 64 ##STR00169##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 65 ##STR00170##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 66 ##STR00171##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 67 ##STR00172##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 68 ##STR00173##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 69 ##STR00174##
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 70 Q --CH.sub.2Ph
--Ph 71 Q ##STR00175## --Ph 72 Q ##STR00176## --Ph 73 Q
##STR00177## --Ph 74 Q ##STR00178## --Ph 75 Q ##STR00179## --Ph 76
Q --CH.sub.2CH.dbd.CH.sub.2 --Ph 77 Q ##STR00180## --Ph 78 Q
##STR00181## --Ph 79 Q --CH.sub.2CH.sub.2Ph --Ph 80 Q
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH --Ph 81 Q
--CH.sub.2CH.sub.2N(CH.sub.3).sub.2 --Ph 82 Q ##STR00182## --Ph 83
Q --CH.sub.3 --Ph 84 Q --CH.sub.2CH.sub.2CH.sub.2SCH.sub.3 --Ph 85
Q --CH.sub.2CH.sub.2CH.sub.2S(O).sub.2CH.sub.3 --Ph 86 Q
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00183## 87 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00184## 88 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 --CH.sub.2CH.sub.2CH.sub.3 89
Q --CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 --CH.sub.3 90 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00185## 91 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00186## 92 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00187## 93 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00188## 94 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00189## 95 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00190## 96 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00191## 97 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00192## 98 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00193## 99 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00194## 100 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00195## 101 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00196## 102 Q
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00197## 103 Q
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00198## 104 Q
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00199## 105 Q
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00200## 106 Q
--CH.sub.2CH.sub.2CH.sub.3 ##STR00201## 107 Q
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3 ##STR00202##
.sup.abenzyloxycarbonyl .sup.b2-quinolinylcarbonyl
TABLE-US-00007 TABLE 5 ##STR00203## Entry A R.sup.3 R.sup.4 1
Cbz-Val i-amyl --C.sub.6H.sub.5 2 Cbz-Leu i-amyl --C.sub.6H.sub.5 3
Cbz-Ile i-amyl --C.sub.6H.sub.5 4 Ac-D-homo-Phe i-Bu methyl 5
Qui-Om(g-Cbz) ##STR00204## --C.sub.6H.sub.5 6 Cbz-Asn
--CH.sub.2CH.dbd.CH.sub.2 --C.sub.6H.sub.5 7 Acetyl-t-BuGly i-amyl
--C.sub.6H.sub.5 8 Acetyl-Phe i-amyl --C.sub.6H.sub.5 9 Acetyl-Ile
i-amyl --C.sub.6H.sub.5 10 Acetyl-Leu i-amyl --C.sub.6H.sub.5 11
Acetyl-His i-amyl --C.sub.6H.sub.5 12 Acetyl-Thr i-amyl
--C.sub.6H.sub.5 13 Acetyl-NHCH(C(CH.sub.3).sub.2(SCH.sub.3))C(O)--
i-amyl --C.sub.6H.sub.5- 14 Cbz-Asn i-amyl --C.sub.6H.sub.5 15
Cbz-Ala i-amyl --C.sub.6H.sub.5 16 (N,N-dimethylglycinyl)Val i-amyl
--C.sub.6H.sub.5 17 (N-methylglycinyl)Val i-amyl --C.sub.6H.sub.5
18 (N,N-dimethylglycinyl)Ile i-amyl --C.sub.6H.sub.3 19
(N-methylglycinyl)Ile i-amyl --C.sub.6H.sub.5 20 Cbz-Ala i-amyl
--C.sub.6H.sub.5 21 Cbz-beta-cyanoAla i-amyl --C.sub.6H.sub.5 22
Cbz-t-BuGly i-amyl --C.sub.6H.sub.5 23 Q-t-BuGly i-amyl
--C.sub.6H.sub.5 24 Q-SCH.sub.3Cys i-amyl --C.sub.6H.sub.5 25
Cbz-SCH.sub.3Cys i-amyl --C.sub.6H.sub.5 26 Q-Asp i-amyl
--C.sub.6H.sub.5 27 Cbz-(NHCH(C(CH.sub.3).sub.2(SCH.sub.3))C(O)--
i-amyl --C.sub.6H.sub.5 28 Cbz-EtGly i-amyl --C.sub.6H.sub.5 29
Cbz-PrGly i-amyl --C.sub.6H.sub.5 30 Cbz-Thr i-amyl
--C.sub.6H.sub.5 31 Q-Phe i-amyl --C.sub.6H.sub.5 32 Cbz-Phe i-amyl
--C.sub.6H.sub.5 33 ##STR00205## i-Butyl --C.sub.6H.sub.4
##STR00206##
TABLE-US-00008 TABLE 5A ##STR00207## MASS MEASUREMENT CALC Entry
R.sup.3 R.sup.4 R.sup.7 MOL FORM M + H FOUND 1 ##STR00208##
##STR00209## ##STR00210## C.sub.27H.sub.38N.sub.2O.sub.5S 503.2661
503.2624 2 ##STR00211## C.sub.28H.sub.40N.sub.2O.sub.5S 517.2736
517.2777 3 ##STR00212## C.sub.29H.sub.42N.sub.2O.sub.5S 531.2893
531.2916 4 ##STR00213## C.sub.32H.sub.40N.sub.2O.sub.5S 565.2736
565.2731 5 ##STR00214## C.sub.30H.sub.35N.sub.3O.sub.5S 550.2376
550.2427 6 ##STR00215## ##STR00216## ##STR00217##
C.sub.30H.sub.38N.sub.2O.sub.5S 539 (M + H) 539 7 ##STR00218##
C.sub.29H.sub.36N.sub.2O.sub.5S ? ? 8
C.sub.30H.sub.38N.sub.2O.sub.5S 539.2580 (M + H) 539.2591 9
##STR00219## ##STR00220## ##STR00221##
C.sub.27H.sub.33N.sub.3O.sub.5S 512.2219 512.2271 10 ##STR00222##
C.sub.28H.sub.35N.sub.3O.sub.5S 526.2376 526.2388 11 ##STR00223##
C.sub.27H.sub.33N.sub.3O.sub.5S 512.2219 512.2287 12 ##STR00224##
C.sub.28H.sub.33N.sub.2O.sub.5ClS 545.1877 545.1887 13 ##STR00225##
C.sub.30H.sub.38N.sub.2O.sub.5S 539.2580 539.2592 14 ##STR00226##
C.sub.31H.sub.40N.sub.2O.sub.5S 553.2736 553.2714 15 ##STR00227##
C.sub.30H.sub.38N.sub.2O.sub.5S 539.2580 539.2632 16 ##STR00228##
C.sub.30H.sub.38N.sub.2O.sub.5S 539 (M + H) 539 17 ##STR00229##
##STR00230## ##STR00231## C.sub.29H.sub.36N.sub.2O.sub.7S.sub.2
589.2042 (M + H) 589.2086 18 ##STR00232##
C.sub.29H.sub.36N.sub.2O.sub.7S.sub.2 595.2124 (M + Li) 595.2103 19
##STR00233## C.sub.29H.sub.36N.sub.2O.sub.7S.sub.2 595.2124 (M +
Li) 595.2191 20 ##STR00234## C.sub.30H.sub.38N.sub.2O.sub.7S.sub.2
609.2281 (M + Li) 609.2313 21 ##STR00235##
C.sub.30H.sub.38N.sub.2O.sub.7S.sub.2 603.2199 (M + H) 603.2247 22
##STR00236## C.sub.30H.sub.38N.sub.2O.sub.7S.sub.2 603.2199 (M + H)
603.2266 23 ##STR00237## ##STR00238## ##STR00239## 24 ##STR00240##
##STR00241## ##STR00242## C.sub.27H.sub.32N.sub.2O.sub.4S 481.2161
481.2213 25 ##STR00243## ##STR00244## ##STR00245##
C.sub.28H.sub.35N.sub.2O.sub.5S 511.2267 511.2319 26 ##STR00246##
##STR00247## ##STR00248## C.sub.29H.sub.36N.sub.2O.sub.5S 525.2423
525.2469 27 ##STR00249## C.sub.29H.sub.36N.sub.2O.sub.5S 525.2428
525.2464 28 ##STR00250## C.sub.29H.sub.36N.sub.2O.sub.5S 525.2423
525.2432 29 ##STR00251## C.sub.29H.sub.36N.sub.2O.sub.6S 541.2372
541.2332 30 ##STR00252## C.sub.29H.sub.36N.sub.2O.sub.6S 541.2372
541.2355 31 ##STR00253## C.sub.29H.sub.36N.sub.2O.sub.6S 541.2372
541.2329
TABLE-US-00009 TABLE 5B ##STR00254## Molecular Mass Entry A Formula
Spectrum ##STR00255## C.sub.29H.sub.35N.sub.3O.sub.7S 576 (M + Li)
##STR00256## C.sub.29H.sub.37N.sub.3O.sub.5S 540 (M + H)
##STR00257## C.sub.31H.sub.41N.sub.3O.sub.5S 568 (M + H)
##STR00258## C.sub.29H.sub.35N.sub.3O.sub.7S 570 (M + H)
##STR00259## C.sub.29H.sub.37N.sub.3O.sub.5S 540 (M + H)
##STR00260## C.sub.31H.sub.41N.sub.3O.sub.5S 568 (M + H)
##STR00261## C.sub.29H.sub.35N.sub.3O.sub.7S 570 (M + H)
##STR00262## C.sub.29H.sub.37N.sub.3O.sub.5S 546 (M + Li)
##STR00263## C.sub.31H.sub.41N.sub.3O.sub.5S 574 (M + Li)
TABLE-US-00010 TABLE 6 ##STR00264## Entry R.sup.1 1
CH.sub.2SO.sub.2CH.sub.3 2 (R)--CH(OH)CH.sub.3 3 CH(CH.sub.3).sub.2
4 (R,S)CH.sub.2SOCH.sub.3 5 CH.sub.2SO.sub.2NH.sub.2 6
CH.sub.2SCH.sub.3 7 CH.sub.2CH(CH.sub.3).sub.2 8
CH.sub.2CH.sub.2C(O)NH.sub.2 9 (S)--CH(OH)CH.sub.3 10
--CH.sub.2C.ident.C--H
TABLE-US-00011 TABLE 7 ##STR00265## Entry R.sup.2 A 1 n-Bu Cbz-Asn
2 cyclohexylmethyl Cbz-Asn 3 n-Bu Boc 4 n-Bu Cbz 5
C.sub.6H.sub.5CH.sub.2 Boc 6 P--F--C.sub.6H.sub.5CH.sub.2 Cbz 7
C.sub.6H.sub.5CH.sub.2 benzoyl 8 cyclohexylmethyl Cbz 9 n-Bu Q-Asn
10 cyclohexylmethyl Q-Asn 11 C.sub.6H.sub.5CH.sub.2 Cbz-Ile 12
C.sub.6H.sub.5CH.sub.2 Q-Ile 13 P--F--C.sub.6H.sub.5CH.sub.2
Cbz-t-BuGly 14 C.sub.6H.sub.5CH.sub.2 Q-t-BuGly 15
C.sub.6H.sub.5CH.sub.2 Cbz-Val 16 C.sub.6H.sub.5CH.sub.2 Q-Val 17
2-naphthylmethyl Cbz-Asn 18 2-naphthylmethyl Q-Asn 19
2-naphthylmethyl Cbz 20 n-Bu Cbz-Val 21 n-Bu Q-Val 22 n-Bu Q-Ile 23
n-Bu Cbz-t-BuGly 24 n-BU Q-t-BuGly 25 p-F(C.sub.6H.sub.4)CH.sub.2
Q-Asn 26 p-F(C.sub.6H.sub.4)CH.sub.2 Cbz 27
p-F(C.sub.6H.sub.4)CH.sub.2 Cbz-Asn 28 C.sub.6H.sub.5CH.sub.2
Cbz-propargylglycine 29 C.sub.6H.sub.5CH.sub.2 Q-propargylglycine
30 C.sub.6H.sub.5CH.sub.2 acetylpropargylglycine
TABLE-US-00012 TABLE 8 ##STR00266## Entry R.sup.3 R.sup.4 1
--CH.sub.2CH(CH.sub.3).sub.2 --C(CH.sub.3).sub.2 2
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00267## 3
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00268## 4
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00269## 5
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00270##
TABLE-US-00013 TABLE 9 ##STR00271## Entry R R.sup.1 1 ##STR00272##
--CH.sub.3 2 ##STR00273## --CH.sub.3 3 ##STR00274##
--CH(CH.sub.3).sub.2 4 ##STR00275## --CH(CH.sub.3).sub.2 5
##STR00276## --C(CH.sub.3).sub.3 6 ##STR00277## --CH.sub.3 7
##STR00278## --CH.sub.3 8 ##STR00279## --CH.sub.3 9 ##STR00280##
--CH.sub.3 10 ##STR00281## --CH.sub.3 11 ##STR00282## --CH.sub.3 12
##STR00283## --CH.sub.3 13 ##STR00284## --CH.sub.3 14 ##STR00285##
--CH.sub.3 15 ##STR00286## 16 ##STR00287##
TABLE-US-00014 TABLE 10 ##STR00288## Entry R.sup.1 R.sup.1'
R.sup.1'' R 1 H H H ##STR00289## 2 H H H ##STR00290## 3 H CH.sub.3
H ##STR00291## 4 H CH.sub.3 CH.sub.3 ##STR00292## 5 H H
CO.sub.2CH.sub.3 ##STR00293## 6 H H H ##STR00294## 7 H H H
##STR00295## 8 H H CONH.sub.2 Cbz 9 H H CONH.sub.2
2-quinolinylcarbonyl
TABLE-US-00015 TABLE 11 ##STR00296## Entry R R' X 1 R = H R' = H X
= H 2 R = Me R' = Me X = H 3 R = H R' = Me X = H 4 R = Me R' = Ne X
= F 5 R = H R' = Me X = F 6 R = Cbz R' = Me X = H 7 R = H R' = Bz X
= H 8 R + R' = pyrrole X = H
TABLE-US-00016 TABLE 12 ##STR00297## Entry Acyl Group (R) 1
benzyloxycarbonyl 2 tert-butoxycarbonyl 3 acetyl 4
2-quinoylcarbonyl 5 phenoxyacetyl 6 benzoyl 7 methyloxaloyl 8
pivaloyl 9 trifluoracetyl 10 bromoacetyl 11 hydroxyacetyl 12
morpholinylacetyl 13 N,N-dimethylaminoacetyl 14 N-benzylaminoacetyl
15 N-phenylaminoacetyl 16 N-benzyl-N-methylaminoacetyl 17
N-methyl-N-(2-hydroxyethyl)aminoacetyl 18 N-methylcarbamoyl 19
3-methylbutyryl 20 N-isobutylcarbamoyl 21 succinoyl
(3-carboxypropionyl) 22 carbamoyl 23 N-(2-indanyl)aminoacetyl
TABLE-US-00017 TABLE 13 ##STR00298## Entry R.sup.3 R.sup.4 1
--CH.sub.3 -n-Butyl 2 -i-Butyl --CH.sub.3 3 -i-Butyl -n-Butyl 4
-i-Propyl -n-Butyl 5 --C.sub.6H.sub.5 -n-Butyl 6 ##STR00299##
-n-Butyl 7 ##STR00300## -n-Butyl 8 ##STR00301## -n-Butyl 9 -i-Butyl
-n-Propyl 10 -i-Butyl --CH.sub.2CH(CH.sub.3).sub.2 11 ##STR00302##
-n-Butyl 12 ##STR00303## -i-Propyl 13 ##STR00304##
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 14 i-Butyl --CH.sub.2CH.sub.3
15 i-Butyl --CH(CH.sub.3).sub.2 16 i-Butyl ##STR00305## 17
##STR00306## --(CH.sub.2).sub.2CH(CH.sub.3).sub.2 18
(CH.sub.2).sub.2CH(CH.sub.3).sub.2 --CH(CH.sub.3).sub.2 19 i-Butyl
--CH(CH.sub.3).sub.2 20 i-Butyl --C(CH.sub.3).sub.3 21 ##STR00307##
--C(CH.sub.3).sub.3 22 --(CH.sub.2).sub.2CH(CH.sub.3).sub.2
--C(CH.sub.3).sub.3 23 --CH.sub.2C6H5 --C(CH.sub.3).sub.3 24
--(CH.sub.2).sub.2C.sub.6H.sub.5 --C(CH.sub.3).sub.3 25 n-Butyl
--C(CH.sub.3).sub.3 26 n-Pentyl --C(CH.sub.3).sub.3 27 n-Hexyl
--C(CH.sub.3).sub.3 28 ##STR00308## --C(CH.sub.3).sub.3 29
--CH.sub.2C(CH.sub.3).sub.3 --C(CH.sub.3).sub.3 30 ##STR00309##
--C(CH.sub.3).sub.3 31 --CH.sub.2C.sub.6H.sub.5OCH.sub.3(para)
--C(CH.sub.3).sub.3 32 ##STR00310## --C(CH.sub.3).sub.3 33
##STR00311## --C(CH.sub.3).sub.3 34
--(CH.sub.2).sub.2C(CH.sub.3).sub.3 --C(CH.sub.3).sub.3 35
--(CH.sub.2).sub.4OH --C(CH.sub.3).sub.3 36 ##STR00312##
--C(CH.sub.3).sub.3 37 ##STR00313## --C(CH.sub.3).sub.3 38
--CH.sub.2CH(CH.sub.3).sub.2 --C.sub.6H.sub.5 39 i-amyl
--CH.sub.2C(CH.sub.3).sub.3 40 ##STR00314##
--CH.sub.2C(CH.sub.3).sub.3 41 ##STR00315##
--CH.sub.2C(CH.sub.3).sub.3 42 i-butyl --CH.sub.2C(CH.sub.3).sub.3
43 --CH.sub.2Ph --Ph 44 ##STR00316## --Ph 45 ##STR00317## --Ph 46
##STR00318## --Ph 47 ##STR00319## --Ph 48 ##STR00320## --Ph 49
--CH.sub.2CH = CH.sub.2 --Ph 50 ##STR00321## --Ph 51 ##STR00322##
--Ph 52 --CH.sub.2CH.sub.2Ph --Ph 53
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2OH --Ph 54
--CH.sub.2CH.sub.2N(CH.sub.3).sub.2 --Ph 55 ##STR00323## --Ph 56
--CH.sub.3 --Ph 57 --CH.sub.2CH.sub.2CH.sub.2SCH.sub.3 --Ph 58
--CH.sub.2CH.sub.2CH.sub.2S(O).sub.2CH.sub.3 --Ph 59
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00324## 60
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00325## 61
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 --CH.sub.2CH.sub.2CH.sub.3 62
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 --CH.sub.3 63
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00326## 64
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00327## 65
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00328## 66
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00329## 67
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00330## 68
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00331## 69
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00332## 70
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00333## 71
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00334## 72
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00335## 73
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00336## 74
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 ##STR00337## 75
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00338## 76
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00339## 77
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00340## 78
--CH.sub.2CH(CH.sub.3).sub.2 ##STR00341## 79
--CH.sub.2CH.sub.2CH.sub.3 ##STR00342## 80
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3 ##STR00343##
.sup.abenzyloxycarbonyl .sup.b2-quinolinylcarbonyl
TABLE-US-00018 TABLE 14 ##STR00344## Entry R.sup.1 R.sup.3 1
C(CH.sub.3).sub.3 CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 2
CH.sub.2C.ident.CH CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 3
C(CH.sub.3).sub.2(SCH.sub.3) CH.sub.2CH.sub.2CH(CH.sub.3).sub.2 4
C(CH.sub.3).sub.2(S[O]CH.sub.3) CH.sub.2CH.sub.2CH(CH.sub.3).sub.2
5 C(CH.sub.3).sub.2(S[O].sub.2CH.sub.3)
CH.sub.2CH.sub.2CH(CH.sub.3).sub.2- 6 C(CH.sub.3).sub.3
CH.sub.2CH(CH.sub.3).sub.2 7 C(CH.sub.3).sub.3 ##STR00345## 8
CH(CH.sub.3).sub.2 CH.sub.2CH(CH.sub.3).sub.2 9
CH(CH.sub.2CH.sub.3) (CH.sub.3) CH.sub.2CH(CH.sub.3).sub.2
TABLE-US-00019 TABLE 14A ##STR00346## Entry R.sup.1 R.sup.3 1
C(CH.sub.3)SCH.sub.3 CH.sub.2CH.sub.2CH(CH.sub.3).sub.2
TABLE-US-00020 TABLE 15 A ##STR00347## ##STR00348## ##STR00349##
##STR00350## ##STR00351## ##STR00352## ##STR00353## ##STR00354##
##STR00355## ##STR00356## ##STR00357## ##STR00358## ##STR00359##
##STR00360## ##STR00361## ##STR00362## ##STR00363## ##STR00364##
##STR00365## ##STR00366## ##STR00367## ##STR00368## ##STR00369##
##STR00370## ##STR00371## ##STR00372##
TABLE-US-00021 TABLE 16 ##STR00373## A R ##STR00374## H or CH.sub.3
##STR00375## H or CH.sub.3 ##STR00376## H or CH.sub.3 ##STR00377##
H or CH.sub.3 ##STR00378## H or CH.sub.3 ##STR00379## H or CH.sub.3
##STR00380## H or CH.sub.3 ##STR00381## H or CH.sub.3 ##STR00382##
H or CH.sub.3 ##STR00383## H or CH.sub.3 ##STR00384## H or CH.sub.3
##STR00385## H or CH.sub.3 ##STR00386## H or CH.sub.3 ##STR00387##
H or CH.sub.3 ##STR00388## H or CH.sub.3 ##STR00389## H or CH.sub.3
##STR00390## H or CH.sub.3
TABLE-US-00022 TABLE 17 ##STR00391## A Group B Group ##STR00392##
##STR00393## ##STR00394## ##STR00395## ##STR00396## ##STR00397##
##STR00398## ##STR00399## ##STR00400## ##STR00401##
TABLE-US-00023 TABLE 17A ##STR00402## A Group B Group ##STR00403##
n = 0,1, or 2 ##STR00404## R' = OH, methoxy, benzyloxy,
--C(NH.sub.2).dbd.NOH, --C(NH.sub.2).dbd.NH ##STR00405## R'' = H or
lower alkyl. ##STR00406## ##STR00407## ##STR00408## ##STR00409##
##STR00410## ##STR00411## ##STR00412## ##STR00413## ##STR00414##
##STR00415## ##STR00416## ##STR00417##
TABLE-US-00024 TABLE 17B R = H or OH R.sup.1 = CH.sub.3, NH.sub.2,
F, Cl or Br R.sup.2 = H or CH.sub.3 ##STR00418## ##STR00419##
##STR00420## ##STR00421##
TABLE-US-00025 TABLE 17B-1 ##STR00422## ##STR00423## ##STR00424##
##STR00425##
TABLE-US-00026 TABLE 17B-2 ##STR00426## ##STR00427##
EXAMPLE 19
The compounds of the present invention are effective HIV protease
inhibitors. Utilizing an enzyme assay as described below, the
compounds set forth in the examples herein disclosed inhibited the
HIV enzyme. The preferred compounds of the present invention and
their calculated IC.sub.50 (inhibiting concentration 50%, i.e., the
concentration at which the inhibitor compound reduces enzyme
activity by 50%) values are shown in Tables 18 through 21. The
enzyme method is described below. The substrate is 2-Ile-Nle-Phe
(p-NO.sub.2)-Gln-ArgNH.sub.2. The positive control is MVT-101
(Miller, M. et al, Science, 246, 1149 (1989)] The assay conditions
are as follows:
Assay Buffer:
20 mM sodium phosphate, pH 6.4 20% glycerol 1 mM EDTA 1mM DTT 0.1%
CHAPS.
The above described substrate is dissolved in DMSO, then diluted 10
fold in assay buffer. Final substrate concentration in the assay is
80 .mu.M.
HIV protease is diluted in the assay buffer to a final enzyme
concentration of 12.3 nanomolar, based on a molecular weight of
10,780.
The final concentration of DMSO is 14% and the final concentration
of glycerol is 18%. The test compound is dissolved in DMSO and
diluted in DMSO to 10.times. the test concentration; 10 .mu.l of
the enzyme preparation is added, the materials mixed and then the
mixture is incubated at ambient temperature for 15 minutes. The
enzyme reaction is initiated by the addition of 40 .mu.l of
substrate. The increase in fluorescence is monitored at 4 time
points (0, 8, 16 and 24 minutes) at ambient temperature. Each assay
is carried out in duplicate wells.
The preceding examples can be repeated with similar success by
substituting the generically or specifically described reactants
and/or operating conditions of this invention for those used in the
preceding examples.
TABLE-US-00027 TABLE 18A Entry Compound IC.sub.50 (namomolar) 1
##STR00428## 16 2 ##STR00429## 1.5 3 ##STR00430## 1.4 4
##STR00431## 27 5 ##STR00432## 29 6 ##STR00433## 10 7 ##STR00434##
3.6 8 ##STR00435## 4.2 9 ##STR00436## 3.5 10 ##STR00437## 100 11
##STR00438## 81 12 ##STR00439## 20
TABLE-US-00028 TABLE 19B Ex. Table Entry IC.sub.50 (uM) or % inhib
6 1a 1 0.011 6 1a 2 0.010 6 1a 3 38% @ 1 uM, 79% @ 10 uM 6 1a 4
0.016 6 1a 5 0.10 6 1a 6 36% @ 10 uM 6 1a 7 0.0096 6 1a 39 0.016 6
1a 40 0.21 6 1a 41 24% @ 1 uM, 74% @ 10 uM 6 1a 50 42% @ 1 uM, 89%
@ 10 uM 6 1a 51 31% @ 1 uM, 76% @ 10 uM 6 1a 52 39% @ 1 uM, 81% @
10 uM 6 1a 53 0.049 6 1a 54 0.0028 6 1a 55 0.10 6 1a 56 0.0036 16 3
1 0.081 16 3 2 38% @ 0.1 uM, 90% @ 1.0 uM 16 3 4 0.0024 16 3 6
0.0018 16 3 8 0.003 16 3 10 0.0025 16 3 12 0.0016 16 4 102 0.0015
16 5 1 0.0014 16 5 14 0.0022 16 5 22 0.0018 16 5 33 0.0044 16 5 34
0.0020 16 7 31 0.0028 16 7 32 0.0015 16 11 1 0.13 16 11 9 41% @ 0.1
uM, 86% @ 1 uM 16 12 10 0.0033 16 14 3 0.0049 16 14 10 0.0032
TABLE-US-00029 TABLE 20 Table Entry IC.sub.50 (uM) or % inhibtion
lA 3 0.02 5A 1 0.04 5A 3 0.02 5A 4 0.01 5A 5 0.026 5A 6 0.023 5A 7
0.007 5A 9 0.067 5A 11 0.018 5A 12 0.006 5A 13 0.0098 5A 14 0.049
5A 16 0.008 5A 17 59% @ 10 .mu.M 5A 18 0.13 5A 19 0.092 5A 20 85% @
1 .mu.M 5A 22 63% @ 1 .mu.M 5A 24 0.047 5A 25 0.014 5A 26 0.005 5A
28 0.015 5A 29 0.19 5A 30 0.03 5A 31 0.02
EXAMPLE 20
The effectiveness of the compounds listed in Table 15 were
determined in the above-described enzyme assay and in a CEM cell
assay.
The HIV inhibition assay method of acutely infected cells is an
automated tetrazolium based calorimetric assay essentially that
reported by Pauwles et al, J. Virol. Methods, 20, 309-321 (1988).
Assays were performed in 96-well tissue culture plates. CEM cells,
a CD4+ cell line, were grown in RPMI-1640 medium (Gibco)
supplemented with a 10% fetal calf serum and were then treated with
polybrene (2 .mu.g/ml). An 80 .mu.l volume of medium containing
1.times.10.sup.4 cells was dispensed into each well of the tissue
culture plate. To each well was added a 100 .mu.l volume of test
compound dissolved in tissue culture medium (or medium without test
compound as a control) to achieve the desired final concentration
and the cells were incubated at 37.degree. C. for 1 hour. A frozen
culture of HIV-1 was diluted in culture medium to a concentration
of 5.times.10.sup.4 TCID.sub.50 per ml (TCID.sub.50=the dose of
virus that infects 50% of cells in tissue culture), and a 20 .mu.L
volume of the virus sample (containing 1000 TCID.sub.50 of virus)
was added to wells containing test compound and to wells containing
only medium (infected control cells). Several wells received
culture medium without virus (uninfected control cells). Likewise,
the intrinsic toxicity of the test compound was determined by
adding medium without virus to several wells containing test
compound. In summary, the tissue culture plates contained the
following experiments:
TABLE-US-00030 Cells Drug Virus 1. + - - 2. + + - 3. + - + 4. + +
+
In experiments 2 and 4 the final concentrations of test compounds
were 1, 10, 100 and 500 .mu.g/ml. Either azidothymidine (AZT) or
dideoxyinosine (ddI) was included as a positive drug control. Test
compounds were dissolved in DMSO and diluted into tissue culture
medium so that the final DMSO concentration did not exceed 1.5% in
any case. DMSO was added to all control wells at an appropriate
concentration.
Following the addition of virus, cells were incubated at 37.degree.
C. in a humidified, 5% CO.sub.2 atmosphere for 7 days. Test
compounds could be added on days 0, 2 and 5 if desired. On day 7,
post-infection, the cells in each well were resuspended and a 100
.mu.l sample of each cell suspension was removed for assay. A 20
.mu.L volume of a 5 mg/ml solution of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
was added to each 100 .mu.L cell suspension, and the cells were
incubated for 4 hours at 27.degree. C. in a 5% CO.sub.2
environment. During this incubation, MTT is metabolically reduced
by living cells resulting in the production in the cell of a
colored formazan product. To each sample was added 100 .mu.l of 10%
sodium dodecylsulfate in 0.01 N HCl to lyse the cells, and samples
were incubated overnight. The absorbance at 590 nm was determined
for each sample using a Molecular Devices microplate reader.
Absorbance values for each set of wells is compared to assess viral
control infection, uninfected control cell response as well as test
compound by cytotoxicity and antiviral efficacy.
TABLE-US-00031 TABLE 21 IC.sub.50 EC.sub.50 TD.sub.50 Entry
Compound (nM) (nM) (nM) 1 ##STR00440## 16 55 27 2 ##STR00441## 1 5
203 3 ##STR00442## 1 11 780 4 ##STR00443## 27 64 28 5 ##STR00444##
19 88 11 6 ##STR00445## >100 380 425 7 ##STR00446## 3 25 39 8
##STR00447## 85 1200 24 9 ##STR00448## 53 398 15 10 ##STR00449## 45
700 12 11 ##STR00450## 3 11 54 12 ##STR00451## 2 12 7.5 13
##STR00452## 3 <16 14 ##STR00453## 4 15 55,000 15 ##STR00454## 5
38 16 ##STR00455## 9 80 62.000 17 ##STR00456## 4 5 59,000 18
##STR00457## 8 19 ##STR00458## 4 20 ##STR00459## 4 21 ##STR00460##
73 22 ##STR00461## 15 18 31,000 23 ##STR00462## 2 24 ##STR00463## 3
25 ##STR00464## 60 120 167,000 26 ##STR00465## 27 ##STR00466## 5
177 300,000 28 ##STR00467## 14 76 213,000 29 ##STR00468## 5 105
196,000 30 ##STR00469## 6 154 154,000 31 ##STR00470## 10 32
##STR00471## 5 98 17,000 33 ##STR00472## 18 68 34 ##STR00473## 67
188 35 ##STR00474## 36 ##STR00475## 310 898 37 ##STR00476## 7
<20 38 ##STR00477## 4 1,100 39 ##STR00478## 16 269 40
##STR00479## 3 41 ##STR00480## 3 11 42 ##STR00481## 2 43
##STR00482## 4 44 ##STR00483## 4 8 45 ##STR00484## 2 5 46
##STR00485## 2 47 ##STR00486## 3 48 ##STR00487## 17 210 49
##STR00488## 6 <20 50 ##STR00489## 14 51 ##STR00490## 9 52
##STR00491## >100 53 ##STR00492## 21 54 ##STR00493## 10 55
##STR00494## 37
The compounds of the present invention are effective antiviral
compounds and, in particular, are effective retroviral inhibitors
as shown above. Thus, the subject compounds are effective HIV
protease inhibitors. It is contemplated that the subject compounds
will also inhibit other retroviruses such as other lentiviruses in
particular other strains of HIV, e.g. HIV-2, human T-cell leukemia
virus, respiratory syncitial virus, simia immunodeficiency virus,
feline leukemia virus, feline immuno-deficiency virus,
hepadnavirus, cytomegalovirus and picomavirus. Thus, the subject
compounds are effective in the treatment and/or proplylaxis of
retroviral infections.
The subject compounds are also effective in preventing the growth
of retroviruses in a solution. Both human and animal cell cultures,
such as T-lymphocyte cultures, are utilized for a variety of well
known purposes, such as research and diagnostic procedures
including calibrators and controls. Prior to and during the growth
and storage of a cell culture, the subject compounds may be added
to the cell culture medium at an effective concentration to prevent
the unexpected or undesired replication of a retrovirus that may
inadvertently or unknowingly be present in the cell culture. The
virus may be present originally in the cell culture, for example
HIV is known to be present in human T-lymphocytes long before it is
detectable in blood, or through exposure to the virus. This use of
the subject compounds prevents the unknowing or inadvertent
exposure of a potentially lethal retrovirus to a researcher or
clinician.
Compounds of the present invention can possess one or more
asymmetric carbon atoms and are thus capable of existing in the
form of optical isomers as well as in the form of racemic or
nonracemic mixtures thereof. The optical isomers can be obtained by
resolution of the racemic mixtures according to conventional
processes, for example by formation of diastereoisomeric salts by
treatment with an optically active acid or base. Examples of
appropriate acids are tartaric, diacetyltartaric,
dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and
then separation of the mixture of diastereoisomers by
crystallization followed by liberation of the optically active
bases from these salts. A different process for separation of
optical isomers involves the use of a chiral chromatography column
optimally chosen to maximize the separation of the enantiomers.
Still another available method involves synthesis of covalent
diastereoisomeric molecules by reacting compounds of Formula I with
an optically pure acid in an activated form or an optically pure
isocyanate. The synthesized diastereoisomers can be separated by
conventional means such as chromatography, distillation,
crystallization or sublimation, and then hydrolyzed to deliver the
enantiomerically pure compound. The optically active compounds of
Formula I can likewise be obtained by utilizing optically active
starting materials. These isomers may be in the form of a free
acid, a free base, an ester or a salt.
The compounds of the present invention can be used in the form of
salts derived from inorganic or organic acids. These salts include
but are not limited to the following: acetate, adipate, alginate,
citrate, aspartate, benzoate, benzenesulfonate, bisulfate,
butyrate, camphorate, camphorsulfonate, digluconate,
cyclopentanepropionate, dodecylsulfate, ethanesulfonate,
glucoheptanoate, glycerophosphate, hemisulfate, heptanoate,
hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate,
nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate,
persulfate, 3-phenylpropionate, picrate, pivalate, propionate,
succinate, tartrate, thiocyanate, tosylate, mesylate and
undecanoate. Also, the basic nitrogen-containing groups can be
quaternized with such agents as lower alkyl halides, such as
methyl, ethyl, propyl, and butyl chloride, bromides, and iodides;
dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl
sulfates, long chain halides such as decyl, lauryl, myristyl and
stearyl chlorides, bromides and iodides, aralkyl halides like
benzyl and phenethyl bromides, and others. Water or oil-soluble or
dispersible products are thereby obtained.
Examples of acids which may be employed to form pharmaceutically
acceptable acid addition salts include such inorganic acids as
hydrochloric acid, sulphuric acid and phosphoric acid and such
organic acids as oxalic acid, maleic acid, succinic acid and citric
acid. Other examples include salts with alkali metals or alkaline
earth metals, such as sodium, potassium, calcium or magnesium or
with organic bases.
Total daily dose administered to a host in single or divided doses
may be in amounts, for example, from 0.001 to 10 mg/kg body weight
daily and more usually 0.01 to 1 mg. Dosage unit compositions may
contain such amounts of submultiples thereof to make up the daily
dose.
The amount of active ingredient that may be combined with the
carrier materials to produce a single dosage form will vary
depending upon the host treated and the particular mode of
administration.
The dosage regimen for treating a disease condition with the
compounds and/or compositions of this invention is selected in
accordance with a variety of factors, including the type, age,
weight, sex, diet and medical condition of the patient, the
severity of the disease, the route of administration,
pharmacological considerations such as the activity, efficacy,
pharmacokinetic and toxicology profiles of the particular compound
employed, whether a drug delivery system is utilized and whether
the compound is administered as part of a drug combination Thus,
the dosage regimen actually employed may vary widely and therefore
may deviate from the preferred dosage regimen set forth above.
The compounds of the present invention may be administered orally,
parenterally, by inhalation spray, rectally, or topically in dosage
unit formulations containing conventional nontoxic pharmaceutically
acceptable carriers, adjuvants, and vehicles as desired. Topical
administration may also involve the use of transdermal
administration such as transdermal patches or iontophoresis
devices. The term parenteral as used herein includes subcutaneous
injections, intravenous, intramuscular, intrasternal injection, or
infusion techniques.
Injectable preparations, for example, sterile injectable aqueous or
oleaginous suspensions may be formulated according to the known art
using suitable dispersing or wetting agents and suspending agents.
The sterile injectable preparation may also be a sterile injectable
solution or suspension in a nontoxic parenterally acceptable
diluent or solvent, for example, as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that may be employed are
water, Ringer's solution, and isotonic sodium chloride solution In
addition, sterile, fixed oils are conventionally employed as a
solvent or suspending medium. For this purpose any bland fixed oil
may be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid find use in the
preparation of injectables.
Suppositories for rectal administration of the drug can be prepared
by mixing the drug with a suitable nonirritating excipient such as
cocoa butter and polyethylene glycols which are solid at ordinary
temperatures but liquid at the rectal temperature and will
therefore melt in the rectum and release the drug.
Solid dosage forms for oral administration may include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound may be admixed with at least one inert diluent
such as sucrose lactose or starch. Such dosage forms may also
comprise, as in normal practice, additional substances other than
inert diluents, e.g., lubricating agents such as magnesium
stearate. In the case of capsules, tablets, and pills, the dosage
forms may also comprise buffering agents. Tablets and pills can
additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration may include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups, and elixirs containing inert diluents commonly used in the
art, such as water. Such compositions may also comprise adjuvants,
such as wetting agents, emulsifying and suspending agents, and
sweetening, flavoring, and perfuming agents.
While the compounds of the invention can be administered as the
sole active pharmaceutical agent, they can also be used in
combination with one or more immunomodulators, antiviral agents or
other antiinfective agents. For example, the compounds of the
invention can be administered in combination with AZT, DDI, DDC or
with glucosidase inhibitors, such as N-butyl-1-deoxynojirimycin or
prodrugs thereof, for the prophylaxis and/or treatment of AIDS.
When administered as a combination, the therapeutic agents can be
formulated as separate compositions which are given at the same
time or different times, or the therapeutic agents can be given as
a single composition.
The foregoing is merely illustrative of the invention and is not
intended to limit the invention to the disclosed compounds.
Variations and changes which are obvious to one skilled in the art
are intended to be within the scope and nature of the invention
which are defined in the appended claims.
From the foregoing description, one skilled in the art can easily
ascertain the essential characteristics of this invention, and
without departing from the spirit and scope thereof, can make
various changes and modifications of the invention to adapt it to
various usages and conditions.
* * * * *